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General Introduction
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Epidemiology of colorectal cancer
Colorectal cancer presents a significant burden of disease throughout the world.1 In the Nether-
lands, colorectal cancer currently is the most common cancer.2 As a result of the introduction of 
a nationwide screening program, the increasing life expectancy and ageing of the population, 
the absolute number of colorectal cancer patients increased importantly, from 7,100 in 1990 to 
15,549 in 2015 (figure 1). Elderly patients account for the majority of patients presenting with 
colorectal malignancies (figure 2). Nowadays, approximately one third of the patients is aged 
≥75 years. 
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Figure 1  Incidence of colorectal cancer in the Netherlands, by year of diagnosis.  
Source  Netherlands Cancer Registry 
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Figure 2 Incidence of colorectal cancer in the Netherlands, by year of diagnosis and 5-year age group.  
Source Netherlands Cancer Registry
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Colorectal cancer is classified according to stage at diagnosis, as defined by the tumour- 
node-metastasis (TNM) staging system.3 Approximately 80% of the newly diagnosed colorectal 
cancer patients present with localized disease (T1-4N1-2M0). In the remaining patients, metastases 
are present at time of diagnosis, typically in the liver, lungs or peritoneal surface.4,5 In addition, 
a considerable proportion (40-50%) of patients experience disease recurrence or develop meta-
static disease during their course of disease.6 Until a few decades ago, patients with metastasized 
disease were treated with palliative intent with disappointing outcome. However, over the past 
three decades, colorectal cancer treatment has made an enormous leap. 
Evolution of systemic therapy in the management of colorectal cancer
Historically, patients with metastasized colorectal cancer were considered incurable and even if 
patients had localized disease amenable to surgery, cure rates were low.7 As a result, the concept 
to treat colorectal cancer with systemic therapy gained interest during the 20th century (figure 3). 
An overview on key clinical studies in the evolution of modern systemic therapy is depicted in 
Table 1.
5-FU Potentiation of
5-FU by LV
Bolus 5-FU/LV vs. 
5-FU: mCRC
Bevacizumab, cetuximab, 
and panitumumab
5-FU/LV:
adjuvant therapy
Capecitabine: mCRC
5-FU with levamisole:
adjuvant therapy
FOLFOX: adjuvant therapy
FOLFOX and 
FOLFIRI: mCRC
1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010
Figure 3  The evolution of systemic therapy for patients with colorectal cancer. 
Source  Gustavsson et al.8 
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Chemotherapy
In 1957, systemic treatment of colorectal cancer was initiated by Charles Heidelberger with the 
discovery of 5-fluorouracil (5-FU)9, an antimetabolite that interferes with DNA biosynthesis by 
inhibiting thymidylate synthase. After the detection of 5-FU potentiation by adding leucovorin 
(LV)10, 5-FU/LV regimens gained acceptance in the early nineties in both the adjuvant7,11 and met-
astatic setting12. However, major advances in the evolution of chemotherapy in colorectal cancer 
were not achieved until the early 2000s when irinotecan (topoisomerase I inhibitor), oxaliplatin 
(alkylating agent) and the 5-FU prodrug capecitabine were introduced and combination thera-
pies were developed. At first in the USA, irinotecan was combined with bolus 5-FU/LV (IFL).13 In 
patients with metastasized colorectal cancer, first-line treatment with IFL resulted in significant-
ly longer progression-free survival (7.0 vs. 4.3 months, p=.004) and overall survival (14.8 vs. 12.6 
months, p=.04) in comparison to first-line treatment with 5-FU/LV.13 However, compared to the Eu-
ropean prevailing oxaliplatin-based regimen (FOLFOX: biweekly infusion 5-FU/LV with oxaliplatin) 
the IFL regimen provided inferior overall survival rates (19.5 vs. 15.0 months, p<.0001).14 Besides, 
the FOLFOX regimen was associated with a more favourable toxicity profile than IFL, with less 
severe nausea, vomiting, diarrhoea and febrile neutropenia. The IFL regimen was abandoned and 
a combination regimen of irinotecan with continuous 5-FU was developed (FOLFIRI). Several trials 
showed similar efficacy for the FOLFIRI and FOLFOX regimens in patients with advanced colorectal 
cancer (table 1).15,16 Both combination therapies (FOLFOX, FOLFIRI) have become standard cyto-
toxic combination regimens for the treatment of metastatic colorectal cancer. Treatment choice is 
based on differences in toxicity profile between these regimens; more gastrointestinal side effects 
with FOLFIRI and more thrombocytopenia and neurotoxicity with FOLFOX.16 Combination che-
motherapy, however, is not indicated as first-line systemic treatment in all patients. The individ-
ual treatment choice between combination or single agent therapy as first-line is dependent on 
patient and tumour related factors and the ultimate aim of the therapy. Single agent therapy is a 
reasonable option for patients with metastatic colorectal cancer with never-resectable metastatic 
disease, or without limiting symptoms and limited risk of rapid deterioration, in whom the aim will 
rather be prolongation of life than maximal shrinkage of metastases. Combination chemotherapy 
may not be preferable as it coincides with increased toxicity. Besides, in terms of overall survival, 
combination chemotherapy has not been shown to be superior to sequential treatment.17-20 Ex-
posure to all three active cytotoxic agents (fluoropyrimidine, oxaliplatin, irinotecan), rather than 
the prescribed first-line regimen is associated with the longest survival.21,22 Therefore, sequential 
therapy starting with a fluoropyrimidine-derived monotherapy has been considered as a valid 
option in at least some patients.23 
Within the adjuvant setting, survival rates improved significantly by the introduction of FOLFOX. 
In 2004, an interim analysis of the pivotal MOSAIC trial showed significantly improved 3-year dis-
ease free survival rates with FOLFOX compared with 5-FU/LV in patients with stage II or stage III 
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colorectal cancer (78% vs. 73%, p=.002), at the cost of higher toxicity rates.24 In 2009, these results 
were updated in the final analysis of the MOSAIC trial, and showed significant improvements in 
both 5-year disease-free survival (73% vs. 67%, p=.003) and 6-year overall survival (79% vs. 76%, 
p=.046).25 This improvement in overall survival was observed only in patients with stage III disease 
(73% vs. 69%, p=.023).25 In the PETACC-3 study on the adjuvant treatment of colorectal cancer, no 
improvements were observed in either disease-free or overall-survival with irinotecan contain-
ing chemotherapy.26 Consequently, FOLFOX is now considered the gold standard in the adjuvant 
treatment of stage III and high risk stage II CRC. 
Another major advance in the treatment of colorectal cancer, both in the adjuvant and metastat-
ic setting, was the introduction of the oral fluoropyrimidine capecitabine, which was shown to 
be at least equally effective to infusional 5-FU with an improved safety profile, except for more 
hand-foot syndrome.27,28 Capecitabine is a patient convenient alternative to treatment regimens 
requiring intravenous infusion of 5-fluorouracil. Besides, it diminishes the use of medical resourc-
es, mainly by avoiding hospital visits for intravenous drug administration and fewer treatment-re-
lated hospitalisations during the course of therapy for adverse drug reactions than with conven-
tional intravenous 5-fluorouracil.29 As a result, a shift has taken place in the Netherlands, with an 
increasing usage of capecitabine in both monotherapy and combination-chemotherapy. 
Targeted therapy
In the early 21st century a new class of agents, usually referred to as targeted therapy, has widened 
the spectrum of systemic therapy in advanced colorectal cancer. Targeted cancer therapies block 
the growth and spread of colorectal cancer by interfering with molecular targets that are involved 
in the growth, progression and spread of cancer. Although the concept of targeting angiogen-
esis was already raised in the 1960’s, when initial attempts were made to characterize tumour 
blood supply30, it was not available until the beginning of the 21st century. In 2004, Hurwitz et al. 
were the first to demonstrate that the addition of bevacizumab, a monoclonal antibody directed 
against the anti-vascular growth factor receptor (VEGF, figure 4a), to first-line IFL resulted in an 
improved overall survival (20.3 vs. 15.6 months, p<.001).31 Thereafter, bevacizumab also proved to 
be effective in combination with multiple backbone chemotherapy regimens19,32,33 and in different 
treatment settings.34,35 The safety profile of bevacizumab is well characterized. Important but rare 
adverse events are haemorrhage, thromboembolism, proteinuria, bowel perforation and hyper-
tension.19,31-34,36-38 In 2006, the anti-epidermal growth factor receptor (EGFR) agents cetuximab and 
panitumumab were introduced and FDA approved (figure 4b). In patients with wild-type KRAS, 
these agents improved survival.39,40 Ever since, there has been an ever-increasing number of tar-
geted agents being tested in clinical trials, such as aflibercept and the tyrosine-kinase inhibitor 
regorafenib. 41,42
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Figure 4   molecular pathways in targeted therapy for colorectal cancer, A. the vascular endothelial growth factor (VEGF) 
signalling pathway, B. The endothelial growth factor receptor (EGFR) signalling pathway. 
Source  El Zouhairi et al. 43
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Table 1  Randomized phase III trials in the evolution of systemic therapy
Colorectal cancer
a. Metastatic setting
Author (year) Regimens Results
Chemotherapy
Poon (1989) bolus 5-FU/LV vs. bolus 5-FU OS: 12.2/12.0 (5-FU  with high/low dose LV 
respectively) vs. 7.7 months (p=.05)
RR: 26%/37% vs. 10%
Cutsem (2001) Capecitabine vs. bolus 5-FU/LV OS 13.2 vs. 12.1 months (p=NS) 
RR 18.9% vs. 15.0% (p=NS) 
TTP: 5.2 vs. 4.7 months (p=NS)
Saltz (2000) IFL vs. bolus 5-FU/LV OS: 14.8 vs. 12.6 months (p=.04)
RR: 39% vs. 21% (p<.001)
PFS: 7.0 vs. 4.3 months (p<.01)
Intergroup N9741 (2004) IFL vs. FOLFOX OS: 19.5 vs. 15.0 months (p=.04)
RR: 45% vs. 31% (p<0.01)
TTP: 8.7 vs. 6.9 months  (p<0.01)
GERCOR (2004) FOLFOX vs. FOLFIRI OS: 21.5 vs. 20.6 months (p=NS)
RR: 56% vs. 54% (p=NS)
PFS: 8.5 vs. 8.0 months (p=NS)
GOIM (2005) FOLFOX vs. FOLFIRI OS 14 vs. 15 months (p=NS)
RR: 31% vs. 34% (p=NS)
TTP: 7 vs. 7 months (p=NS)
Targeted therapy
AVF(2004) IFL ± bevacizumab OS: 20.3 vs. 15.6 months (p<.001)
RR: 44.8% vs. 34.8% p=<.001
PFS: 10.6 vs. 6.2 months (p<.001)
Tebbutt (2010) Capecitabine ± bevacizumab OS: 16.4 vs. 18.9 months (NS) 
RR: 38.1% vs. 30.3% (NS)
PFS: 8.5 vs. 5.7% months (p<.001)
Kabbinavar (2005) bolus 5-FU/LV ± bevacizumab OS: 16.6 vs. 12.9 months (p=NS) 
RR: 20.6 vs. 15.2 (p=NS) 
PFS: 9.2 vs. 5.5 months (p=<.001)
Saltz (2008) FOLFOX ± bevacizumab OS: 21.3 vs. 19.9 months (p=NS) 
RR: 47% vs. 49% (p=NS) 
PFS: 9.4 vs. 8.0 months (p<0.01)
ECOG 3200 (2007) FOLFOX ± bevacizumab OS: 12.9 vs. 10.8 months (p<.001)
RR 22.7% vs. 8.6% (p<.001)
PFS: 7.3 vs. 4.7 months (p<.001)
ML18147 (2013) Bevacizumab beyond progression OS: 11.2 vs. 9.8 (p<.01)
CRYSTAL (2009, 2011) FOLFIRI ± cetuximab Wild type KRAS:
OS: 23.5 vs. 20.0 months (p<.05)
RR: 57.3% vs. 39.7% (p<.01)
PFS: 9.9 vs. 8.4 months (p<0.01)
PRIME (2010) FOLFOX ± panitumumab Wild type KRAS: 
OS: 23.9 vs. 19.7 months (p=NS) 
PFS: 9.6 vs. 8.0 months (p<0.05)
COIN (2011) FOLFOX ± cetuximab Wild type KRAS: 
OS: 17.0 vs. 17.9 months (p=NS)
RR: 64% vs. 57% (p=0.05)
PFS: 8.6 vs. 8.6 months (p=NS)
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Colorectal cancer
b. Adjuvant setting
Chemotherapy
Moertel (1990) bolus 5-FU/LV 3-5 year OS: 71% vs. 55%
X-ACT (2005) Capecitabine 3-year OS: 81% vs. 78% (p=.05)
3-year DFS 64% vs. 61% (p=NS)
MOSAIC (2004, 2009) FOLFOX vs. 5-FU2/LV 6-year OS: 79% vs. 76% (p<.05)
5-year DFS: 73% vs. 67% (p<.01)
PETACC-3 FOLFIRI vs. 5-FU2/LV 5-year OS: 74% vs 71% (p=NS)
5- year DFS: 57% vs. 54% (p=NS)
5-FU2/LV (de Gramont)=biweekly infusional 5FU/LV
The gap between clinical research and everyday clinical practice
Underrepresentation in clinical trials
With the evolution of systemic therapy and results of large randomized phase III trials, treatment 
guidelines on colorectal cancer changed. The external validity of clinical trial-based recommenda-
tions, however, is limited as clinical trials often use eligibility criteria that often do not represent the 
patients in every clinical practice.44 Clinical trials usually select patients with minimal comorbidity 
and good performance score in order to obtain a homogenous study population and to improve 
internal validity. Besides, response evaluation is an important feature of the clinical evaluation of 
cancer therapies and therefore, most clinical trials evaluating systemic therapy exclude patients 
in whom radiographic imaging is difficult, such as in patients with peritoneal metastases.45 As a 
result, several subsets of patients, such as elderly patients, patients with significant co-morbidities 
and patients with peritoneal metastases, accounting for a significant proportion of colorectal can-
cer patients, are underrepresented in clinical trials. If elderly patients are included in trials, these 
are the fit patients without relevant comorbidities and not the frail patients seen in everyday prac-
tice. In the absence of randomized data and the lack of evidence-based treatment guidelines for 
such patients, clinicians are increasingly confronted with the discrepancy between research and 
clinical practice.46 As a result, clinicians may offer suboptimal treatment to these patients, or alter-
natively, expose them to unanticipated risks. Other sources of information are needed to evaluate 
the effects of modern systemic therapy in the subsets of colorectal cancer patients, in whom evi-
dence-based treatment recommendations are currently lacking. 
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The need for population-based studies 
Population-based studies offer insight into the real-world use, tolerability and effectiveness of the 
various systemic treatment options among unselected patients. Such studies may help clinicians 
to bridge the gap of knowledge between selected patients in clinical trials and unselected pa-
tients as encountered in everyday clinical practice.47,48 Concomitant with this awareness, several 
countries worldwide have created large-scale national cancer registries.49 Detailed data on sys-
temic therapy, however, are frequently missing in national cancer registries as such data collection 
is very costly and time consuming, in particular if recurrent disease is taken into account.50 As a 
result, there are virtually no real-life data published which can help medical oncologists  to discuss 
the benefits and drawbacks of the various systemic treatment options with patients. Such data are 
needed, in particular for patients who are currently underrepresented in clinical trials.
Aims and outline of the thesis 
This thesis aims to bridge the gap between clinical studies and daily practice, by providing insight 
into the real-world use, tolerability and effectiveness of the various systemic treatment options 
among unselected patients, in whom evidence is currently lacking. 
The content of this thesis is divided into three parts, with the following main objectives: 
•  To provide insight in the everyday use and tolerability of adjuvant chemotherapy regimens 
and its impact on the palliative systemic treatment of metastases in patients with colon cancer 
(part I).
•  To assess the daily-based use and impact of age on the palliative systemic treatment of 
patients with metachronous metastases from primary resected colorectal cancer (part II).
•  To evaluate the role of currently available treatment options in colorectal cancer patients with 
peritoneal metastases (part III). 
Part I: Adjuvant treatment and subsequent palliative treatment of metastatic colorectal cancer 
In chapter 2, we evaluate the intensity and tolerability of adjuvant chemotherapy regimens 
(CAPOX, CapMono) among elderly stage III colon cancer patients. Detailed insight is provided in 
the completion of all planned cycles, the received cumulative dosage of the prescribed adjuvant 
regimens and its association with grade III-IV toxicities. In chapter 3, we investigate whether these 
adjuvant regimens influence the subsequent choice of palliative chemotherapy in patients with 
metachronous metastases. 
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Part II: The palliative treatment of recurrent metastatic colorectal cancer  
In the next three chapters the use, tolerability and effectiveness of palliative systemic therapy in 
unselected patients with metachronous metastases from colorectal cancer is evaluated. In chapter 
4, we focus on bevacizumab in addition to palliative chemotherapy (chapter 4). The intent of this 
chapter is to provide insight into the actual implementation of bevacizumab in daily practice and 
to identify its role in the treatment of metachronous metastases. In the following two chapters, we 
evaluate the impact of age on the daily-based use and effectiveness of palliative systemic therapy. 
In chapter 5, we provide a detailed overview on the age-related use of first-line palliative systemic 
regimens. Data are presented on the prescribed first-line systemic regimen, initial dosages, the 
number of received cycles and cumulative dosages. In chapter 6, we evaluate the number of pa-
tients accessing second and further lines of treatment and evaluated the total number of received 
systemic agents, in relation to survival. 
Part III: The treatment of peritoneal metastases
The third part of this thesis focuses on the subset of colorectal cancer patients presenting with 
peritoneal metastases and provides evidence for the currently available treatment options. In 
chapter 7, the potential role of bevacizumab in addition to palliative chemotherapy is evaluated in 
patients with synchronous peritoneal metastases. In chapter 8, trends in the use of cytoreductive 
surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) are evaluated. In chapter 9, 
it was evaluated whether the increasing use of both loco-regional and systemic treatment strate-
gies over time resulted in significantly improved survival rates. 
Finally, a summary of the main findings, methodological considerations, and implications of the 
results presented in this thesis were described in the general discussion (chapter 10).
Data sources 
Netherlands Cancer Registry
The Netherlands Cancer Registry (NCR) collects data on all newly diagnosed cancer patients in 
the Netherlands since 1989, covering the entire Dutch population of approximately 17 million 
inhabitants. The NCR comprises 9 administrational regions, each covering 7 to 20 hospitals. These 
regions form a network of health care professionals and institutions for cancer and palliative care 
in the Netherlands. All pathology laboratories participate in the Dutch Pathology Network (PAL-
GA), which subsequently submits the data to the NCR. Trained registration clerks actively collect 
data on diagnosis, patient characteristics, staging and detailed information about initial treatment 
(delivered within 6 months from diagnosis) from the medical records using the registration and 
coding manual of the NCR. In this registration system, the classification of the primary tumour is 
determined by the TNM classification system.3 In case of missing pathologic data, the clinical TNM 
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stage is used. Anatomical site of the tumour is registered according to the International Classifica-
tion of Diseases for Oncology (ICD-O).51 Information on the vital status of the patients is obtained 
from the nationwide municipal personal records database. 
Additional data collection 
Thanks to a grant from The Netherlands Organisation for Health Research and Development 
(grand numbers 113102004,152002012 and 152001022) and an unrestricted grant from Roche, 
additional data could be collected on adjuvant chemotherapy (chapter 2-3) and the development 
and treatment of recurrent disease (chapter 4-6). During 2010-2011, additional data were collect-
ed on the development and treatment of recurrent disease for patients with colorectal cancer 
diagnosed between 2003 and 2008 in the Eindhoven area of the NCR. Metachronous metastases 
were defined as distant metastasis of primary colorectal cancer in other organs, excluding regional 
lymph nodes, diagnosed at least 3 months after initial diagnosis.  
The use of these data sources, reflecting everyday clinical practice, provides us with the opportu-
nity to study the three main objectives as outlined in this introduction.
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Abstract
Purpose: To provide insight in the use, intensity and toxicity of therapy with capecitabine and ox-
aliplatin (CAPOX) and capecitabine monotherapy (CapMono) among elderly stage III colon cancer 
patients treated in everyday clinical practice.
Methods: Data from the Netherlands Cancer Registry were used. All stage III colon cancer patients 
aged ≥70 years diagnosed in the southeastern part between 2005-2012 and treated with CAPOX 
or CapMono were included. Differences in completion of all planned cycles, cumulative dosages 
and toxicity between both regimens were evaluated.
Results: 193 patients received CAPOX and 164 patients received CapMono. 33% (n=63) of the 
patients receiving CAPOX completed all planned cycles of both agents, whereas 55% (n=90) of 
the patients receiving CapMono completed all planned cycles (p<0.0001). The median cumula-
tive dosage capecitabine was lower for patients treated with CAPOX (163,744mg/m2, interquartile 
range [IQR] 83,397-202,858mg/m2) than for patients treated with CapMono (189,195mg/m2, IQR 
111,667-228,125mg/m2, p=0.0003). 54% (n=105) of the patients treated with CAPOX developed 
grade III-V toxicity, whereas 38% (n=63) of the patients treated with CapMono developed grade 
III-V toxicity (p=0.0026). After adjustment for patient and tumour characteristics, CapMono was 
associated with a lower odds of developing grade III-V toxicity than CAPOX (odds ratio 0.54, 95% 
confidence interval 0.33-0.89). For patients treated with CAPOX, the most common toxicities were 
gastrointestinal (29%), haematological (14%), neurological (11%) and other toxicity (13%). For 
patients treated with CapMono, dermatological (17%), gastro-intestinal (13%) and other toxicity 
(11%) were the most common.
Conclusion: CAPOX is associated with significantly more grade III-V toxicities than CapMono, 
which had a pronounced impact on the cumulative dosage received and completion of all planned 
cycles. In this light, CapMono seems preferable over CAPOX.
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Introduction
In the Netherlands, approximately 55% of the patients newly diagnosed with colon cancer are 
aged ≥70 years at the time of colon cancer diagnosis1. Due to demographic developments and 
the introduction of a screening program for colorectal cancer up to 75 years, the number of el-
derly colon cancer patients will increase even further. Despite colon cancer being a disease of the 
ageing, patients aged 70-75 years were underrepresented in clinical trials that established the 
efficacy of adjuvant chemotherapy in stage III colon cancer. Patients aged >75 years may even be 
excluded as, e.g., in the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in 
the Adjuvant Treatment of Colon Cancer (MOSAIC) trial, Xeloda [capecitabine] in Adjuvant Colon 
Cancer Therapy (X-ACT) trial and the National Surgical Adjuvant Breast and Bowel Project (NSABP) 
protocol C-07 trial2-4. 
In the X-ACT trial, 83% of patients receiving capecitabine completed their treatment course, but 
57% required dose modifications. Overall, the toxicity profile of capecitabine was superior to the 
combination of fluorouracil (FU) and leucovorin (LV) with the exception of a greater frequency of 
hand-foot syndrome3. The NSABP C-07 trial showed that serious adverse events and treatment 
discontinuations due to toxicity were more evident with oxaliplatin-containing regimens than 
with a combination of FU and LV alone5. Subgroup analyses of these trials showed that patients 
aged 70-75 years were more likely to discontinue treatment prematurely as compared to younger 
patients4,6. Additionally, dose modifications and reductions were required more often4 and grade 
IV-V toxicity was experienced at a higher rate6. Since these trials were not specifically designed 
for elderly patients, the results may not be applicable to unselected elderly patients treated in 
clinical practice, who are often more vulnerable than elderly patients included in randomised 
clinical trials. Observational studies have shown that elderly patients are less often treated with 
adjuvant chemotherapy and less often receive oxaliplatin-containing regimens7-11. Additionally, 
also in population-based studies, dose reductions and treatment discontinuations were more fre-
quent among elderly7,10. However, with the exception of the study by Kim et al.9, no distinction was 
made between the different single-agent chemotherapies (i.e. capecitabine or FU) and combina-
tion therapy (i.e. FULV and oxaliplatin (FOLFOX) or capecitabine and oxaliplatin (CAPOX))7,8,10. One 
population-based study including colon cancer patients from all ages showed a rapid shift from 
the use of FOLFOX to the use of CAPOX from January 2005 to December 200612. 
To date, little is known about the extent to which elderly patients in daily practice are treated 
with CAPOX or capecitabine monotherapy (CapMono). Moreover, there are hardly any popula-
tion-based studies describing the intensity of and adherence to these adjuvant regimens among 
elderly stage III colon cancer patients in detail. Furthermore, it is unknown to what degree unse-
lected elderly develop toxicity from the various regimens. Therefore, the aim of the current study 
is to provide insight in the use, intensity and related toxicity of both CAPOX and CapMono among 
elderly stage III colon cancer patients treated in everyday clinical practice.
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Methods
Data collection
Data from the population-based Netherlands Cancer Registry (NCR), more specifically from the 
Eindhoven area, were used. This region collects data on all newly diagnosed cancer patients in the 
southeastern part of the Netherlands. The registry area comprises about 2.4 million inhabitants 
(~15% of the Dutch population) and encompasses 10 community hospitals. Information on pa-
tient and tumour characteristics, diagnosis and treatment is routinely extracted from the medical 
records by trained administrators of the cancer registry. Anatomical site of the tumour is registered 
according to the International Classification of Disease – Oncology. The tumour-node-metastasis 
(TNM) classification is used for stage notification of the primary tumour, according to the edition 
valid at time of cancer diagnosis. Comorbidities are registered according to a slightly modified ver-
sion of the Charlson Comorbidity index. The quality of the data is high, due to thorough training of 
the registration team and computerised consistency checks at regional and national levels. 
For the study population, additional data were collected from the medical records by experienced 
registration administrators. This encompassed detailed information on adjuvant chemotherapy: 
regimen and agents, number of cycles received and cumulative dosage of each agent. Depending 
on the hospital in which patients were treated, standard treatment with CAPOX consisted of 6 or 
8 cycles. Standard dosage for each cycle is 2000 mg/m2 capecitabine on days 1-14 and 130 mg/m2 
oxaliplatin on day 1. The next cycle starts at day 21. Standard treatment with CapMono consisted 
of 6 or 8 cycles with each cycle including a dosage of 2000 or 2500 mg/m2 capecitabine on days 
1-14 and the next cycle starting at day 21. Grade III to V toxicity according to the Common Termi-
nology Criteria (CTC) for Adverse Events version 4.0 that appeared after the start of chemotherapy 
and within 3 months after the last day of chemotherapy was also documented. For each toxicity, 
the highest grade that occurred was recorded.
 
Study population
All stage III (pT1-4N1-2M0) colon cancer patients aged ≥70 years who underwent resection and were 
diagnosed between 2005-2012 were included.  Stage was based on the pathological TNM classi-
fication. Tumour localisation was divided into anatomical subsites: proximal colon (C18.0-C18.5), 
distal colon (C18.6-C18.7) and unknown or overlapping subsites of the colon (C18.8-C18.9). 
Statistical analyses
Descriptive statistics were used to provide an overview of the study population by adjuvant che-
motherapy regimen, to give insight in the treatment intensity of both regimens, and to present 
toxicity according to regimen. Multivariable logistic regression analysis was used to assess which 
variables influenced receipt of CAPOX versus CapMono. Variables included in the model were gen-
der, age, comorbidity, American Society of Anaesthesiologists (ASA) score, pathological T, patho-
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logical N, subsite tumour, differentiation grade and period of diagnosis. 
Differences in the number of cycles, cumulative dosages received and completion of all planned 
cycles between both regimens was calculated using Wilcoxon Rank-Sum tests and Χ2-tests as ap-
propriate. Multivariable logistic regression was used to assess which variables influenced comple-
tion of all planned cycles after stratification by regimen. Included in this model were grade III-V 
toxicity and the same patient- and tumour characteristics as listed in the model above. 
For each grade III-V toxicity that appeared in more than 10% of the patients, the association with 
treatment characteristics (completion of all planned cycles, number of cycles, cumulative dosage) 
was investigated after stratification by regimen, using Χ2-tests, Fisher’s Exact Test and Wilcoxon 
Rank-Sum tests as appropriate. Multivariable logistic regression was used to assess the indepen-
dent effect of regimen on grade III-V toxicity after adjustment for gender, age, comorbidity, ASA 
score, pathological T, pathological N, tumour subsite, differentiation grade and period of diagno-
sis. P values below 0.05 were considered statistically significant. SAS/STAT® statistical software (SAS 
System 9.4; SAS Institute, Cary, NC) was used for all analyses. 
Results 
A total of 1156 stage III colon cancer patients aged ≥70 years who underwent resection and were 
diagnosed in 2005-2012, were identified (figure 1). Over the total study period, 35% of the patients 
(n=406) received adjuvant chemotherapy. A large majority (88%, n=357) of the patients who were 
treated with adjuvant chemotherapy received CAPOX or CapMono. The joint proportion of CAPOX 
and CapMono versus other regimens increased over time from 68% in 2005-2006 to 91% in 2007-
2008 to 92% in 2009-2010 and to 98% in 2011-2012 (P<0.0001).
Figure 1  Overview of patients included in the study.
Patients who underwent resection only 
N=750
Stage III (pT1-4N1-2M0) colon cancer 
patients aged ≥70 years, diagnosed in 
2005-2012 who underwent resection.
CAPOX
N=193
CapMono
N=164
FOLFOX
N=31
Other/unknown
N=18
Patients who received adjuvant  
chemotherapy N=406
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Use and intensity of CAPOX and CapMono
One hundred ninety-three patients received CAPOX and 164 patients received CapMono. Table 
1 shows the association between several patient and tumour characteristics and regimen. Older 
patients (75-79 years versus 70-74 years: 35% versus 73%, adjusted odds ratio [OR] 0.17, 95% confi-
dence interval 0.10-0.29 and ≥80 years versus 70-74 years: 14% versus 73%, adjusted OR 0.05, 95% 
CI 0.02-0.17) and patients diagnosed in 2005-2006 (2005-2006 versus 2011-2012: 40% versus 55%, 
adjusted OR 0.38, 95% CI 0.17-0.87) were less likely to receive CAPOX instead of CapMono.
Table 1   Crude percentages and adjusted ORs for receipt of  CAPOX versus CapMono among elderly patients with stage 
III colon cancer treated with CAPOX or CapMono (n=357).
Total number 
of patients
Number & percentage receiving 
CAPOX
OR (95% CI) for receiving 
CAPOX
Gender
   Male
   Female
186
171
109 (59)
  84 (49)
1.00 (reference)
0.73 (0.44-1.21)
Age
   70-74 years
   75-79 years
   ≥80 years
194
134
29
142 (73)
 47 (35)
   4 (14)
1.00 (reference)
0.17 (0.10-0.29)
0.05 (0.02-0.17)
Comorbidity
   0 
   1
   ≥2
   Unknown
99
100
149
9
65 (66)
48 (48)
75 (50)
1.00 (reference)
0.61 (0.31-1.19)
0.64 (0.34-1.21)
ASA score
   I-II
   III-IV
   Unknown
230
49
78
133 (58)
  21 (43)
1.00 (reference)
0.54 (0.26-1.15)
Pathological T
   1-2 
   3
   4
46
255
56
  22 (48)
145 (57)
  26 (46)
0.56 (0.26-1.20)
1.00 (reference)
0.62 (0.31-1.24)
Pathological N 
   1
   2
234
123
124 (53)
  69 (56)
1.00 (reference)
1.51 (0.88-2.57)
Subsite tumour
   Proximal colon
   Distal colon
   Other/NOS
202
150
5
100 (50)
 90 (60)
1.00 (reference)
1.24 (0.73-2.11)
Differentiation grade
   Well/moderate 
   Poor/undifferentiated
   Unknown
247
85
25
140 (57)
 42 (49)
1.00 (reference)
0.73 (0.40-1.34)
Period of diagnosis
   2005-2006
   2007-2008
   2009-2010
   2011-2012
63
89
109
96
25 (40)
56 (63)
59 (54)
53 (55)
0.38 (0.17-0.87)
1.39 (0.68-2.87)
1.07 (0.56-2.03)
1.00 (reference)
CI, confidence interval; NOS, not otherwise specified; OR, odds ratio. Adjusted for all variables listed. Included in the analyses but not shown for comorbidity 
unknown, ASA score unknown, subsite other/NOS and differentation grade unknown. 
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Table 2 provides an overview of the number of cycles received and the cumulative dosage re-
ceived according to regimen. Within the CAPOX regimen, the median number of cycles capecit-
abine received was 7, while the median number of cycles oxaliplatin received was 5. The median 
cumulative dosage capecitabine received was 163,744 mg/m2 and the median cumulative dosage 
for oxaliplatin was 604 mg/m2. In the CapMono regimen, the median number of cycles received 
was 8 and the median cumulative dosage was 189,195 mg/m2. The median number of cycles 
capecitabine did not differ between both regimens (P=0.720), but the median cumulative dosage 
capecitabine received was lower for patients treated with CAPOX than for patients treated with 
CapMono (P=0.0003).
Table 2  Treatment intensity of CAPOX and CapMono among elderly patients with stage III colon cancer treated with 
CAPOX or CapMono.
CAPOX
(n=193)
CapMono
(n=164)
Oxaliplatin Capecitabine Capecitabine
Number of cycles received
   Median
   Interquartile range
   Minimum-maximum
   Unknown
n
5
2 - 7
1 - 8
1
n
7
3 - 8
1 - 8
1
n
8
4 - 8
1 - 8
6
Total dosage received 
   Median
   Interquartile range
   Minimum-maximum
   Unknown
mg/m2
604
261 - 768
109 - 1176
13
mg/m2
163,744
83,397 - 202,858
1,869 - 253,270
13
mg/m2
189,195
111,667 - 228,125
4,980 - 294,329
21
Completion of all planned cycles differed between CAPOX and CapMono (P<0.0001); 33% (n=63) 
of the patients receiving CAPOX completed all planned cycles of both agents, whereas 55% (n=90) 
of the patients receiving CapMono completed all planned cycles. Among the elderly who discon-
tinued CAPOX prematurely, 63% discontinued both oxaliplatin and capecitabine, 31% discontin-
ued oxaliplatin only and 6% discontinued capecitabine only. In a multivariable logistic regression 
model, only the presence of any grade III-V toxicity was independently related to early discontinu-
ation of both CAPOX and CapMono (table 3).
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Table 3   Crude percentages and adjusted odds ratios for completing all planned cycles of CAPOX or CapMono among 
elderly patients with stage III colon cancer.
CAPOX (n=193) CapMono (n=164)
total n n (%) OR (95% CI) total n n (%) OR (95% CI)
Gender
   Male
   Female
109
84
41 (38%)
22 (26%)
1.00 (reference)
0.58 (0.28-1.19)
77
87
47 (61%)
43 (49%)
1.00 (reference)
0.66 (0.33-1.32)
Age
   70-74 years
   75-79 years
   ≥80 years
142
47
4
47 (33%)
16 (34%)
0 (0%)
1.00 (reference)
1.24 (0.56-2.73)
<0.001
52
87
25
31 (60%)
46 (53%)
13 (52%)
1.00 (reference)
0.61 (0.27-1.38)
0.52 (0.17-1.60)
Comorbidity
   0 
   1
   ≥2
65
48
75
19 (29%)
21 (44%)
20 (27%)
1.00 (reference)
1.73 (0.71-4.20)
0.74 (0.31-1.78)
34
52
74
17 (50%)
31 (60%)
40 (54%)
1.00 (reference)
2.38 (0.88-6.45)
1.31 (0.50-3.42)
ASA score
   I-II
   III-IV
133
21
48 (36%)
7 (33%)
1.00 (reference)
0.90 (0.28-2.84)
97
28
53 (55%)
17 (61%)
1.00 (reference)
1.33 (0.47-3.73)
Pathological T
   1-2 
   3
   4
22
145
26
9 (41%)
48 (33%)
6 (23%)
1.72 (0.57-5.14)
1.00 (reference)
0.48 (0.16-1.43)
24
110
30
16 (67%)
59 (54%)
15 (50%)
1.60 (0.56-4.54)
1.00 (reference)
0.78 (0.31-1.96)
Pathological N 
   1
   2
124
69
41 (33%)
22 (32%)
1.00 (reference)
1.27 (0.60-2.69)
110
54
60 (55%)
30 (56%)
1.00 (reference)
1.28 (0.59-2.75)
Subsite tumour
   Proximal colon
   Distal colon
100
90
31 (31%)
31 (34%)
1.00 (reference)
1.01 (0.49-2.08)
102
60
51 (50%)
38 (63%)
1.00 (reference)
1.94 (0.88-4.25)
Differentiation grade
   Well/moderate 
   Poor/undifferentiated
140
42
49 (35%)
10 (24%)
1.00 (reference)
0.62 (0.25-1.55)
107
43
60 (56%)
23 (53%)
1.00 (reference)
0.88 (0.37-2.05)
Period of diagnosis
   2005-2006
   2007-2008
   2009-2010
   2011-2012
25
56
59
53
9 (36%)
19 (34%)
16 (27%)
19 (36%)
0.79 (0.22-2.77)
1.23 (0.50-3.01)
0.55 (0.22-1.38)
1.00 (reference)
38
33
50
43
18 (47%)
21 (64%)
26 (52%)
25 (58%)
0.36 (0.12-1.08)
1.08 (0.34-3.39)
0.85 (0.33-2.19)
1.00 (reference)
Any grade III-V toxicity
   No
   Yes 
88
105
39 (44%)
24 (23%)
1.00 (reference)
0.34 (0.17-0.68)
101
63
65 (68%)
25 (40%)
1.00 (reference)
0.24 (0.11-0.52)
CI, confidence interval; NOS, not otherwise specified; OR, odds ratio. Adjusted for all variables listed. Included in the analyses but not shown for comorbidity 
unknown, ASA score unknown, subsite other/NOS and differentation grade unknown.
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Grade III-V toxicity
An overview of the number and proportion of patients with grade III-V toxicity that occurred per 
regimen is presented in table 4. Overall, 54% (n=105) of the patients treated with CAPOX devel-
oped any grade III-V toxicity, whereas 38% (n=63) of the patients treated with CapMono devel-
oped any grade III-V toxicity (P=0.0026). Additionally, among patients receiving CAPOX as com-
pared to patients receiving CapMono, grade III (53% versus 38%, P=0.0048) and grade IV toxicity 
(8% versus 1%, P=0.0038) occurred more frequently. Only 1 case of grade V toxicity was reported. 
Also in a multivariable logistic regression model, adjusted for  gender, age, comorbidity, ASA score, 
pathological T, pathological N, tumour subsite, differentiation grade and period of diagnosis, was 
CapMono associated with a lower odds of developing any grade III-V toxicity than CAPOX (adjust-
ed OR 0.54, 95% CI 0.33-0.89). The other listed variables were not associated with any grade III-V 
toxicity (results not shown). 
For patients treated with CAPOX, most common toxicities were gastrointestinal (26%, mostly nau-
sea/vomiting and diarrhoea), haematological (14%), neurological (11%) and other toxicity (13%, 
mostly fatigue). For patients treated with CapMono, dermatological (17%), gastrointestinal (13%, 
mostly diarrhoea) and other toxicity (11%, mostly fatigue) were most common.
Table 4   Number and proportion of elderly stage III colon cancer patients with CTC grade III-V toxicities, by chemo- 
therapy regimen.
CAPOX (n=193) CapMono (n=164)
Grade III Grade IV Grade V Total
n (%)
Grade III Grade IV Grade V Total
n (%)
Haematological toxicity 20 7 0 27 (14%) 3 0 1 4 (2%)
Gastrointestinal toxicity 46 4 0 50 (26%) 22 0 0 22 (13%)
Cardiovascular toxicity 11 1 0 12 (6%) 7 0 0 7 (4%)
Pulmonary toxicity 3 0 0 3 (2%) 2 0 0 2 (1%)
Dermatological toxicity 5 0 0 5 (3%) 28 0 0 28 (17%)
Neurological toxicity 21 0 0 21 (11%) 2 0 0 2   (1%)
Renal/genital/urinary toxicity 5 0 0 5   (3%) 2 0 0 2   (1%)
Other toxicity 22 3 0 25 (13%) 17 1 0 18 (11%)
Any toxicity* 103 15 0 105 (54%) 63 2 1 63 (38%)
*In this row, the number of patients in the columns grade III, IV and V do not add up to the number of patients in the column total, because patients can have 
more than one toxicity.
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Associations between treatment intensity and toxicity
Table 5 presents the number of cycles and cumulative dosages received for both regimens according 
to the presence or absence of the most common grade III-V toxicity. For patients treated with CAPOX, 
the cumulative dosage received of both capecitabine and oxaliplatin was lower for patients with 
gastro-intestinal toxicity. Additionally, the received cumulative dosage of capecitabine but not of 
oxaliplatin was higher for patients with neurological toxicity and lower for patients with other tox-
icity (i.e. fatigue). With regard to the number of cycles received, similar results were found, although 
the number of cycles of capecitabine did not differ for patients with or without neurological toxicity, 
while the number of cycles of oxaliplatin received was higher for patients with neurological toxicity. 
For patients treated with CapMono, both the received cumulative dosage of capecitabine and the 
number of cycles was significantly lower for patients with diarrhoea or other toxicity (i.e. fatigue). 
Table 5   Number of cycles and total dosage of CAPOX or CapMono received among elderly patients with stage III colon 
cancer, according to grade III-V toxicity.
CAPOX (n=193) Capecitabine Oxaliplatin
cycles, n 
(median, IQR)
dosage, mg/m2
(median, IQR)
cycles, n 
(median, IQR)
dosage, mg/m2
(median, IQR)
Haematological toxicity 
   Yes
   No
P
5 (2-8)
7 (4-8)
0.174
146,618 (59,484-183,178)
164,281 (90,314-204722)
0.281
3 (2-8)
6 (2-6)
0.555
495 (253-757)
605 (263-768)
0.637
Gastrointestinal toxicity
   Yes
   No
P
3 (1-8)
8 (6-8)
<0.0001
59,783 (28,292-159,636)
176,232 (135,539-209,184)
<0.0001
2 (1-5)
6 (3-7)
<0.0001
254 (129-633)
647 (380-779)
<0.0001
Neurological toxicity
   Yes
   No
P
8 (6 - 8)
7 (3 - 8)
0.130
181,729 (150,520 - 218,169)
163,468   (81,492 - 199,959)
  0.038
6 (5 - 7)
5 (2 - 6)
0.045
648 (524 - 803)
586 (258 - 763)
0.068
Other toxicity
   Yes
   No
P
4 (2-8)
7 (4-8)
0.013
90,550 (55,197-155,556)
166,179 (115,420-202,879)
0.023
4 (2-7)
6 (2-7)
0.278
540 (256-793)
607 (261-767)
0.584
CapMono (n=164) Capecitabine
cycles, n 
(median, IQR)
dosage, mg/m2
(median, IQR)
Gastrointestinal toxicity
   Yes
   No
P
4 (2-8)
8 (5-8)
0.006
86,547 (49,018-168,603)
197,862 (144,763-232,555)
0.0002
Dermatological toxicity
   Yes
   No
P
8 (5-8)
8 (4-8)
0.523
187,314 (145,797 - 231,579)
189,862 (101,030 - 228,125)
0.684
Other toxicity
   Yes
   No
P
5 (2-8)
8 (5-8)
0.024
123,190 (61,222-173,205)
195,654 (139,026-229,150)
0.028
P value indicates significance of the Wilcoxon rank-sum test. IQR, interquartile range.
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Discussion
The aim of this study was to provide insight in the use, intensity and related toxicity of both CAPOX 
and CapMono among elderly stage III colon cancer patients treated in everyday clinical practice. 
This study showed that only 35% of the elderly stage III colon cancer patients received adjuvant 
chemotherapy, which is in line with previous population-based studies from the Netherlands8,13 
but somewhat lower than the 40-50% reported in other international studies7,14. 
In the years included in this study (2005-2012), adjuvant chemotherapy consisted of CAPOX or 
CapMono in 87%, while FU-based regimens were prescribed sparsely. In contrast, 87% received 
FULV in the previous period (1997-2004)15. The use of capecitabine instead of FU in the Nether-
lands is high in comparison to other countries. A population-based study from France including 
patients from all ages showed that almost 95% of the patients receiving chemotherapy, was treat-
ed with either FOLFOX or FULV in 2004-200916. Another French study that only included the year 
2009, showed higher proportions of capecitabine, especially among elderly11. Additionally, a sin-
gle-centre retrospective study suggests that in Canada, regardless of age, FOLFOX was prescribed 
more often than CAPOX in the years 2006-201117. The shift towards capecitabine-based regimens 
in the Netherlands over the last decade is related to the fact that capecitabine-based regimens 
are non-inferior to and less toxic than FU-based regimens3,4, are more convenient for the patient 
and have a more favourable reimbursement policy for hospitals. On the other hand, especially 
among elderly cancer patients in which polypharmacy is common, possible drug interactions with 
capecitabine should be taken into account when deciding on capecitabine administration. For 
example, interaction with anticoagulant coumarin derivates have been previously shown18. How-
ever, in practice, oral anticoagulants are often replaced by dalteparin instead of that the use of 
capecitabine is waived. 
Patients aged ≥70 years were less likely to receive CAPOX instead of CapMono, which is in line with 
previous studies showing that elderly patients were less likely to receive oxaliplatin-containing 
regimens7-11. This most likely reflects the highly debated additional benefit from adding oxaliplatin 
to fluoropyrimidine chemotherapy in elderly patients19-21. One trial in which the effect of the differ-
ent chemotherapy regimens on 3-year disease-free survival are compared among elderly patients 
with colon cancer is now ongoing22.
Elderly patients receiving CAPOX less frequently completed all planned cycles compared to pa-
tients receiving CapMono (33% versus 55%, P<0.0001). Although the median number of capecit-
abine cycles did not differ between regimens, the median cumulative dosage of capecitabine 
was lower for patients who received CAPOX compared to patients who received CapMono. This is 
probably related to the fact that the standard dosage for capecitabine is lower in the CAPOX reg-
imen compared to the CapMono regimen (2000 versus 25000 mg/m2). In addition, increased tox-
icity with the CAPOX regimen can also have impacted the cumulative dosage of capecitabine. The 
38  | Chapter 2
fact that patients treated with CAPOX received a lower median cumulative dosage capecitabine 
than patients treated with CapMono seems counterproductive, as it has been suggested that the 
main benefit from adjuvant treatment is derived from the fluoropyrimidine. 
The proportions of patients completing their adjuvant treatment as described in our study are 
mostly lower compared to currently available studies. Not only in comparison to large phase III 
trials such as the X-ACT trial4 in which 74% of the patients aged 70-75 years completed their treat-
ment course but also compared to other population-based studies including elderly. In the study 
by Kim et al., 51% of patients aged ≥65 years treated with CAPOX or FOLFOX and 23% of the 
patients aged ≥65 years treated with either CapMono or FU-LV completed less than 75% of their 
cycles9. Results from the study by Laurent et al. showed that among patients aged ≥70 years and 
treated with FOLFOX, early discontinuation (i.e. <12 cycles) was present in 33% for 5-FU and in 69% 
for oxaliplatin23. In yet another population-based study, 40% of patients aged ≥65 years discontin-
ued chemotherapy7. No distinction was made in type of adjuvant chemotherapy. We found that 
only the presence of any grade III-V toxicity was independently related to early discontinuation of 
both CAPOX and CapMono. The relationship between toxicity and treatment discontinuation was 
not often investigated in previous studies, except for the study by Kim et al., in which differences 
in treatment discontinuation between patients treated with monotherapy (capecitabine + FU) or 
combination chemotherapy (CAPOX + FOLFOX) according to the presence of non-haematolog-
ical and haematological toxicity was investigated9. A difference was found between both types 
of chemotherapy in discontinuation due to haematological toxicity (3% versus 17% respectively, 
P=0.0004) but no difference in discontinuation due to non-haematological toxicity (28% versus 
34% respectively, P=0.20)9.
Especially for elderly patients with competing causes of death, adjuvant treatment should lead to 
gains in quality of life, symptom control and preserved functional status beyond survival benefit24. 
In this light, and given the uncertain effect of the addition of oxaliplatin on (overall) survival in 
elderly patients19-21, is it important to consider the prevalence of chemotherapy-induced toxici-
ty. Grade III-V toxicity was more evident with CAPOX (54%) than with CapMono (38%). This is in 
line with previous studies showing higher toxicity rates with oxaliplatin-containing regimens5,9. 
Previous studies have shown that the incidence of severe toxicity is not only determined by the 
chemotherapeutic agents itself but also by patient characteristics. The study by Extermann et al.25 
showed that the risk of severe toxicity is significant for any older patient receiving chemotherapy. 
Patient differences in Eastern Cooperative Oncology Group performance status, nutritional status 
and mental status contributed two to three times more than chemotherapy differences to the risk 
of non-haematological toxicity25. The study by Hurria et al. described the importance of a scoring 
system dominated by patient characteristics (based upon a geriatric assessment) in predicting 
chemotherapy toxicity26. Other studies have also shown the impact of geriatric factors on patient 
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selection for (type of ) chemotherapy and risk of toxicity. These factors included for example mal-
nutrition and functional and cognitive impairment27,28.
Among patients treated with CAPOX, mostly oxaliplatin-related toxicity occurred. Especially grade 
III-IV neurological toxicity, i.e. neuropathy, which occurred in 11%, can have a disabling and pro-
longed effect with a major influence on quality of life24,29. In a previous study we reported that 
among patients treated with oxaliplatin, neuropathy-related symptoms are still reported 2 to 11 
years after diagnosis30. 
Another toxicity of concern in the CAPOX regimen is diarrhoea. In our study the rate of gastroin-
testinal toxicity was twice as high with CAPOX compared with CapMono. In a trial comparing con-
tinuous or intermittent chemotherapy (COIN), which included patients with metastatic colorectal 
cancer, has shown that the incidence of grade III-IV diarrhoea was also higher among patients 
receiving CAPOX ± cetuximab compared to patients receiving FOLFOX ± cetuximab31,32. Addition-
ally, another trial in the metastatic setting which included exclusively frail and elderly patients (the 
Fluorouracil, Oxaliplatin, CPT11 [irinotecan]: Use and Sequencing 2 (FOCUS2) trial) reported that 
the overall risk of grade ≥III toxicity was higher with capecitabine compared to FU, with specifi-
cally higher rates of nausea, vomiting, diarrhoea, anorexia and hand-foot syndrome33. As studies 
in the adjuvant setting showed a favourable toxicity profile for capecitabine3,34, literature data are 
discordant. 
In the X-ACT trial, grade III hand-foot syndrome occurred in 17% of the patients receiving capecit-
abine4. In our study, 17% of the patients receiving CapMono developed dermatological complica-
tions such as hand-foot syndrome. In contrast, only 3% of the patients treated with CAPOX devel-
oped dermatological complications. This presumably reflects the lower dosage of capecitabine in 
the CAPOX regimen in comparison with the monotherapy regimen.
The current study also investigated the associations between the most common grade III-V tox-
icity and the median number of cycles and cumulative dosage received. In general, toxicity that 
occurred rapidly was associated with a lower median number of cycles and cumulative dosage 
received, such as gastro-intestinal toxicity (i.e. nausea/vomiting and diarrhoea). Other toxicity was 
cumulative, appeared in a later stage during the treatment course and did not result in lower 
median number of cycles and cumulative dosages received, such as haematological toxicity, neu-
ropathy and hand-foot syndrome. It is also possible that, when these toxicities occur and need 
to be mitigated, cycles are delayed instead of the dosage being reduced or cycles prematurely 
discontinued. 
A limitation of our study is that only grade ≥III toxicity was recorded. Kalsi et al. previously showed 
that  even low grade toxicities can lead to treatment modification and early discontinuation in 
older patients35. 
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In conclusion, still only one third of stage III colon cancer patients aged ≥70 years received adju-
vant chemotherapy. CAPOX is associated with more grade III-IV toxicities than CapMono, which 
had a pronounced impact on treatment intensity as patients receiving CAPOX more often discon-
tinued treatment before all planned cycles were completed and received a lower cumulative dos-
age capecitabine as compared to patients receiving CapMono. As the main benefit from adjuvant 
therapy arises from fluoropyrimidine agents, CapMono seems preferable over CAPOX in elderly 
patients. Of course, effects on recurrence-free survival and quality of life should be taken into ac-
count as well. Nonetheless, the current study provides new insights that will help medical oncolo-
gists to discuss more adequately the benefits and drawbacks of the regimens with elderly patients. 
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Abstract
Background: In the current era of modern adjuvant chemotherapy, treatment of recurrent meta-
static colon cancer presents clinicians with significant challenges. There are no clinical studies or 
population-based data on the impact of adjuvant chemotherapy on subsequent chemotherapy 
choice in patients with metastatic colon cancer.
Methods: All consecutive patients diagnosed in the Eindhoven area between 2003-2008 with 
stage I-III colon cancer were extracted from the Netherlands Cancer Registry. Additional data on 
the development and treatment of metachronous metastases were collected between 2010-2011. 
We evaluated the influence of prior adjuvant chemotherapy on the subsequent type of palliative 
chemotherapy. 
Results: Of the total number of 224 patients who received palliative systemic therapy for the 
treatment of metachronous metastases, 50% were previously exposed to adjuvant chemotherapy 
(n=111). Prior adjuvant therapy was associated with a lower odds for treatment with first-line com-
bination chemotherapy (mostly oxaliplatin-based) if metastases occurred <1 year compared to no 
prior adjuvant therapy (OR 0.3, 95% CI 0.13-0.89). No such differences were observed if metastases 
occurred >1 year after primary tumour diagnosis (OR 0.6, 95% CI 0.30-1.14). 
Conclusion: Oncologists’ choice of palliative chemotherapy is influenced by prior adjuvant ther-
apy. Notably, this trend was observed only if metastases developed <1 year after primary tumour 
diagnosis, which may indicate the feasibility of oxaliplatin reintroduction if metastases develop 
later. Continued investigations into the efficacy and tolerability of this approach are needed. 
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Introduction 
Colon cancer (CC) is one of the most common malignancies in the Netherlands with 10,911 new 
cases in 2015, of who about 3,700 are expected to ultimately die of the disease.1 
Since the 1990s, adjuvant chemotherapy – initially fluoropyrimidine monotherapy and since 2004 
combinations with oxaliplatin – significantly improved the survival rate of patients with resected 
CC. Despite improved cure rates with adjuvant therapy, still a relatively large proportion (20%) of 
the patients with early stage (I-III) CC eventually develops metastases.2 Although some patients 
have isolated metastases suitable for curative surgery, most patients with metastatic CC are in-
curable. For the latter group, treatment generally consists of palliative systemic therapy, aiming to 
prolong overall survival and maintain quality of life. 
At the moment, little is known about the effect of prior adjuvant chemotherapy on the subse-
quent use of different types of systemic therapy. The present study aims to provide insight into 
the impact of prior adjuvant chemotherapy on the subsequent use of different types of palliative 
chemotherapy in a large consecutive series of non-selected CC patients. 
Methods
Patients and data
Data were retrieved from the Eindhoven area of the Netherlands Cancer Registry (NCR), which 
collects data of all newly diagnosed cancer patients in a large part of the Southern Netherlands. 
This area comprises approximately 2.4 million inhabitants (~15% of the Dutch population), six 
pathology departments, ten hospitals and two radiotherapy institutions. Information on patient 
and tumour characteristics are collected from medical records by specially trained registry staff 
after notification by pathologists and medical registration offices. The tumour-node-metastasis 
(TNM) classification is used for stage notification of the primary tumour. Anatomical site of the 
tumour is registered according to the International Classification of Diseases for Oncology (ICD-O). 
Due to thorough training of the registration personnel and computerized consistency checks, 
the quality of the data is high. For the present study, additional data on the development and 
treatment of metachronous metastases were collected between 2010 and 2011 for patients di-
agnosed between 2003 and 2008 with stage I-III CC (n=3721). Metachronous metastases were 
defined as distant metastases of primary CC in other organs, diagnosed at least 3 months after ini-
tial diagnosis. Median time from primary diagnosis to data collection was 5.3 years (range 1.5-8.8 
years). All consecutive patients with metachronous metastases from primary resected stage I-III 
CC (C18.0-C18.9) were selected (n=615). Patients undergoing surgery for metastases (n=147) or 
receiving best supportive care (n=244) were excluded, resulting in a study population of patients 
receiving palliative systemic therapy (n=224, Figure 1).
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Figure 1  Flowchart
primary resected stage I-III colon carcinoma (n=3721)
metachronous metastases (n=615)
Excluded: surgery for metastases (n=147)
Excluded: best supportive care (n=244)
Palliative chemotherapy (n=224)
Statistical analyses
Palliative chemotherapy was classified according to the number (single-agent chemotherapy, 
combination chemotherapy) and type of prescribed cytotoxic agents (oxaliplatin-based, irinotec-
an-based, fluoropyrimidine monotherapy).  Differences in patient and tumour characteristics were 
compared and analyzed using a two-sided Chi2 test or Fisher’s exact test if sample sizes were too 
small. Multivariable logistic regression analyses were used to evaluate the impact of prior adjuvant 
chemotherapy (yes vs. no, model 1), the impact of prior adjuvant therapy according to disease-free 
interval (≤1 year vs. > 1 year, model 2) and the impact of the prescribed adjuvant regimen (oxal-
iplatin-based vs. fluoropyrimidine monotherapy, model 3)  on the type of first-line chemotherapy. 
Adjustments were made for all univariate significant or clinically relevant variables (age, comor-
bidity, primary tumour localization, time from initial CC diagnosis to metastases). P values below 
0.05 were considered statistically significant. SAS/STAT® statistical software (SAS system 9.4, SAS 
Institute, Cary, NC) was used for all analyses. 
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Results
The final study population included 224 patients receiving palliative systemic therapy for meta-
chronous metastases from primary resected stage I-III CC. Mean age was 68 years at time of meta-
chronous metastases diagnosis (SD 9.8), 29% was ≥75 years. Half of the patients (n=111) received 
prior adjuvant chemotherapy.
Patient and tumour characteristics 
In the palliative setting, 120 of the 224 patients received first-line combination chemotherapy (ox-
aliplatin-based n=110, irinotecan-based n=10) and 104 patients received first-line single agent 
chemotherapy with either a fluoropyrimidine (n=79) or irinotecan (n=25). An overview on patient 
and tumour characteristics according to palliative chemotherapy is shown in Table 1.
Type of first-line chemotherapy according to prior adjuvant chemotherapy
Patients who received combination chemotherapy were less often exposed to prior adjuvant che-
motherapy than patients who received single-agent chemotherapy (Table 1; 43% vs 57%, p<0.05). 
This was confirmed in a multivariable regression analysis (table 2; model 1), in which the likelihood 
of combination chemotherapy was significantly lower for patients who received prior adjuvant 
chemotherapy compared to patients who did not (OR 0.4, 95% CI 0.22-0.78). Patients who received 
prior adjuvant chemotherapy were less likely to receive oxaliplatin-based chemotherapy than pa-
tients who did not receive prior adjuvant chemotherapy (OR 0.4, 95% CI 0.23-0.80). These results 
were related primarily to patients who developed metastases ≤1 year after primary tumour diag-
nosis (Table 2; model 2) and who were previously exposed to oxaliplatin (Table 2; model 3). 
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Table 1   Patient and tumour characteristics of patients receiving palliative chemotherapy for metachronous  
metastases from primary resected stage I-III CC (n=224). 
Palliative chemotherapy 
(n=224)
Palliative chemotherapy (n=224)
Single-agent 
CTx
(n=104)
Combination CTx 
(n=120)
Oxaliplatin
based CTx
(n=110)
Irinotecan based 
CTx 
(n=35)
FU
monotherapy
(n=79)
N (%) N (%) p-value N (%) N (%) N (%) p-value
Gender
   Male 
   Female
39 
65
(38) 
(62)
 
50 
70
 
(42) 
(58)
 
0.53 46
64
 
(42) 
(58)
 
10 
20
 
(43) 
(57)
28 
51
(35) 
(65)
0.62
  Age (years)
  <65 
   65-74
   ≥ 75 
27
36 
41
(26) 
(35) 
(39)
43 
52
25
(36) 
(43) 
(21)
<0.01 38 
47 
25
(35) 
(43) 
(23)
21 
13 
1
(60) 
(37) 
(3)
11 
28 
40
(14) 
(35) 
(51)
<0.0001
  Comorbidity*
  0 
   1  
   ≥2 
   Unknown 
32 
29 
32 
11
(31) 
(28) 
(31) 
(11)
41 
36 
38 
5
(34) 
(30) 
(32) 
(4)
0.33 40
31
35
4
(36) 
(28) 
(32) 
(4)
10
10
9
6
(29) 
(29) 
(26) 
(17)
23 
24 
26 
6
(29) 
(30) 
(33)
(8)
0.22
Primary tumour localization
   Proximal colon
   Distal colon
   Other/NOS
58 
41 
5
(56) 
(39) 
(5)
49 
67 
4
(41) 
(56) 
(3)
<0.05
 
45 
61
4
(41) 
(55) 
(4)
20 
13 
2
(57) 
(37) 
(6)
42 
34 
3
(53)
(43)
(4)
0.28
Period of primary tumour 
diagnosis
   2003-2004 
   2005-2006 
   2007-2008
20 
48 
36
(19) 
(46) 
(35)
26 
63 
31
(22) 
(53) 
(26)
0.36 22
59
29
(20) 
(54) 
(26)
8
17
10
(23) 
(49) 
(29)
25 
23 
31
(32) 
(29) 
(39)
0.69
Time to metastases (months)
   ≤12
   12-24
   >24
36 
34 
34
 
(35)
(33) 
(33)
 
36 
41 
43
 
(30) 
(34)
(36)
 
0.75
 
30 
38 
42
(27) 
(35) 
(38)
 
17 
14
4
 
(49) 
(40) 
(11)
 
33 
27 
19
(42) 
(34) 
(24)
 
<0.05
Number of organs affected
   1 organ
   2 organs
   ≥3 organs
44 
34 
26
(42) 
(33) 
(25)
54 
36
30
(45) 
(30) 
(25)
0.89 48
35
27
(44) 
(32) 
(25)
17
8
12
(49) 
(23) 
(29)
33
27
19
(42) 
(34) 
(24)
0.82 
Adjuvant chemotherapy
   No
   Yes
         Combination
         Single-agent
         Missing
45
59
34
21
4
(43)
(57) 
(69) 
(43) 
(8)
68 
52 
27 
21
4
(57) 
(43) 
(52) 
(40) 
(8)
<0.05
0.83
63
47
22
21
4
(57) 
(43)
(47) 
(45) 
(9)
5
30
21
7
2
(14) 
(86) 
(70) 
(23) 
(7)
45
34
18
14
2
(57)
(43)
(53) 
(41) 
(6)
<0.0001 
 
0.35
*comorbidity at primary diagnosis. CTx: chemotherapy 
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Table 2   An overview on type of first-line palliative chemotherapy according to prior adjuvant therapy, adjusted for all 
factors listed below.
Total 
Of which 
combination CTx
Of which
oxaliplatin-based CTx
N (%) OR (95%CI) N (%) OR (95%CI)
Model 1
Adjuvant CTx
No
Yes
113
111
68 (60) 
52 (47)
Ref 
0.4 (0.22-0.78)
63 (56) 
47 (42)
Ref 
0.4 (0.23-0.80)
Model 2
Adjuvant CTx
No 
Yes, metastases ≤ 12 months
Yes, metastases > 12 months
113
30
81
68 (60)
11 (37)
41 (51)
Ref 
0.3 (0.11-0.88)
0.5 (0.23-1.01)
63 (56)
8 (27)
39 (48)
Ref
0.3 (0.10-0.82)
0.5 (0.26-1.09)
Model 3
Adjuvant CTx
Cap/FU
CAPOX/FOLFOX
42 
61
21 (50) 
27 (44)
Ref
0.6 (0.24-1.49)
21 (50) 
22 (36)
Ref 
0.4 (0.14-0.97)
Metastases ≤ 12 months
Cap/FU
CAPOX/FOLFOX
Metastases > 12 months
Cap/FU
CAPOX/FOLFOX
12
16 
 
30
45
6 (50) 
4 (25) 
 
15 (50) 
23 (51)
*
Ref
0.7 (0.24-2.23)
6 (50) 
1 (6) 
 
15 (50) 
21 (47)
* 
 
 
Ref
0.6 (0.21-1.92)
Adjusted for univariate significant or clinically relevant variables; age, comorbidity, primary tumour localization, time to metastases. 
Model 3: results not shown for adjuvant regimen unknown (n=8). 
*multivariate analysis not possible due to limited number of patients 
CTx: chemotherapy; N: number of patients; OR: odds ratio; CI: confidence interval; Cap: capecitabine; FU: fluorouracil; CAPOX: capecitabine-oxaliplatin; FOLFOX: 
fluorouracil-oxaliplatin.
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Discussion
To the best of our knowledge, this is the first population-based study providing insight into the im-
pact of adjuvant chemotherapy on subsequent chemotherapy choice in patients with metastatic 
CC. Prior adjuvant therapy was shown to reduce the probability of receiving first-line combination 
chemotherapy (in particular oxaliplatin-based chemotherapy) if metastases developed ≤1 year, 
but not if metastases developed >1 year after primary tumour diagnosis. 
The present study reflects a period in which adjuvant therapy has been redefined. The benefit of 
adjuvant therapy was established already in the early 1990s.3 In 2004, the addition of oxaliplatin 
to infusional 5-fluorouracil/leucovorin (FOLFOX) was shown to increase 3-year disease free surviv-
al rates from 72.9% to 78.2% (p=0.002).4-7 National guidelines changed, recommending oxalipla-
tin-based therapy as the standard adjuvant therapy in stage III and high-risk stage II CC.8 In 2009, 
the final analysis of data from the MOSAIC trial confirmed these results, with improvements in 
5-year disease-free (73% vs. 67%, p=0.003) and 6-year overall-survival (79% vs 76.0%, p=0.046). 
This improvement in overall survival was observed only in patients with stage III disease (73% 
vs. 69%, p=0.23) Consequently, oncologists have been increasingly confronted with metastatic 
CC patients who were previously treated with adjuvant chemotherapy. In the current study, 50% 
of the patients with metastatic CC received prior adjuvant therapy, of whom 59% were exposed 
to oxaliplatin. In line with Dutch practice guidelines, the majority of patients received oxalipla-
tin-based chemotherapy (mainly CAPOX), whereas fewer patients were treated with single-agent 
chemotherapy (mostly capecitabine).
In the present population-based study with everyday clinical practice data, oncologists’ choice of 
palliative chemotherapy was significantly influenced by prior adjuvant therapy if metastases oc-
curred ≤1 year after primary tumour diagnosis. In these patients, combination chemotherapy was 
less frequently prescribed. Patients were less likely to receive oxaliplatin-based chemotherapy, in 
particular if patients were previously exposed to oxaliplatin. This may be explained by persistent 
troublesome neuropathy and the consideration of refractory disease as metastases occurred 
within 6 months after completion of the adjuvant treatment.9,10 In these cases, irinotecan-based 
chemotherapy (either single-agent or combination chemotherapy) may be considered a good 
alternative, especially since there are no significant difference in terms of efficacy between first-
line irinotecan and oxaliplatin-based chemotherapy, as long as the patient was exposed to all the 
drugs.11,12 Besides, concomitant use of targeted agents may also be considered in the current era 
of evolving targeted therapy, especially since it has been hypothesized that this may prevent or 
reverse resistance to oxaliplatin.13  
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Interestingly, we observed equal proportions of combination chemotherapy and oxaliplatin-based 
chemotherapy if metastases developed more than one year after primary tumour diagnosis, also 
after stratifying for the prescribed adjuvant regimen. Although these results need to be interpret-
ed with caution due to the limited number of patients and the lack of outcome data, it may impli-
cate the feasibility of re-treatment with oxaliplatin after prior adjuvant therapy. Oxaliplatin reintro-
duction has been noted also in the OPTIMOX trials, in which patients with metastatic disease were 
assigned to FOLFOX7 or FOLFOX4 in a stop and go fashion.14,15 Continued investigations into the 
efficacy and tolerability of this approach are merited. 
The retrospective nature of the data collection presents several limitations to this study. At first, 
it should be mentioned that CC patients were included between 2003-2008, although oxaliplatin 
was not considered standard until 2004. Besides, no data could be captured on the reasons (not) 
to prescribe specific regimens. Whether persistent neuropathy or other toxicity was an obstacle 
to re-administration of specific cytotoxic agents is unknown. In addition, quality of life issues and 
overall/disease-free response rates could not be determined. Nevertheless, the present study 
present real-world data providing insight into everyday clinical practice, which is of utmost impor-
tance as it there are currently no randomized data guiding clinicians.
Conclusion
The present consecutive series of primary resected stage I-III CC patients provides insight into 
actual daily practice and shows that oncologists’ choice is significantly influenced by prior adju-
vant therapy. Notably, this trend was observed only if metastases developed <1 year, which may 
indicate the feasibility of oxaliplatin reintroduction if metastases develop later. Continued investi-
gations into the efficacy and tolerability of this approach are needed. 
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Abstract
Background: Although the efficacy of bevacizumab has been established in patients with meta-
static colorectal cancer (mCRC), population-based studies are needed to gain insight into the ac-
tual implementation of bevacizumab in daily practice. Since these studies are lacking for patients 
with metachronous metastases, the aim of this study is to evaluate the current role of bevacizum-
ab in the treatment of metachronous metastases of CRC. 
 
Methods: Data on the use of bevacizumab as palliative treatment of metachronous metastases 
were collected for patients diagnosed with M0 CRC between 2003 and 2008 in the Eindhoven 
Cancer Registry (n=361). Median follow up was 5.3 years. 
Results: 185 patients received bevacizumab in addition to first-line palliative chemotherapy 
(51%), ranging from 36% to 80% between hospitals of diagnosis (p<0.0001). Combined cytostatic 
regimens (CAPOX/FOLFOX in 97%) were prescribed in the majority of patients (63%) and were 
associated with a higher odds for additional treatment with bevacizumab than single-agent cyto-
static regimens (OR 9.9, 95% CI 5.51-18.00). Median overall survival (OS) rates were 21.6 and 13.9 
months with and without the addition of bevacizumab to palliative systemic treatment respec-
tively (p<0.0001). The addition of bevacizumab to palliative chemotherapy was associated with a 
reduced hazard ratio for death (HR 0.6, 95% CI 0.45-0.73) after adjustment for patient- and tumor 
characteristics and the prescribed chemotherapeutic regimen.
Conclusion: Bevacizumab is adopted as a therapeutic option for metachronous metastasized CRC 
mainly in addition to first-line oxaliplatin-based regimens, and was associated with a reduced risk 
of death. The presence of inter-hospital differences in the prescription of bevacizumab reflected 
important differences in attitude and policies in clinical practice. Ongoing efforts should be made 
to further define the position of targeted agents in the treatment of metastatic colorectal cancer.
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Introduction 
Metastatic disease is a common manifestation in patients with advanced colorectal cancer (CRC). 
Approximately one fifth of patients presents with metastasized disease at diagnosis1-3 and 20% of 
patients with initial M0 disease develops metachronous metastases.4
Fluorouracil based palliative chemotherapy has been the mainstay of treatment for many years. 
Over the past decade, the systemic treatment of metastatic CRC (mCRC) has changed consider-
ably. The availability of the cytostatic drugs irinotecan and oxaliplatin has improved the prognosis 
of mCRC patients.5 Moreover, advances in the understanding of molecular oncology have served 
for the development of targeted agents such as the anti-vascular endothelial growth factor block-
ing agent (VEGF-a) bevacizumab. Although the efficacy of bevacizumab has been established in 
patients with mCRC6, the role of bevacizumab in clinical practice remains a topic of debate. Pop-
ulation-based data are useful in reflecting community based practice. To date, no such popula-
tion-based figures of patients with metachronous metastases are available. Therefore the aim of 
this study is to provide population-based data on the use and effect on overall survival of bevaci-
zumab in the palliative treatment of metachronous metastasized CRC in the Netherlands. 
Methods
Patients and data
Data from the population-based Netherlands Cancer Registry (NCR), more specifically from 
the Eindhoven area, were used. The Eindhoven Cancer Registry (ECR) collects data of all pa-
tients with newly diagnosed cancer in a large part of the Southern Netherlands. The ECR cov-
ers an area of approximately 2.4 million inhabitants, six pathology departments, ten hospi-
tals and two radiotherapy institutions. Patient and tumor characteristics are collected from 
medical records by specially trained registry staff after notification by pathologists and medi-
cal registration offices, resulting in high quality of the data. The completeness of cancer regis-
tration is estimated to exceed 95%. In the ECR, primary tumors are classified according to the 
TNM classification of Malignant Tumors by the international Union Against Cancer (UICC), 7th 
edition.7 Additional data were retrospectively collected on metachronous metastases for pa-
tients diagnosed between 2003 and 2008 with stage I-III CRC. Hospitals were asked to partici-
pate in the study by giving permission to use their data from the ECR and by giving permis-
sion for the retrospective registration of additional data. All hospitals voluntarily participated. 
Metachronous metastases were defined as distant metastases of primary CRC in other organs, 
diagnosed at least 3 months after CRC diagnosis. However, the majority of metachronous me-
tastases diagnoses (94%) occurred at least 6 months after CRC diagnosis. Patterns of metastatic 
disease were determined based on the site of metastasis according to the International Classifi-
cation of Diseases for Oncology (ICD-O), which could involve multiple localizations. Median time 
from primary diagnosis to data collection was 5.3 years (range 1.5-8.8 years). All consecutive pa-
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tients with metachronous metastases from primary resected CRC were selected (n=1010). Patients 
diagnosed with metachronous metastases before 2005 (n=100) were excluded as bevacizumab 
is registered and recommended as a therapeutic option in addition to first-line chemotherapy 
in the Netherlands since 2005.8 Subsequently, patients undergoing surgery for metastases were 
excluded (n=232), resulting in a study population treated with palliative intent (n=678) of whom 
361 received palliative chemotherapy (with or without palliative procedures; bypass, anastomosis, 
stoma). These latter patients were categorized into two treatment groups according to the pre-
scription of bevacizumab in addition to palliative chemotherapy (Figure 1). In the current study, 
we focused on the first-line palliative treatment as this is the indication for which bevacizumab is 
registered in the Netherlands. 
Figure 1   An overview on the palliative systemic treatment of metachronous metastases for patients diagnosed between 
2003 and 2008 with stage I-III colorectal cancer in the south of the Netherlands. 
Primary resected stage I-III CRC (N=5671)
Metachronous metastases (N=1010)
Excluding: 
Diagnosis metastases  
<2005 (N=100)
Surgery for metastases (N=232)
Palliative chemotherapy (N=361)
Chemotherapy + bevacizumab (N=185)
Chemotherapy - bevacizumab (N=176) 
Metachronous metastases  with palliative 
treatment intent (N= 678)
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Statistical analysis
Variation in the prescription of bevacizumab between hospitals of diagnosis in the ECR-region 
was assessed using a χ2 test. Also, differences in patient and tumor characteristics and the pre-
scription of bevacizumab between chemotherapeutic regimens were tested by means of a χ2 test. 
To discriminate independent predictors of treatment with bevacizumab, a multivariable logistic 
regression model was used. Adjustments were made for relevant patient and tumor character-
istics: gender, age, comorbidity at time of CRC diagnosis, primary tumor localization, adjuvant 
chemotherapy, time to metastases, period of metastases diagnosis, number of metastases and 
the prescribed first-line chemotherapeutic regimen. In order to limit potential endogeneity bias 
due to the population-based nature of the data, a propensity score matched sample was created. 
Propensity scores were determined with a logistic regression model in which bevacizumab was 
the variable of interest and the independent variables were factors potentially associated with the 
use of bevacizumab (similar to variables taken into account in the multivariable logistic regression 
analysis). Patients were then matched within tight bounds of the propensity scores (probability 
could vary by no more than 1%). Overall survival time was defined as the time from diagnosis of 
the first metachronous metastatic site to death or lost to follow-up. Patients still alive at the end 
of follow-up (January 1st, 2014) and those who emigrated were censored. Crude survival estimates 
according to the prescription of bevacizumab were calculated with the Kaplan-Meier method and 
presented up to 48 months in both the total study population and the propensity score matched 
sample. Median survival (MS) was presented in months and corresponding 95% confidence in-
tervals (CIs). A log-rank test was carried out to evaluate significant differences between survival 
curves. Multivariable Cox regression analyses were performed in both the total study population 
and propensity score matched sample to evaluate the independent effect of additional bevaci-
zumab on the risk of death. Adjustments were made for the clinically relevant variables age, co-
morbidity, localization of primary tumor, adjuvant chemotherapy, time to metastases, period of 
metastases diagnosis, number of metastases, prescribed first-line chemotherapeutic regimen and 
the total number of systemic lines for the treatment of metastases. All analyses were performed 
with SAS/STAT® statistical software (SAS system 9.3; SAS institute, Cary, NC). 
Ethical considerations 
In the Netherlands, the NCR and Dutch hospitals have a formal agreement that all cancer patients are 
informed about registration in the Cancer Registry and the possibility to decline registration. Accord-
ing to the Dutch law, all cancer patients are included in the NCR unless the patient has objected to be 
registered. Therefore, consent of the patient for this specific study was not applicable. 
The NCR retrospectively collects data from medical records and is obligated to work according to 
laws in which the privacy of patients and doctors is fixed in regulations; the law about protection 
of privacy and the law “Geneeskundige BehandelOvereenkomst”. An independent Committee of 
Privacy reassures that the NCR works compliant to these regulations. In the Netherlands, retro-
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spective studies with data collected from medical charts do not fall under the scope of the Medical 
Research Involving Human Subjects Act (‘Wet Medisch-wetenschappelijk Onderzoek”) as patient 
integrity is not violated in these studies. Therefore, this study was exempted from further medical 
ethics review. 
Results
Out of 5671 primary resected stage I-III CRC patients diagnosed between 2003 and 2008, 1010 
patients developed metachronous metastases (18%). In total, 361 patients received first-line sys-
temic therapy for the palliative treatment of metachronous colorectal metastases. Palliative pro-
cedures including a diverting stoma, bypass or anastomosis were performed in a minority of the 
patients (n=18,5%). Bevacizumab was prescribed in 51% of the patients (n=185), with proportions 
varying from 36% to 80% between the 10 hospitals in the ECR region (p<0.0001, Figure 2). An 
overview of patient and tumor characteristics according to the addition of bevacizumab to first-
line systemic therapy is shown in Table 1. 
Figure 2   Proportion of patients receiving first-line palliative chemotherapy plus bevacizumab according to hospital of 
diagnosis (n=361). 
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Patient and tumor characteristics  
Of the 361 patients treated with first-line systemic therapy, 219 patients received combination 
chemotherapy (CAPOX/FOLFOX in 96%) and 142 patients received single-agent chemotherapy 
(capecitabine 74%, irinotecan 20%). Patient and tumor characteristics of patients treated with 
these chemotherapeutic regimens are shown in Table 1. Patients receiving combination chemo-
therapy were younger, had less comorbidities, were more often diagnosed with rectal tumors 
and less often received prior adjuvant chemotherapeutic treatment than patients receiving 
single-agent chemotherapy. Moreover, patients treated with combination chemotherapy more 
frequently received bevacizumab (n=153, 70%) than patients treated with single-agent chemo-
therapy (n=32, 23%, p<0.0001).
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Predictors of treatment with bevacizumab
In multivariable regression analysis including adjustment for the type of prescribed first-line chemo-
therapeutic regimen, several factors were shown to influence the probability to receive additional first-
line bevacizumab (Table 2). It was confirmed that patients treated with combination chemotherapy 
were more likely to receive bevacizumab than patients treated with single-agent chemotherapy (OR 
9.666, 95% CI 5.43-17.05). Moreover, the odds for treatment with bevacizumab was higher for patients 
diagnosed with metastases in a recent time period than patients diagnosed with metastases shortly 
after the introduction of bevacizumab in Dutch guidelines (2005-2006). The probability to receive bev-
acizumab was lower for patients with ≥2 comorbidities than patients without comorbidity (OR 0.4, 95% 
CI 0.21-0.81) No association was observed between age and the use of bevacizumab. However, elderly 
patients (≥ 75 years) were less likely to receive combination chemotherapy (OR 0.2, 95% CI 0.11-0.30). 
 
Table 1   Patient and tumor characteristics according to the addition of bevacizumab to first-line systemic therapy (n=361).
N=361 Without bevacizumab
(n=176)
With bevacizumab
(n=185)
Combination CTx
(n=219)
Single-agent CTx
(n=142)
N (%) N (%) P-value N (%) N (%) P-value
Gender 
  Male
  Female
 
75 
101
 
(43) 
(57)
 
72 
113
 
(41) 
(59)
0.69 126 
93
(58) 
(42)
 
89 
53
 
(63) 
(37)
0.33
Age (years) 
  <60
  60-75 
  ≥75
36 
91 
49
 
(20)  
(52)  
(28)
 
57 
111 
17
 
(31) 
(60) 
(9)
<0.0001 71 
128 
20
 
(32)  
(59)  
(9)
 
24 
72 
46
 
(17) 
(51) 
(32)
<0.0001
Comorbidity 
  No  
  1 comorbid condition 
  ≥2 comorbid conditions 
  Unknown
 
50 
49 
63 
14
 
(28) 
(28) 
(36) 
(8)
 
81
56 
33 
15
 
(44) 
(30) 
(18)
(8)
<0.001 
 
 
0.13
 
38 
36 
52 
14
 
(28) 
(26) 
(36) 
(19)
 
91
66 
44 
18
 
(42) 
(30) 
(20)
(8)
<0.01
 Primary tumor localization
  Rectum
  Colon
68 
108
(39) 
(61)
85 
100
(46) 
(54)
107 
112
(49) 
(51)
47 
95
(33) 
(67)
<0.01
Adjuvant CTx
  No
  Yes
 
103 
73
 
(59) 
(41)
 
100 
85
 
(54) 
(46)
0.34
 
137 
82
 
(63) 
(37)
 
67 
75
 
(47) 
(53)
<0.01
Time to metastases (years)
  < 1 year 
  1-2 years
  ≥ 2 years
 
57 
56 
63
 
(32) 
(32) 
(36)
 
43 
71 
71
 
(23) 
(38) 
(38)
0.12
 
57 
82 
80
 
(26) 
(37) 
(37)
 
42 
46 
54
 
(30) 
(32) 
(38)
0.59
Period of diagnosis 
metastases
   2005-2006 
   2007-2008 
   2009-2011
 
70 
57
49
 
(40) 
(32) 
(28)
 
41 
78 
66
 
(22) 
(42) 
(36)
<0.01
 
69 
83
67
 
(31) 
(38) 
(31)
 
42 
52 
48
 
(30) 
(37) 
(34)
0.81
Number of organs affected 
   1 organ 
   2 organs 
   ≥ 3 organs
 
72 
69 
35
 
(41) 
(39) 
(20)
 
85 
59 
41
 
(46) 
(32) 
(22)
0.29
 
92 
83 
44
 
(42) 
(38) 
(20)
 
65 
44 
33
 
(46) 
(31) 
(23)
0.39
First-line CTx
  Single agent CTx
  Combination CTx
 
110
66
 
(63) 
(37)
 
32 
153
 
(27) 
(83)
<0.0001
Bevacizumab
  Yes
  No
 
153
66
 
(70) 
(30)
 
32 
110
 
(23) 
(77)
<0.0001
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Table 2   Proportion of patients treated with bevacizumab among patients who received chemotherapy, and predictors 
of treatment with bevacizumab in first line, adjusted for all factors listed (n=361). 
N=361 N (%) OR 95% CI
Gender 
  Male
  Female
 
72 
113
 
(49) 
(53)
 
Ref 
1.3
 
 
0.79-2.16
Age (years) 
  <60
  60-74 
  ≥75
 
57 
111 
17
 
(60) 
(56) 
(26)
 
Ref 
1.1 
0.5
 
 
0.61-2.05 
0.22-1.27
Comorbidity 
  No 
  1 comorbid condition 
  ≥2 comorbid conditions 
  Unknown
 
81 
56 
33 
15
 
(62) 
(54) 
(34) 
(48)
 
Ref 
0.8 
0.4 
0.7
 
 
0.42-1.45 
0.21-0.81 
0.27-1.65
Primary tumor localization
    Rectum
    Colon
 
85 
100
 
(55) 
(48)
 
Ref
0.9
 
 
0.37-2.26
Adjuvant chemotherapy 
    No
    Yes 
 
100 
85
 
(49) 
(54)
 
Ref 
1.7
 
 
0.98-2.96
Time to metastases (years)
    < 1 year 
    1-2 years
    ≥ 2 years
 
43 
71 
71
 
(43) 
(55) 
(53)
 
Ref 
1.5 
1.2
 
 
0.78-2.82 
0.60-2.30
Period of diagnosis metastasis
    2005-2006 
    2007-2008
    2009-2011
41 
78 
66
(37) 
(58) 
(57)
Ref 
3.0 
3.3
1.62-5.70 
1.67-6.74
Number of organs affected
    1 organ 
    2 organs 
    ≥ 3 organs
85 
59 
41
(54) 
(46) 
(53)
Ref 
0.5 
0.9
0.29-0.91 
0.46-1.74
First-line chemotherapy
    Single agent chemotherapy
    Combination chemotherapy
 
32 
153
 
(23) 
(70)
 
Ref 
9.6
 
5.43-17.05
N; number of patients receiving bevacizumab in the first-line of systemic treatment. %; percentage of patients receiving bevacizumab in the first-line of systemic 
treatment. OR; odds ratio, CI; confidence interval. 
Survival analysis 
As shown in Figure 3, the addition of bevacizumab to first-line palliative chemotherapy was associat-
ed with an improved median overall survival, from 14 months (95% CI 11-16) to 22 months (95% CI 
19-24) (log rank p<0.0001). In the propensity score matched sample, including 60 patients (with bev-
acizumab n=30, without bevacizumab n=30), comparable results were found with a median overall 
survival of 13 months (95%CI 7.62-18.92) versus 25 months (95%CI 7.62-18.92) (log rank p<0.05). In 
multivariable analysis, the addition of bevacizumab to palliative chemotherapy resulted in a reduced 
hazard ratio on death, in both the total study population (HR 0.6, 95% CI 0.45-0.73) and propensity 
score matched sample (HR 0.3; 95% CI 0.14-.079, Table 3). After stratification for the prescribed first-
line chemotherapeutic regimen, the beneficial effect of the addition of bevacizumab was observed 
in the subset of patients receiving combination chemotherapy (HR 0.6; 95% CI 0.40-0.81), but not in 
patients treated with single-agent chemotherapy (HR 0.9, 95% CI 0.60-1.54). 
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Figure 3  Overall survival according to the addition of bevacizumab to first-line systemic therapy (n=361). 
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Table 3   Multivariable Cox regression analysis modelling the independent effect of additional bevacizumab on the risk of 
death, adjusted for all factors listed. 
Total study population (N=361) Propensity score matched sample (N=60)
HR 95% CI P-value HR 95% CI P-value
Age (years) 
    <60
    60-74 
    ≥75
 
Ref 
1.0 
1.3
 
 
0.76-1.38 
0.87-1.90
 
 
0.86 
0.21
 
Ref 
1.8 
0.8
1.82-4.13 
0.20-3.53
0.15
0.80
Comorbidity 
    No 
    1 comorbid condition 
    ≥2 comorbid conditions 
    Unknown
 
Ref 
0.9 
0.8 
0.7
 
 
0.69-1.22 
0.54-1.04 
0.47-1.17
 
 
0.56 
0.08 
0.19
 
Ref 
1.1 
1.0 
0.6
 
 
0.40-2.86 
0.34-3.01 
0.21-1.98
 
 
0.88 
1.07 
1.00
Primary tumor localization
    Rectum
    Colon
 
Ref
1.3
 
 
1.01-1.65
 
 
<0.05
 
Ref 
0.6
 
 
0.21-1.98
 
 
0.35
Adjuvant CTx 
    No
    Yes 
 
Ref 
1.0
 
0.82-1.34
 
 
0.68
 
Ref 
1.0
 
 
0.44-2.32
 
0.97
Time to metastases (years)
    < 1 year 
    1-2 years
    ≥ 2 years
 
Ref 
1.1 
1.0
 
 
0.87-1.57 
0.72-1.31
 
 
0.28 
0.85
 
Ref 
0.7 
0.4
 
 
0.25-1.87 
0.16-1.22
 
 
0.46 
0.11
Period of diagnosis metastasis
    2005-2006 
    2007-2008
    2009-2011
Ref 
1.1 
1.1
0.81-1.64 
0.78-1.71
0.42 
0.47
Ref 
2.3 
2.5
0.64-8.34 
0.67-9.62
0.20 
0.16 
Number of organs affected
    1 organ 
    2 organs 
    ≥ 3 organs
Ref 
1.2 
1.6
0.96-1.63 
1.12-2.21
0.19 
<0.01
Ref 
1.8 
4.3
0.74-4.78 
1.48-13.00
0.18 
<0.01
First-line CTx    
    Single agent chemotherapy
    Combination chemotherapy
 
Ref 
0.9
 
0.69-1.27
 
 
0.69
 
Ref 
0.2
 
 
0.07-0.49
 
 
<0.001
Additional bevacizumab
    No
    Yes
 
Ref 
0.6
0.49-0.89 <0.01 0.3 0.14-0.79 <0.05
Number of systemic lines 
    1 line
    2 lines 
    ≥ 3 lines
Ref 
0.6 
0.4
0.44-0.84 
0.31-0.58
<0.01 
<0.0001
 
0.5 
0.3
 
0.16-1.74 
0.13-0.72
 
0.29 
<0.01
N; number of patients, HR; hazard ratio, CI; confidence interval
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Discussion 
To our knowledge, this is the first study providing population-based data on the use of bevacizum-
ab in the metachronous setting, which has been suggested to differ from synchronous manifesta-
tion of disseminated disease with respect to tumor biology and prognostics.9-11 Bevacizumab was 
prescribed in approximately half of the patients with metachronous metastases receiving first-line 
palliative treatment between 2005 and 2011 in the southern part of the Netherlands, achieving a 
median overall survival of 22 months. Prescription of bevacizumab varied significantly between 
hospitals of diagnosis and depended on the prescribed chemotherapeutic regimen. 
The inter-hospital variation in the adoption of bevacizumab as observed in our study may reflect 
differences in policy and attitude towards the use of this anti-angiogenic agent in daily practice.12 
Bevacizumab was FDA-approved following the landmark publication by Hurwitz et al in which a 
survival benefit was demonstrated in patients treated with irinotecan, bolus fluorouracil and leu-
covorin (IFL).6 However, by the time bevacizumab was adopted in clinical practice, a shift towards 
oxaliplatin-based chemotherapy had taken place in the Netherlands.13-15 Due to the initial absence 
of efficacy data in addition to these oxaliplatin containing regimens and the controversial results 
that were reported later on16, the role of bevacizumab remained a highly debated topic. Also, the 
recent introduction of antibodies against epidermal growth factor receptors (EGFR)17 strengthened 
the debate, as the question was raised which targeted agent should be preferred in the first-line 
systemic treatment.18 In order to prevent an expanding gap between “believers” and “non-believ-
ers” in the current era of evolving treatment options for mCRC, ongoing efforts are needed to estab-
lish an evidence based opinion on the use of bevacizumab. 
In line with the Dutch guidelines, the majority of patients with metachronous metastases received 
oxaliplatin-based chemotherapy (CAPOX or FOLFOX) whereas fewer patients were treated with 
single-agent chemotherapy (mostly capecitabine). Elderly patients and patients with multiple 
comorbidities were less often considered candidates for treatment with oxaliplatin-based che-
motherapy, reflecting the generally accepted opinion that individual components of a systemic 
regimen should be selected on a number of factors, including patient related factors such as age, 
performance status and comorbidity.19 Moreover, we observed that adjuvant chemotherapy in-
fluenced the choice of chemotherapy for the treatment of metachronous metastases. If adjuvant 
chemotherapy was prescribed, patients were less likely to receive combination chemotherapy as 
palliative treatment. This probably reflects the persistence of troublesome oxaliplatin induced poly-
neuropathy after adjuvant chemotherapy.20 Since 2004, adjuvant oxaliplatin-based chemotherapy 
is considered the standard treatment schedule in the Netherlands for high risk stage II and stage 
III colonic tumors.21,22 For rectal tumors, however, adjuvant chemotherapy is generally not recom-
mended, which probably explains the relatively higher proportion of oxaliplatin-based regimens 
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for the treatment of metastases in this subset of patients. 
The likelihood of treatment with bevacizumab was shown to depend strongly on the prescribed 
chemotherapeutic regimen for the metastatic disease. If a patient was considered a candidate 
for combination-chemotherapy, bevacizumab was prescribed in approximately 70% of the cases. 
On the opposite, if single-agent chemotherapy was prescribed, only 23% of the patients received 
bevacizumab. These findings are in line with results from observational cohort studies in the U.S.13-
15 Of course, it could be speculated that bevacizumab was prescribed in combination with further 
lines of chemotherapy, as the results from the CAIRO III study revealed equal results for combined 
and sequential treatment chemotherapy strategies.23 However, very few patients included in the 
current study received bevacizumab in further lines of treatment (data not shown). 
In accordance with observations from the current literature in which age has been identified as 
one of the most important factors when deciding the type of therapy for patients with mCRC24,25, 
we observed that elderly patients (≥ 75 years) were less likely to receive combination-chemother-
apy than younger patients. However, advanced age did not influence the probability to receive 
bevacizumab if adjustments were made for the prescribed chemotherapeutic regimen. Thus, age 
influenced primarily the choice of cytostatic backbone. This observation reflects the lack of data 
on the benefit-risk ratio of combination-chemotherapy regimens in older patients. It has been 
shown that the bevacizumab related adverse events do not increase with age, except for arterial 
thromboembolic events.26 However, for this complication other patient related factors appeared 
to be stronger predictive factors than age.26 Bevacizumab should therefore be considered a poten-
tial   therapeutic option for elderly patients with mCRC and age alone should not be considered an 
absolute contraindication.27 
The addition of bevacizumab to first-line palliative therapy was associated with a median over-
all survival of 22 months, which is consistent with reports from observational studies on mCRC 
from the period 2002-2007.13-15 Of course, this observed improvement in overall survival with the 
addition of bevacizumab was biased by the prescription of more potential cytostatic backbone 
regimens in the presence of bevacizumab, and by patient selection by the treating physician. 
Nevertheless, after adjustment for important prognostic factors such as the prescribed chemo-
therapeutic regimen, a reduced hazard of death was observed in patients receiving additional 
bevacizumab. Moreover, results remained present in the propensity score matched sample, in 
which an effort is made to limit potential endogeneity bias. After stratification for the type of 
chemotherapy, the beneficial effect of additional bevacizumab achieved significance only in the 
subset of patients treated with combination-chemotherapy, probably because patient numbers 
were too small in the subset of single-agent backbone therapy. Although these non-randomized 
observational data should be interpreted with caution, together with the demonstrated benefit of 
bevacizumab across chemotherapy regimens in several RCTs6,16,28-30 and observational studies13-15, 
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they strengthen the suggestion that bevacizumab is likely to add activity to various chemotherapy 
regimens with which it is combined. 
Despite the accurate and concise patient registration, use of the ECR also implies limitations to 
our data. No data on relevant prognostic factors such as extent of metastatic burden were avail-
able. Moreover, data on patient and tumor characteristics such as comorbidity are registered by 
registration personnel approximately 6-9 months after primary tumor diagnosis. Therefore, it is 
not possible to provide data on the specific comorbidities present at the time of treatment for 
metachronous metastases.
In conclusion, in this population-based study it was revealed that addition of bevacizumab to the 
first line treatment of metachronous metastases of CRC is likely to be an independent beneficial 
factor for overall survival in patients receiving oxaliplatin containing chemotherapy. Moreover, a 
significant inter-hospital difference in the prescription of bevacizumab was found, reflecting dif-
ferences in attitude towards and policies in the use of bevacizumab in clinical practice. Ongoing 
efforts should be made to further define the position of targeted agents in the treatment of meta-
chronous metastases from CRC.
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Chapter 5
“The impact of age on first-line systemic therapy in patients with 
metachronous metastases from colorectal cancer”
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Abstract
Objectives: The paucity of evidence for the optimal use of systemic therapy in elderly patients 
with metastatic colorectal cancer (mCRC) poses significant challenges to cancer specialists. The 
present population-based study provides insight into the impact of age on palliative system-
ic therapy in patients with metachronous metastases from CRC, in order to optimize the deci-
sion-making process.
Methods: Data on the development and treatment of metachronous metastases were collected 
for patients with primary resected CRC diagnosed between 2003 and 2008 in the Eindhoven area 
of the Netherlands Cancer Registry. Patients undergoing surgery for metastases were excluded, 
resulting in a study population treated with palliative intent, with or without systemic therapy 
(n=746).
Results: 385 patients received palliative systemic therapy (52%). Patients aged ≥75 years were 
less likely to receive systemic therapy (31% ≥75 years vs 73% <60 years) and more likely to re-
ceive single-agent chemotherapy than combination-chemotherapy. Elderly patients (≥75 years) 
treated with capecitabine-oxaliplatin (CAPOX) received fewer cycles (51% ≤3 oxaliplatin cycles, 
43% ≤3 capecitabine cycles) and lower cumulative dosages compared to patients aged <75 years, 
although initial dosages were similar. If capecitabine monotherapy (CapMono) was administered, 
starting dosages were 2,414mg/m2/d <75 years and 1,992mg/m2/d ≥75 years (p<0.05), but no 
differences in number of received cycles or cumulative dosages were observed. 
Conclusion: Age beginning at 75 years significantly influenced palliative systemic therapy. Even 
in selected elderly patients, first-line treatment with CAPOX was associated with less cycles and 
lower cumulative dosages compared to younger patients. With single-agent fluoropyrimidine 
therapy, however, no such results were observed.  
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Introduction
Colorectal cancer (CRC) is one of the most common cancers worldwide and currently the third 
most common malignancy in the Netherlands.1 The occurrence of CRC increases with age, with 
54% being 70 years or older and over one third being 75 years or older.1 
Most cancer deaths result from progressive growth of metastases. Metastases are present at the 
time of diagnosis in approximately one fifth of the patients with CRC 2,3 and another relatively large 
proportion (14-34%) develops metachronous metastases during the course of disease.4-6 
Over the past decades, treatment modalities for metastatic CRC (mCRC) have made a substantial 
leap. Although nowadays an increasing proportion of patients with mCRC receive surgical treatment 
with curative intent, the majority of patients are still ineligible for curative treatment modalities 
and remain dependent on palliative treatment. Also, treatment has evolved for these patients. Var-
ious systemic regimens, combining cytotoxic agents and targeted agents, have become available. 
Guidelines on mCRC are based on trials in which the elderly are generally underrepresented.7 Be-
cause ageing is an individual process, treatment recommendations for fit, younger patients cannot 
automatically be extrapolated to older patients. Due to the paucity of evidence for the feasibility 
and optimal use of these systemic regimens in elderly patients with mCRC, decisions on optimal 
management for the growing number of elderly patients with mCRC poses significant challeng-
es to cancer specialists. High quality population-based data, reflecting daily based practice, are 
needed to further optimize the decision-making process. Such data are currently lacking in the 
subset of patients with metachronous metastases from CRC, in which data collection is very time 
consuming and costly. Therefore, the aim of the present population-based study was to provide 
insight into the impact of age on the palliative treatment of metachronous metastases from CRC 
in daily practice. 
Methods
Data collection
Data from the population-based Netherlands Cancer Registry (NCR), more specifically from the 
Eindhoven area, were used. This registry collects data of all patients with newly diagnosed cancer 
in a large part of the Southern Netherlands and comprises approximately 2.4 million inhabitants 
(~15% of the Dutch population), six pathology departments, ten hospitals and two radiotherapy 
institutions. Information on patient and tumor characteristics are collected from medical records 
by specially trained registry staff after notification by pathologists and medical registration offices. 
In this registry, the tumor-node-metastasis (TNM) classification is used for stage notification of 
the primary tumor.8 Anatomical site of the tumor is registered according to the International Clas-
sification of Diseases for Oncology (ICD-O).9 Comorbidity at cancer diagnosis was obtained from 
the medical records and was registered according to a slightly modified version of the Charlson 
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Comorbidity index.10 Data on socioeconomic status were based on individual fiscal data on the 
economic value of home and household income, which was provided at an aggregated level for 
each postal code.11 Due to thorough training of the registration personnel and computerized con-
sistency checks at regional and national levels, the quality of the data is high. Completeness of the 
data is estimated to be at least 95%.12 
For the present study, additional data were retrospectively collected between 2010-2011 on 
metachronous metastases for patients diagnosed between 2003 and 2008 with non-metastatic 
CRC (stage I-III). Hospitals were asked to participate in the study by giving permission to use their 
data from the NCR and by giving permission for the retrospective registration of additional data. 
All hospitals voluntarily participated. Metachronous metastases were defined as distant metas-
tases of primary CRC in other organs, diagnosed at least 3 months after CRC diagnosis. Median 
time from primary diagnosis to data collection was 5.3 years (range 1.5-8.8 years). The additional 
data collection encompassed detailed information on fist-line systemic therapy for metachronous 
metastases, both chemotherapy and targeted therapy; which regimen and agents, dosages, and 
number of cycles of each agent received. In the Netherlands, all hospitals have multidisciplinary 
tumor boards. Nowadays, more than 90% of the patients are discussed in these boards.13 Even 
though geriatricians are present in every hospital, it is unknown whether they were available for 
oncologic consultation. 
All consecutive patients with metachronous metastases from primary resected stage I-III CRC 
(C18.0-C18.9, C190, C209) were selected. Patients undergoing surgery for metastases were exclud-
ed, resulting in a study population treated with palliative intent, with or without systemic therapy. 
Patients were divided into categories according to their age at time of metachronous metastases 
diagnosis and the usage of first-line systemic therapy was assessed. 
Statistical analyses
Descriptive statistics were used to provide an overview on patient and tumor characteristics of the 
total study population (n=746). Variation in the receipt of palliative systemic therapy between age 
categories and hospital of diagnosis was assessed using a χ2 test. Multivariable logistic regression 
analysis was used to assess the independent influence of age on the receipt of palliative systemic 
therapy. Adjustments were made for relevant patient and tumor characteristics: gender, comor-
bidity and socioeconomic status at time of CRC diagnosis, primary tumor localization, adjuvant 
chemotherapy, time to metastases, period of metastases diagnosis, the number of affected organs, 
and hospital of diagnosis. Differences in the received chemotherapeutic backbones between age 
categories were assessed and tested using a χ2 test. Initial dosages (mg/m2/d), cumulative dosag-
es (mg/m2), and the number of received cycles in the first-line of systemic treatment were calcu-
lated for the most frequently prescribed cytostatic agents and regimens; capecitabine-oxaliplatin 
(CAPOX) and capecitabine-monotherapy (CapMono). Univariate linear regression analysis was ap-
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plied to investigate the association between age at time of metastases diagnosis and the received 
initial dosage of cytostatic agents in the most frequently prescribed regimens (CAPOX, CapMono). 
Differences in cumulative dosages (mg/m2) and total number of received cycles between age cat-
egories were tested by means of a Wilcoxon Rank-Sum test. P values below 0.05 were considered 
statistically significant. SAS/STAT® statistical software (SAS system 9.4, SAS Institute, Cary, NC) was 
used for all analyses. 
Ethical considerations 
In the Netherlands, the NCR and Dutch hospitals have a formal agreement that all patients with 
cancer are informed about registration in the Cancer Registry and the possibility to decline reg-
istration. According to the Dutch law, all patients with cancer are included in the NCR unless the 
patient has objected to be registered. Therefore, consent of the patient for this specific study was 
not applicable. 
The NCR retrospectively collects data from medical records and is obligated to work according to 
laws in which the privacy of patients and doctors is fixed in regulations; the law about protection 
of privacy and the law “Geneeskundige BehandelOvereenkomst”. An independent Committee of 
Privacy reassures that the NCR works compliant to these regulations. In the Netherlands, retro-
spective studies with data collected from medical charts do not fall under the scope of the Medical 
Research Involving Human Subjects Act (‘Wet Medisch-wetenschappelijk Onderzoek”) as patient 
integrity is not violated in these studies. Therefore, this study was exempted from further medical 
ethics review. 
Results 
A total of 1007 patients with metachronous metastases from primary resected stage I-III CRC were 
identified. Patients undergoing surgery for metastases were excluded (n=261), resulting in a study 
population of 746 patients treated with palliative intent, with or without systemic therapy (Figure 
1). Mean age at time of metachronous metastases diagnosis was 71.0 years (SD 10.7 years) and 
42% was 75 years or older (n=315). An overview on patient and tumor characteristics is shown in 
Table 1. 
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Figure 1   Overview of patients included in the study.
Primary resected stage I-III CRC 
2003-2008 
N=5671
Metachronous metastases 
N=1007
Palliative treatment of metastases
N=746
Excluded: 
surgery for metastases (n=261)
No palliative systemic therapy 
N=361
Palliative systemic therapy
N=385
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Table 1   Patient and tumor characteristics of the total study population of patients with metachronous metastases from 
primary resected stage I-III CRC treated with palliative intent, with or without systemic therapy (n=746).
Total Palliative systemic therapy
(n=746) Yes (n=385) No (n=361)
N (%) N (%) N (%) p-value
Gender
   Male
   Female
329
417
(44)
(56)
154
231
(40)
(60)
175
186
(48)
(52)
<0.05
Age (years)*
   <60
   60-70
   70-75
   ≥ 75
113
171 
147 
351
(15)
(23) 
(20) 
(42)
83
110 
92 
100
(22)
(29) 
(24) 
(26)
30
61
55
215
(8)
(17) 
(15) 
(60)
<0.0001
Comorbidity 
   No 
   1 comorbid condition
   ≥ 2 comorbid conditions 
   Unknown
 
219 
216 
260 
51
 
(29) 
(29) 
(25) 
(7)
141 
112 
104 
28
 
(37) 
(29) 
(27) 
(7)
 
78 
104 
156 
23
 
(22) 
(29) 
(43) 
(6)
 
<0.0001
Socioeconomic status 
   Low 
   Intermediate
   High
   Institutionalized 
   Unknown
203 
305 
202 
25 
11
(27) 
(41) 
(27) 
(3) 
(1)
86
174
110
7 
8
(22) 
(45) 
(29) 
(2) 
(2)
117 
131 
92 
18 
3
(32) 
(36) 
(25) 
(5) 
(1)
<0.001
Primary tumor localization 
   Rectum
   Colon
276  
470
(37) 
(63)
160 
225
(42) 
(58)
116 
245
(32) 
(68)
<0.01
Adjuvant chemotherapy
   No
   Yes
499 
247
(67) 
(33)
226 
159
(59) 
(41)
273 
88
(76) 
(24)
<0.0001 
Time to metastases (years)
   <1 year
   1-2 years
   ≥2 years
247 
255 
244
(33) 
(34)
(33)
119 
136 
130
(31) 
(35) 
(34)
128 
119 
114
(35) 
(33) 
(32)
0.42 
 
  Period of diagnosis metastases
   2003-2005
   2006-2008 
   2009-2011
162 
380 
204
(22) 
(51)
(27)
77 
197 
111
(20) 
(51) 
(29)
85 
183 
93
(24) 
(51) 
(26)
0.42
  Number of organs affected
   1 organ
   2 organs
   ≥3 organs
388
244
114
(52)
(33)
(15)
168
135
82
(44)
(35)
(21)
220
109
32
(61)
(30)
(9)
<0.0001
* at time of metastases diagnosis.
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The use of palliative systemic therapy 
Of the total number of 746 patients treated with palliative intent, 385 patients received palliative 
systemic therapy (51.6%). Proportions varied significantly between hospitals, in particular in pa-
tients aged ≥75 years (from 17% to 63%, p<0.05, Figure 2). The probability to receive palliative 
systemic therapy decreased with age (73% <60 years vs. 31% ≥75 years, p<0.0001). As illustrated 
in figure 3A, the main decline was observed in patients aged ≥75 years. This was confirmed in a 
multivariate analysis with adjustment for relevant patient and tumor characteristics (Table 2). The 
odds for treatment with palliative systemic therapy was significantly lower in patients aged ≥75 
years compared to patients <60 years (OR 0.2, 95%CI 0.12-0.38, p<0.0001), but no significance was 
achieved in patients aged between 70-75 years compared to patients <60 years (OR 0.6, 95%CI 
0.36-1.16, p=0.14). Besides, presence of comorbidity at initial diagnosis, the number of affected 
organs and hospital of diagnosis were shown to influence the likelihood of treatment with pallia-
tive systemic therapy.
Figure 2   Inter-hospital variation in the prescription of palliative systemic therapy according to age at time of metastases 
diagnosis, A. patients aged <75 years, B. patients aged ≥75 years.
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Table 2   Predictors of treatment with palliative systemic therapy, adjusted for all factors listed (n=746). 
N=746 N (%) OR 95%CI P-value
Gender
   Male
   Female
154
231
(47)
(55)
Ref
1.2
0.90-1.76 0.17
Age (years)*
   <60
   60-70
   70-75
   ≥ 75
83
110 
92 
100
(73)
(64) 
(63) 
(32)
Ref
0.7 
0.6 
0.2
0.40-1.24 
0.36-1.16 
0.12-0.38
0.22 
0.14 
<0.0001
Comorbidity 
   No 
   1 comorbid condition
   ≥ 2 comorbid conditions 
   Unknown
 
141 
112 
104 
28
 
(64) 
(52) 
(40) 
(55)
 
Ref 
0.7 
0.5 
0.6
0.48-1.15 
0.33-0.79 
0.31-1.23
0.18 
<0.01 
0.17
Socioeconomic status
   Low 
   Intermediate
   High
   Institutionalized 
   Unknown
86 
174 
110 
7 
8
(42) 
(57)
(54)
(28) 
(73)
0.8 
1.1 
Ref 
0.5 
2.8
0.53-1.32 
0.77-1.73 
0.18-1.48 
0.60-13.09
0.45 
0.46 
0.22 
0.18
Primary tumor localization 
   Rectum
   Colon
160 
225
(58) 
(48)
Ref 
0.8
0.56-1.14 0.45
Adjuvant chemotherapy
   No
   Yes
226 
159
(45) 
(64)
Ref 
1.2
0.83-1.82 0.29
Time to metastases (years)
   <1 year
   1-2 years
   ≥2 years
119 
136 
130
(48) 
(53) 
(53)
Ref 
1.1 
1.3
0.74-1.69 
0.86-2.11
0.56 
0.18
  Period of diagnosis metastases
   2003-2005
   2006-2008 
   2009-2011
77 
197 
111
(48) 
(52) 
(54)
Ref 
1.1 
1.3
 
0.75-1.69 
0.86-2.11
0.39 
0.25
Number of organs affected
   1 organ
   2 organs
   ≥3 organs
168
135
82
(54)
(55)
(72)
Ref
1.4
2.3
1.03-2.11
1.52-4.21
<0.05
<0.001
Hospital of diagnosis 
   A
   B
   C
   D
   E
   F
   G
   H
   I
   J
 
71 
30 
28 
75 
41 
33 
42 
21 
21 
23
 
(60) 
(63) 
(35) 
(56) 
(53) 
(50) 
(64) 
(48) 
(45) 
(33)
 
Ref 
1.1 
0.3 
0.7 
0.8 
0.4 
1.1 
0.6 
0.5 
0.3
 
 
0.51-2.42 
0.16-0.63 
0.43-1.34 
0.42-1.56 
0.24-0.96 
0.58-2.31 
0.28-1.36 
0.28-1.10 
0.17-0.70
 
 
0.78 
<0.01 
0.35 
0.53 
<0.05 
0.66 
0.23 
0.08 
<0.01
* at time of metastases diagnosis. N; number of patients receiving palliative systemic therapy.  %; percentage of patients receiving palliative systemic therapy. OR; 
odds ratio, CI; confidence interval. 
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First-line systemic therapy
Of the total number of 385 patients receiving palliative systemic therapy, 217 patients (56%) re-
ceived oxaliplatin-combined chemotherapy, with either capecitabine (CAPOX, n=197) or 5-fluoro-
uracil (FOLFOX, n=20). Fluoropyrimidines (capecitabine, 5-fluorouracil) were prescribed as mono-
therapy in approximately one third of the patients (n=125, mostly capecitabine n=115). Irinotecan 
was prescribed in 41 patients (10%), as monotherapy (n=27) or in combination with a fluoropyrim-
idine (CAPIRI or FOLFIRI, n=14). In two patients, only a targeted agent was prescribed. There were 
significant differences in chemotherapy regimens between age categories, as shown in Figure 3B. 
In patients aged 75 years or older there was a strong increase in the use of fluoropyrimidine mono-
therapy (62% ≥75 years versus 9% <60 years) and a decrease in the use of oxaliplatin-containing 
chemotherapy (37% ≥75 years versus 67% <60 years). 
Targeted agents (bevacizumab in 98%) were added to first-line systemic therapy in 45% of the 
patients (n=174) and were prescribed mainly in addition to combination chemotherapy (n=139, 
80%). Only 29% of the elderly patients (≥75 years) received systemic treatment including a target-
ed agent, compared to 55% in patients aged <60 years (p<0.0001).
Figure 3   The use of palliative systemic therapy (A, n=746) and the prescribed chemotherapeutic regimen (B, n=385),  
according to age at time of metastases diagnosis. 
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Initial dosages of chemotherapy
Age did not influence the prescribed initial dosage in patients receiving CAPOX (p=0.64). The me-
dian initial dosage of oxaliplatin was 129mg/m2 (IQR 124-131) and the median initial dosage of 
capecitabine was 1,977mg/m2/d (IQR 1,902-2,034).
For patients receiving CapMono, the median initial dosage of capecitabine was 2,127mg/m2/d 
(IQR 1,901-2,454). The received initial capecitabine dosage decreased with age (p<0.0001). Median 
initial capecitabine dosage was 1,992mg/m2/d (IQR 1,753-2,158) in patients ≥75 years compared 
to 2,414mg/m2/d (IQR 2,047-2,488) in patients <75 years (p<0.0001). 
Cumulative dosages of chemotherapy
Table 3 provides an overview of the cumulative dosage and total number of received cycles ac-
cording to chemotherapy regimen and age at time of metastases diagnosis. Within the CAPOX-reg-
imen, median cumulative dosages of both oxaliplatin and capecitabine were significantly lower in 
patients aged ≥75 years compared to patients aged <75 years (p<0.05). For patients receiving 
CapMono no differences were observed in the received cumulative dosage (p=0.30).
Total number of received chemotherapy cycles
Within the CAPOX regimen, treatment was discontinued significantly earlier in patients ≥75 years 
compared to patients aged <75 years (p<0.05, Table 3). Approximately half of the elderly patients 
(≥75 years) received ≤3 oxaliplatin cycles (51%) and 43% received ≤3 capecitabine cycles, com-
pared to respectively 28% and 21% in patients aged <75 years. In patients treated with CapMono, 
no differences were observed in the received total number of capecitabine cycles between age 
categories (p=0.16).
Table 3   Cumulative dosages and total number of received cycles of cytostatic agents in the first line of palliative  
chemotherapy, according to age at time of metastases diagnosis.
CAPOX CapMono
Oxaliplatin Capecitabine Capecitabine
<75 yrs    ≥75 yrs <75 yrs           ≥75 yrs <75 yrs          ≥75 yrs
N total 162      35 162             35 59             56
Cumulative 
dosage
Median
Interquartile range
Unknown
mg/m2
718
378-796
29
mg/m2 
398 
130-766
0
P-value
0.02
mg/m2
167,741
78,161-305,085 
33
mg/m2
105,217
26,016-256,442 
1
P-value
0.03
mg/m2
138,403
73,454-199,943
9
mg/m2
111,924
60,277-284,591 
9
P-value
0.30
Number of cycles 
Median
Interquartile range
≤3 cycles
3-6 cycles
>6 cycles
Unknown
N (%)
6.0 
3-6
44 (28) 
91 (57)
24 (15) 
3
N (%)
3.0 
1-6
 
18 (51) 
14 (40) 
3 (9) 
0
P-value
0.05
0.02
N (%) 
6.0 
5-12
 
31 (21) 
44 (30) 
72 (49) 
15
N (%) 
6.0 
1-10
 
15 (43) 
6 (17)
14 (40) 
0
P-value
0.10
0.02
N (%) 
5.0 
3-8
20 (38) 
17 (32) 
16 (30) 
6
N (%) 
5.0 
2-11
23 (43) 
9 (17) 
22 (41) 
2
P-value
0.36
0.16
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Discussion
The present population-based study provided insight into the impact of age on palliative sys-
temic therapy in real-life non-trial patients with metachronous metastases from CRC. An age of 
75 years or older significantly influenced the receipt of palliative treatment. Patients aged ≥75 
years were less likely to receive systemic therapy and more frequently received single-agent che-
motherapy than their younger counterparts. If combination chemotherapy (mostly CAPOX) was 
administered, initial dosages were similar but cycles were discontinued earlier, resulting in lower 
cumulative dosages. 
Although metachronous metastases occur in a substantial proportion of patients with CRC, there 
are only few population-based studies focusing specifically on this group of patients.4,6,14 The ma-
jority of these studies focused at one particular site of metastases and neither of these studies 
addressed the use of palliative systemic therapy nor the impact of ageing on systemic treatment. 
In both younger and older patients, palliative systemic therapy aims to reduce tumor load and 
hereby improve or eliminate distressing symptoms.15,16 In addition, systemic therapy improves 
overall survival (OS) and time to progression (progression free survival; PFS).16 The beneficial ef-
fect of adjuvant chemotherapy in colon cancer has shown to be independent of age17 and it is 
expected that this applies also for palliative chemotherapy in the presence of metastases.18 Never-
theless, elderly patients are still likely to be less intensively treated in clinical practice19-21, probably 
due to concerns on safety, tolerability, and efficacy. In a previous population-based study by Ho 
and colleagues less than 50% of the elderly patients (>70 years) received palliative systemic che-
motherapy.22 Similar proportions were observed in a French nationwide study. In this study, 48% 
of the elderly patients with stage IV CRC (≥75 years) received palliative chemotherapy.20 In our 
study with a mean age of 71.0 years (SD 10.7), a decrease in the use of palliative systemic therapy 
was observed with increasing age. The decline was observed mainly in patients aged 75 years or 
more. This was confirmed in a multivariate analysis, in which the probability to receive systemic 
therapy was significantly lower for patients aged ≥75 years compared to patients aged <60 years, 
whereas no significance was observed in patients aged 70-75 years. Only 31% of the patients aged 
≥75 years received palliative systemic therapy, which compares dismal to the proportions report-
ed previously by population-based studies20-22, probably due to differences in patients selection. 
In the present study, only patients with unresectable metachronous metastases were included, 
whereas most population-based studies included all patients with stage IV CRC. Our results indi-
cate that, in daily practice, age over 75 years may be appropriate to define the elderly patients with 
mCRC, which has also been suggested by Kozloff and colleagues.23 Continued investigations are 
needed for this group of patients. 
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Significant inter-hospital variation was observed in the prescription of palliative systemic therapy. 
In patients aged 75 years or more, there was an even more prominent inter-hospital variation with 
proportions varying between 17% and 63%, reflecting the paucity of evidence for systemic treat-
ment in the elderly. Clinical trials conducted in adult populations typically included younger pa-
tients (<65 years), limiting the available evidence for elderly patients in treatment guidelines.24 In 
order to prevent under-usage of chemotherapy in elderly patients, elderly cancer gained more in-
terest over the past decade. It has become clear that enrollment barriers for older patients need to 
be overcome and that older age should be redefined.25 Although numerous solutions have been 
proposed, those that have been implemented have limited success.26 Still, few elderly patients are 
enrolled in clinical trials7 and even if elderly patients are enrolled, they often do not reflect the 
elderly as seen in everyday clinical practice. Future efforts are needed, especially in the current era 
with evolving systemic treatment options. 
Fluoropyrimidines have long been the only available systemic treatment for advanced CRC. Over 
time, chemotherapeutic regimens combining fluoropyrimidines with oxaliplatin or irinotecan 
have emerged as preferable regimens in fit patients with good performance status.27-29 
In the current population-based study, oxaliplatin-containing regimens (mostly CAPOX) were the 
most frequently prescribed first-line cytostatic backbone (56%). A significant decline in the use 
of oxaliplatin-containing chemotherapy was observed in older patients, especially in patients 
aged ≥75 years (37%). If oxaliplatin-containing regimens were prescribed, similar initial dosag-
es were prescribed in younger and older patients. In line with treatment guidelines30, oxaliplatin 
and capecitabine dosages were respectively 130mg/m2 and 2000mg/m2/d. Cumulative dosages 
within the CAPOX regimen were significantly lower in patients ≥75 years compared to patients 
<75 years. Oxaliplatin was discontinued ≤3 cycles in 51% of the patients aged ≥75 years and also 
capecitabine was discontinued earlier in patients aged ≥75 years compared to patients <75 years. 
These results align with the highly debated clinical benefit of first-line doublet regimens in elderly 
patients. Results from trials establishing the evidence for first-line doublet- regimens were not 
validated in elderly patients, resulting in an initial lack of evidence.27,28 Ever since, several studies 
have attempted to further  explore the role of first-line doublet regimens in the elderly but still, 
data remain controversial.18,31-36. In the Focus2 trial, the addition of oxaliplatin to capecitabine/5-FU 
improved response rate but failed to significantly improve PFS in frail or unfit patients.34 In a recent 
meta-analysis, doublet-chemotherapy was associated with a modest benefit in terms of PFS, but 
no benefit in OS.36 Irinotecan containing regimens (CAPIRI/FOLFIRI) have been associated with 
increased toxicity in elderly patients35,36 and according to the French randomized phase III trial 
(FFCD 2001-02) there are no PFS or OS data justifying this increase in toxicity.37 Also on a popula-
tion-based level, the addition of intravenous chemotherapy has been associated with increasing 
adverse effects in elderly patients with CRC patients.38
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Within the CapMono regimen, initial prescribed dosages were lower in elderly patients. Median 
initial capecitabine dosages were 2,414 mg/m2/d in patients <75 years compared to 1,992 mg/
m2/d in patients ≥75 years, probably reflecting toxicity concerns. Initial evidence on the efficacy 
and tolerability of capecitabine compared to conventional 5-FU was established with capecitabine 
dosages of 1250mg/m2/bi-daily.39 In the FOCUS2 study with elderly and frail patients, however, 
80% of the standard licensed dosages were prescribed (CapMono 1000mg/m2/bi-daily, CAPOX 
800mg/m2/bi-daily) and even then, higher toxicity and lower quality of life was observed with 
capecitabine.34 Capecitabine was specifically associated with increased rates of nausea, vomiting, 
diarrhea, anorexia and hand-foot syndrome.34 Despite the differences in prescribed initial dosages 
between elderly and younger patients, the current study did not observe differences in either the 
cumulative capecitabine dosage or the total number of received cycles. Thus, the higher starting 
dosage (1250mg/m2/bi-daily) as prescribed in younger patients (<75 years) did not result in higher 
cumulative dosages. Besides, our data demonstrate that even selected elderly patients (≥75 years) 
receiving CAPOX often discontinued treatment early, whereas this was not the case if CapMono 
was administered. Continued investigations are needed to predict toxicity in elderly patients with 
cancer. Instruments such as geriatric assessments may be helpful to measure independent clinical 
predictors of morbidity and mortality in older adults40, such as cognitive function and autonomy.41
Targeted agents (mostly bevacizumab) were prescribed in 29% of the elderly patients (≥75 years) 
compared to 51% in patients<75 years. Targeted agents were added primarily to combined-cyto-
static regimens, which were administered mainly to younger patients. In 2005 bevacizumab was 
introduced and recommended for the treatment of stage IV CRC in the Netherlands. At that time, 
evidence on the use of bevacizumab was derived mainly from studies that recruited primarily 
younger patients.42,43 Nowadays, several trials44 and observational studies23,45 have shown similar 
improved PFS and OS rates also in elderly patients (>65 years). Therefore, the addition of bevaci-
zumab has become standard.45
The non-randomized nature of this study obviously presents a potential risk of bias. Relevant pa-
tient characteristics such as comorbidity and socio-economic status were registered only at initial 
CRC diagnosis. Moreover, performance score and the reasons (not) to prescribe systemic therapy 
were often not noted in patient charts and as a result, these data were not useful. Despite these 
limitations, this large population-based study has the advantage to avoid selection bias by includ-
ing a long-term series of consecutive patients. Moreover, all data were collected by independent 
registration clerks which prevents bias that may occur when data collection relies on clinicians. 
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Conclusion
In daily practice, age beginning at 75 years was shown to influence palliative systemic treatment 
of metachronous mCRC. In the selected group of elderly patients (≥75 years) receiving combi-
nation-chemotherapy (CAPOX), first-line systemic treatment was discontinued earlier compared 
to younger patients, resulting in lower cumulative dosages of both cytostatic agents. Within the 
CapMono regimen, however, no differences were observed in either the received number of cycles 
or the received cumulative dosage, despite lower starting dosages in elderly patients. 
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Abstract
Background: Although the spectrum of systemic treatment for metastatic colorectal cancer 
(mCRC) has widened, there is a paucity of evidence for the feasibility and optimal use of these 
systemic agents in elderly patients. The present study provides real-world data on the age-related 
systemic treatment and survival of CRC patients with non-resectable metachronous metastases. 
Methods: All consecutive patients with non-resectable metastases from primary resected CRC 
were extracted from the Eindhoven area of the Netherlands Cancer Registry (NCR). Patients re-
ceiving palliative systemic therapy were enrolled (n=385). Systemic treatment and survival were 
analyzed according to age at diagnosis of metastases.
Results: Patients aged ≥75 years more often received first-line single-agent chemotherapy than 
their younger counterparts (63% vs. 32%, p<0.0001). First-line single-agent chemotherapy was 
often prescribed without additional targeted therapy (78%). Advanced age (≥75 years) was asso-
ciated with a lower probability of receiving all active cytotoxic agents compared to patients aged 
<60 years at time of diagnosis of metastases (OR 0.2, 95% CI 0.10-0.77). In a multivariable Cox re-
gression analysis with adjustment for age and other relevant prognostic factors, the total number 
of received systemic agents was the only predictor of death (HR 0.7, 95% CI 0.61-0.81). 
Conclusion: The beneficial effect of treatment with all active systemic agents on survival (simul-
taneously or sequentially prescribed) should be taken into account when considering systemic 
therapy in patients with mCRC. In light of our results, future studies are warranted to clarify the role 
of potential targeted therapy in elderly mCRC patients, who are often not candidates for combina-
tion chemotherapy and treatment with all active cytotoxic agents. 
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Introduction
Colorectal cancer (CRC) is the second most lethal cancer in the Netherlands. Most cancer-related 
deaths result from the progressive growth of metastases, which are present at time of diagnosis 
in approximately 20% of the patients1-3 or occur during the course of disease in another 14-34% 
of the patients.4-8 
Since the late 1990’s, the spectrum of systemic treatment in metastatic CRC (mCRC) has widened. 
Various systemic regimens combining fluoropyrimidines, oxaliplatin and irinotecan have become 
available, and more recently different monoclonal antibodies were introduced including bevaci-
zumab, cetuximab and panitumumab. 
The use of targeted therapy in addition to the available cytotoxic agents has been positively asso-
ciated with survival.9,10 The feasibility and optimal sequence of the administration of these system-
ic agents in elderly patients, however, is unclear. With the traditional underrepresentation of elder-
ly patients in clinical trials11, randomized data are scarce. High quality real-life studies are needed 
as the increasing proportion of elderly mCRC patients poses significant challenges to cancer spe-
cialists. The aim of the current study was to provide insight into the impact of age on the systemic 
treatment and survival of patients with unresectable metachronous metastases from CRC outside 
the setting of a randomized clinical trial. 
Methods
Data collection
Data from the population-based Netherlands Cancer Registry (NCR), more specifically from the 
Eindhoven area, were used. This registry records data on all patients with newly diagnosed cancer 
in the southern part of the Netherlands, an area with approximately 2.4 million inhabitants (~15% 
of the Dutch population), six pathology departments, ten hospitals and two radiotherapy insti-
tutions. Information on patient and tumor characteristics are collected from medical records by 
specially trained registry staff after notification by pathologists and medical registration offices, 
resulting in high quality of the data. In the NCR, primary tumors are classified according to the TNM 
classification of Malignant Tumors by the international Union Against Cancer (UICC), 7th edition.12 
Anatomical site of the tumor is registered according to the International Classification of Diseases 
for Oncology (ICD-O). A slightly modified version of the Charlson comorbidity index was used to 
register comorbidities. 
For the present study, additional data were retrospectively collected between 2010 and 2011 on 
metachronous metastases for patients diagnosed between 2003 and 2008 with non-metastatic 
CRC (stage I-III). Hospitals were asked to participate in the study by giving permission to use their 
data from the NCR and by giving permission for the retrospective registration of additional data. 
Metachronous metastases were defined as distant metastases of primary CRC in other organs, di-
agnosed at least 3 months after CRC diagnosis. Median time from primary diagnosis to data collec-
tion was 5.3 years (1.5-8.8 years). The additional data collection encompassed detailed information 
on systemic therapy, both chemotherapy and targeted therapy. 
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All consecutive patients with metachronous metastases from primary resected stage I-III CRC 
(C18.0-C18.9 , C190, C209) were selected (n=1007). Patients undergoing surgery for metastases 
(n=261) or only supportive care (n=361) were excluded for the present study, resulting in a study 
population of patients treated with palliative systemic therapy (n=385). Patients were divided into 
categories according to their age at time of metachronous metastases diagnosis (<60 years, 60-
75 years, ≥75 years) and palliative systemic treatment was assessed according to the number of 
received systemic agents and systemic treatment lines. 
Statistical analyses
Descriptive statistics were used to provide an overview on patient and tumor characteristics of the 
total study population (n=385). First-line systemic regimens were categorized according to the 
number of prescribed cytotoxic agents (single-agent chemotherapy, combination-chemother-
apy) and the additional prescription of targeted therapy. Variation in the use of these systemic 
regimens between age categories was assessed using a χ2 test. Duration of first-line treatment was 
calculated and presented as median duration in months. Differences in first-line duration between 
age categories were assessed and tested using a Wilcoxon Rank-Sum test. Subsequently, propor-
tions of patients receiving second-line systemic therapy were calculated and a multivariable logis-
tic regression analysis was applied to investigate the independent influence of age on the receipt 
of second-line therapy. Adjustments were made for relevant patient and tumor characteristics: 
gender, comorbidity and socioeconomic status at time of CRC diagnosis, primary tumor localiza-
tion, adjuvant chemotherapy, time to metastases, period of diagnosis of metastases, follow-up 
time since metastases diagnosis, the number of affected organs and the prescribed first-line reg-
imen. This model was also applied to investigate the influence of age on the odds of exposure to 
all three active cytotoxic agents.  
Overall survival time was defined as the time from diagnosis of the first metachronous metastatic 
site to death or lost to follow-up. Patients still alive at the end of follow-up (February 1st, 2016) and 
those who emigrated were censored. Crude survival estimates were calculated for both the total 
study population and according to age with the Kaplan-Meier method; crude survival rates were 
presented up to 48 months. A log-rank test was carried out to evaluate differences between sur-
vival curves. Median survival (MS) was presented in months and corresponding 95% confidence 
intervals (CIs). Multivariable Cox regression analyses were used to identify independent prognos-
tic factors. Adjustments were made for clinically relevant variables that were applied in the multi-
variable logistic regression analysis, also including the total number of received systemic agents. 
P values below 0.05 were considered statistically significant. SAS/STAT® statistical software (SAS 
system 9.4, SAS Institute, Cary, NC) was used for all analyses. 
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Results 
In total, 385 patients received palliative systemic therapy for the treatment of metachronous me-
tastases from primary resected CRC. Mean age at time of metachronous metastases diagnosis was 
67.5 years (SD 10, range 26-90 years). An overview of patient and tumor characteristics is shown 
in Table 1. 
Table 1   Patient and tumor characteristics of the total study population of patients with metachronous metastases from 
primary resected stage I-III CRC treated with palliative systemic therapy (n=385).
N=385 N (%)
Gender
   Male
   Female
154
231
(40)
(60)
Age (years) at time of metastases diagnosis
   <60
   60-75
   ≥ 75
83
202 
100
(22)
(52) 
(26)
Comorbidity at primary CRC diagnosis
   No 
   1 comorbid condition
   ≥ 2 comorbid conditions 
   Unknown
 
141 
112 
104 
28
 
(37) 
(29) 
(27) 
(7)
Socioeconomic status at primary CRC diagnosis
   Low 
   Intermediate
   High
   Institutionalized 
   Unknown
86 
174 
110 
7 
8
(22) 
(45) 
(29) 
(2) 
(2)
Primary tumor localization 
   Rectum
   Colon
160  
225
(42) 
(58)
Adjuvant chemotherapy
   No
   Yes
226 
159
(59) 
(41)
Time to metastases (years)
   <1 year
   1-2 years
   ≥2 years
247 
255 
244
(31) 
(35)
(34)
  Period of diagnosis of metastases
   2003-2005
   2006-2008 
   2009-2011
77 
197 
111
(20) 
(51)
(29)
  Number of organs affected
   1 organ
   2 organs
   ≥3 organs
168
135
82
(44)
(35)
(21)
 CRC; colorectal cancer.
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First-line systemic therapy
Table 2 provides an overview on the palliative systemic treatment of metachronous metastases 
from primary resected CRC. Of the total number of 385 patients, 60% received first-line combina-
tion chemotherapy (of which 94% oxaliplatin-based) and 40% received single-agent chemother-
apy (of which 82% fluoropyrimidines). Targeted agents (mostly bevacizumab) were prescribed in 
174 patients (45%), primarily in addition to combination chemotherapy. Significant differences in 
first-line systemic regimens were observed between age categories; elderly patients (≥75 years) 
more often received single-agent chemotherapy than their younger counterparts (63% ≥75 years 
vs 27% <60 years).
Median duration of first-line treatment was 3.6 months (IQR 1.3-8.4). Significant differences in first-
line treatment time were observed between age categories, with respectively 4.1 months (IQR 
2.06-11.72) in patients <60 years, 3.6 months (IQR 1.57-8.37) in patients aged 60-75 years and 3.4 
months (IQR 0.68-7.59) in patients aged ≥75 years. 
Table 2   Palliative systemic treatment of metachronous metastases from primary resected CRC, according to age at 
diagnosis of metastatic disease (n=385). 
Total  
N=385
<60 yrs 
N=83
60-75 yrs 
N=202
≥75 yrs 
N=100
N (%) N (%) N (%) N (%) p-value
First-line
  Single-agent CTx
    + targeted therapy
    - targeted therapy
  Combination CTx
    + targeted therapy
    - targeted therapy
 
154 
  34 
 120 
231
140 
  91
 
(40) 
(22) 
(78) 
(60) 
(61) 
(39)
 
22 
5 
17 
61 
41 
20
 
(27) 
(23) 
(77) 
(73) 
(67) 
(33)
 
69 
21 
48 
133 
78 
55
 
(34) 
(30) 
(70) 
(66) 
(59) 
(41)
 
63 
8 
55 
37 
21 
16
 
(63)
(13)
(87) 
(37) 
(57) 
(43)
<0.0001
0.04 
 
0.45
 Total treatment 
 Cytotoxic agents
    1
    2
    3
117
184
84
(30)
(48)
(22)
17
36
30
(21)
(43)
(36)
46
111
45
(23)
(55)
(22)
54
37
9
(54)
(37)
(9)
<0.0001
 Targeted agents 
    0
    1
    2
169 
190 
26
(44) 
(49) 
(7)
 
27 
48 
8
 
(32) 
(58) 
(10)
 
79 
107 
16
 
(39) 
(53) 
(8)
 
63 
35 
2
 
(63) 
(35) 
(2)
 
<0.001
CTx=chemotherapy; cytotoxic agents: fluoropyrimidines (fluorouracil/capecitabine), oxaliplatin, irinotecan; Targeted agents: anti-VEGF (bevacizumab), anti-EG-
FR (cetuximab/panitumumab). 
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Second and further lines of systemic treatment
Less than half of the patients (40%) received second-line therapy (n=154, Figure 2a). With increas-
ing age, the proportion of patients receiving secondary treatment decreased, from 55% in patients 
<60 years to 26% in patients aged ≥75 years (p<0.0001, Figure 2b). This was confirmed in a multi-
variable analysis (Table 3) in which patients aged ≥75 years at time of metachronous metastases 
diagnosis were less likely to receive second-line treatment than patients aged <60 years (OR 0.3, 
95% CI 0.16-0.80).
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Figure 2   Proportion of patients receiving second and further lines of systemic treatment (a), according to age at time of 
diagnosis of metachronous metastases (b)  (n=385). 
≥
Figure 1   First-line chemotherapeutic regimens according to age at time of diagnosis of metachronous metastases 
(n=385). 
102  | Chapter 6
Total number of received systemic agents during treatment course 
-Cytotoxic agents
Fluoropyrimidines were prescribed at any time during treatment course in 93% of the patients 
(mostly capecitabine), whereas oxaliplatin and irinotecan were prescribed in respectively 61% and 
37%. A minority of the patients (22%) were exposed to all three cytotoxic agents (Table 2). Ad-
vanced age (≥75 years) was associated with a lower probability to receive all three active cytotoxic 
agents compared to patients aged<60 years at time of metastases diagnosis (OR 0.2, 95% CI 0.10-
0.77, Table 3). Patients receiving first-line combination chemotherapy were more likely to receive 
all three cytotoxic agents than patients treated with first-line single-agent chemotherapy (OR 7.1, 
95% CI 3.16-16.11). 
-Targeted agents 
In total, 56% of the patients received additional targeted therapy during their course of disease 
(n=216). Over time, the use of targeted therapy increased from 30% in 2003-2005 to 64% in 2009-
2011. This trend was observed regardless of age, although in elderly patients (≥75 years) propor-
tions increased primarily since 2009 whereas the increase in younger patients was observed already 
since 2005. Overall, proportions were significantly lower in patients aged ≥75 years (37%,Table 2). 
Bevacizumab was the most frequently prescribed targeted agent (n=207), which was added pri-
marily to first-line systemic therapy (81%). Epidermal growth factor (EGFR) inhibitors (cetuximab/
panitumumab) were administered to 35 patients (9%), mainly in addition to second-line treat-
ment(n=23). 
Survival and predictors of death 
Median overall survival (OS) of the total study population was 16.6 months (95% CI 14.42-19.19). 
Significant differences in OS time were observed between age categories, with respectively 14.2 
months (95% CI 11.33-16.69) in patients ≥75 years and 20.3 months (95% CI 13.96-22.60) in pa-
tients <60 years (p<0.01). After adjustment  for relevant patient and tumor characteristics and 
treatment variables (first-line systemic therapy, number of exposed systemic agents) advanced 
age (≥75 years) was no longer significantly associated with OS (HR 1.3, 95% CI 0.90-1.86, p=0.16). 
Although significant in univariate analysis (HR 0.7, 95% CI 0.57-0.86, p<0.01), first-line combination 
chemotherapy also did not achieve significance in multivariate analysis (HR 1.2, 95% CI 0.86-1.56, 
p=0.33), but the number of exposed systemic agents remained significantly associated with OS 
(HR 0.7, 95% CI 0.61-0.81, P<0.0001).
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Table 3   Predictors of treatment with second-line treatment and exposure to all three available cytotoxic agents, adjust-
ed for all factors listed (n=385). 
Second-line treatment All three active cytotoxic drugs
N=385 (%) OR 95% CI P-value (%) OR 95% CI P-value
Gender
   Male
   Female
(40)
(40)
Ref
0.9
0.54-1.44 0.62 (23)
(21)
Ref
0.9
0.10-0.70 0.84
Age (years) 
at  time of metastases diagnosis
   <60
   60-75
   ≥ 75
(55)
(41) 
(26)
Ref
0.6 
0.3
0.32-1.09 
0.16-0.81
0.09 
<0.05
(36)
(22) 
(9)
Ref
0.5 
0.2
0.27-1.05 
0.10-0.77
0.42 
<0.01
Comorbidity 
at primary CRC diagnosis
   No 
   1 comorbid condition
   ≥ 2 comorbid conditions 
   Unknown
 
(46) 
(36) 
(34) 
(50)
 
Ref 
0.7 
0.9 
1.0
 
 
0.40-1.31 
0.49-1.78 
0.38-2.61
 
 
0.28 
0.83 
0.99
 
(26)
(21) 
(18) 
(21)
 
Ref 
0.9 
1.2 
0.8
 
 
0.46-1.81 
0.56-2.58 
0.24-2.40
 
 
0.80 
0.63 
0.64
Socioeconomic status 
at primary CRC diagnosis
   Low 
   Intermediate
   High
   Institutionalized
(38) 
(40) 
(42) 
(57)
1.2 
1.0 
Ref
2.4
0.65-2.49 
0.63-1.89 
 
0.39-14.98
0.48 
0.75 
 
0.33
(20) 
(24) 
(19) 
(29)
1.3 
1.4 
Ref
2.8
0.59-3.07 
0.73-2.78 
 
0.35-22.97
0.46 
0.29 
0.32
Primary tumor localization 
   Rectum
   Colon
46) 
(36)
Ref
0.8
0.46-1.24 0.27 (27) 
(18)
Ref 
0.8
0.47-1.56 0.62
Adjuvant chemotherapy
   No
   Yes
(39) 
(42)
Ref 
1.0
0.51-1.41 0.90 (24) 
(19)
Ref 
0.8
0.47-1.56 
0.57
Time to metastases (years)
   <1 year
   1-2 years
   ≥2 years
(40) 
(49) 
(31)
Ref
1.5
1.0
0.85-2.80 
0.49-1.83
0.14 
0.87
(25) 
(29) 
(12)
Ref
1.6 
0.7
0.81-3.12
0.32-1.68
0.18 
0.47
Period of diagnosis of metastases
   2003-2005
   2006-2008 
   2009-2011
(47) 
(46) 
(25)
Ref 
1.0 
0.6
 
0.57-1.97 
0.28-1.28
 
0.84 
0.18
(31) 
(24)
(12)
Ref 
0.6 
0.4
 
0.34-1.37
0.16-1.09
 
0.25 
0.07
Number of organs affected
   1 organ
   2 organs
   ≥3 organs
(38)
(39)
(46)
Ref
0.9
1.2
0.55-1.64
0.67-2.36
0.85
0.47
(23)
(22)
(21)
Ref
0.7
0.6
0.38-1.36
0.32-1.45
0.31
0.32
First-line systemic therapy
   Single-agent chemotherapy
   Combination chemotherapy
(33)
(44)
Ref
1.0
0.64-1.82 0.77 (5)
(33)
Ref
7.1
3.16-16.11 <0.0001
Ref: reference; OR: Odds Ratio; CI: confidence interval; CRC: colorectal cancer 
also adjusted for follow-up time since metastases diagnosis
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Discussion
In the present population-based study we provided insight into the age-related systemic treatment 
and survival of patients with unresectable metachronous metastases from primary resected CRC. 
We demonstrated that in everyday clinical practice only 26% of the elderly patients started sec-
ond-line treatment. Since most elderly patients received first-line single-agent chemotherapy 
without targeted therapy, elderly patients were less likely to receive all active systemic agents 
during their course of treatment, which was associated negatively with survival.
Overall, more than half (60%) of the mCRC patients received first-line combination chemotherapy 
with or without a targeted agent. As first-line treatment, combination chemotherapy has been 
associated with prolonged progression-free survival (PFS) and OS compared with single-agent 
chemotherapy.13-16 Nevertheless, only a minority of the elderly patients (≥75 years) received com-
bination chemotherapy (37%), probably due to concerns on tolerability and toxicity. For a sub-
group of patients with indolent disease, irrespective of age,  there is no indication for combina-
tion chemotherapy. In the FOCUS2 trial investigating chemotherapy options in frail and elderly 
patients with advanced CRC, patients were randomly assigned to either intravenous fluorouracil 
with levofolinate, capecitabine, oxaliplatin and fluorouracil with levofolinate, or oxaliplatin and 
capecitabine. Treatment was started at 80% of the standard dose as full-dose regimens are of-
ten considered unsuitable in elderly and frail patients. The addition of oxaliplatin did not improve 
PFS.17 Besides, the French FFCD2001-02 trial failed to demonstrate improved OS rates with irinote-
can combination-chemotherapy versus single-agent fluorouracil with levofolinate although even 
greater toxicity rates were reported with irinotecan combination-chemotherapy.18 
Regardless of the sequence of administration, exposure to all active cytotoxic agents during 
treatment has been associated with prolonged survival.19 In view of this observation, it has been 
suggested that the sequential use of active single agents might be preferable to initial combi-
nation chemotherapy as this could conceivably reduce overall toxicity. Three European trials di-
rectly addressed this issue. In the FOCUS and FFCD 2000-05 trial, initial monotherapy followed by 
combination chemotherapy was non-inferior to initial combination therapy.20,21 These results were 
endorsed by the CAIRO trial in which the sequential treatment strategy (first-line capecitabine, 
second-line irinotecan, third-line CAPOX) provided a similar benefit to initial combination treat-
ment (first-line CAPIRI, second-line CAPOX).22 
The sequential treatment strategy, however, has several limitations. At first, it should not be initi-
ated patients with potentially resectable metastases or severe cancer-related symptoms in whom 
the primary goal is downsizing of the tumor, as response rates are superior with combination che-
motherapy.13,15 Besides, sequential treatment implies that patients are still fit for second and fur-
ther lines of treatment after progressing, which might not be the case in patients with an aggres-
sive disease or a poor performance status. According to the study by Grothey et al, with data from 
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seven phase III trials, 50% to 80% of the patients received second-line treatment after failure of 
first-line treatment.19 In the present population-based study, higher dropouts rates were observed 
in everyday clinical practice (60% after first-line) due to the impact of a relatively large number of 
elderly patients. Only 26% of the elderly patients (≥75 years) received second-line therapy. This 
percentage is in line with the study by Sorbye et al, in which a poor performance status at start of 
first-line chemotherapy was identified as a poor predictor for administration of second-line treat-
ment.23 
In our study, only 22% of the mCRC patients were exposed to all three cytotoxic drugs during their 
course of treatment. The likelihood of receiving all active cytotoxic agents was significantly lower 
with the use of first-line single-agent chemotherapy (5%) than with initial combination therapy 
(33%). These results are in line with data from the FOCUS and CAIRO trial, although proportions 
of patients receiving all cytotoxic agents in these two trials were higher. With the sequential treat-
ment, 19% of the patients in the FOCUS trial and 36% of the patients in the CAIRO trial received 
all cytotoxic agents, whereas proportions were respectively 33% and 55% with initial combination 
treatment.21,22 The dismal proportions as observed in our study probably arose from the relatively 
large proportion of elderly patients in daily based practice. In the present study, advanced age 
(≥75 years) was independently associated with a lower probability to access all three active cyto-
toxic drugs compared to patients aged <60 years. 
During the current study period, elderly patients (≥75 years) were not only less likely to receive all 
active cytotoxic agents during their course of treatment, but also less frequently received targeted 
therapy. Initially, evidence on the use of bevacizumab – the first available and registered targeted 
agent in The Netherlands– was derived from a trial in which a currently outdated chemotherapy 
regimen (IFL) was used and elderly patients were underrepresented.9 Nowadays, several studies 
have suggested that bevacizumab is both safe and effective in combination with multiple che-
motherapy backbone regimens24, also in elderly patients25-27 and that age itself should no longer 
be regarded an absolute contraindication. Probably as a result, bevacizumab was prescribed in-
creasingly over time28, also in elderly mCRC patients. Evidence on the use of other targeted agents 
such as anti-EGFR therapies (cetuximab, panitumumab) in elderly KRAS-wild type mCRC patients, 
however, remains scarce and less clear.29 Recently, it has been suggested that single-agent pa-
nitumumab may be a well-tolerated and active therapeutic option for frail elderly patients with 
wild-type RAS tumors.30 More studies are needed to clarify the role of anti-EGFR therapies in the 
population of elderly mCRC patients, especially as targeted agents may sometimes be the only 
therapeutic option for frail elderly patients who are unable to tolerate chemotherapy. 
Several phase III trials13-15,31,32 and retrospective cohort studies28,33 have demonstrated survival rates 
exceeding 21.5 months in mCRC patients treated with modern systemic regimens, which seems 
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in line with the median OS of 20.2 months in patients <60 years as observed in our study. Inferior 
results, however, were observed in elderly mCRC patients (≥75 years), with a median OS of 14 
months. These results, along with results from a prior Nordic population-based registry34, raise 
concerns over our ability to improve treatment options for elderly mCRC patients. In a multivariate 
analysis with adjustments for available prognostic factors, we found that only the number of ex-
posed systemic agents was associated with OS, which suggests the need of a strategy to make all 
active agents available to patients with mCRC. Of course, these results need to be interpreted with 
caution due to the invariable presence of selection bias in this non-randomized study (patients 
who receive all drugs must live longer, since they need to be in shape for this), which cannot be 
fully out ruled in a multivariate analysis. Nevertheless, our results indicate that in elderly patients, 
initial treatment with the highest potential of improving both survival and maintaining quality 
of life is needed as most of these patients are not candidates for second-line treatment. Further 
studies are warranted to further define the role of targeted therapy in elderly mCRC patients who 
often are not candidates for intensive chemotherapy. 
To the best of our knowledge, this is the first population-based study describing the whole spec-
trum of systemic treatment and survival of a long-term series of consecutive CRC patients with 
non-resectable metachronous metastases. The non-randomized nature of this study also presents 
a potential risk of (selection) bias. Reasons (not) to prescribe specific systemic regimens were not 
available. Besides, relevant patient characteristics such as comorbidity and performance score 
were registered only at initial CRC diagnosis. Moreover, performance score was often not noted in 
patient charts (missing in >50%) and as a result, these data were not useful. Data on RAS/BRAF mu-
tation status were also not present. Despite these limitations, this large population-based study 
presents real-world data which are of need in today’s developing cancer care. 
Conclusion
In daily practice, most elderly patients with non-resectable metachronous metastases from prima-
ry resected CRC receive first-line single-agent chemotherapy without a targeted therapy. Only a 
minority of the elderly mCRC patients receives a second line of treatment. As a consequence, very 
few elderly patients received all active systemic agents during their course of treatment, shown 
to be the only independent predictor of death. Future studies are needed to clarify the role of 
targeted therapy in elderly mCRC patients, who are often not candidates for combination chemo-
therapy. 
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Abstract
Background: The majority of colorectal cancer (CRC) patients presenting with peritoneal carci-
nomatosis (PC) depends on palliative systemic treatment options. However, data on the use and 
effect of systemic treatment strategies including targeted agents for the palliative treatment of 
colorectal PC are lacking. We conducted a nationwide population-based study with data from the 
period in which the targeted agent bevacizumab was introduced in the Netherlands. 
Methods: The study included all patients diagnosed between 2007 and 2014 with synchronous 
PC from CRC  treated with only palliative systemic therapy. We assessed the use of bevacizumab, 
the standard choice of targeted treatment in addition to first-line chemotherapy. Multivariable lo-
gistic regression analyses were performed to calculate predictors for the additional prescription of 
bevacizumab. Survival estimates were calculated and multivariable Cox analyses were performed 
to estimate hazard ratios (HR’s) of death, according to treatment.
Results: In total, 1235 patients received palliative chemotherapy of whom 436 received bevaci-
zumab (35%). Patients aged 75 years or older and patients with PC from colonic tumors were less 
likely to receive chemotherapy plus bevacizumab. The addition of bevacizumab to palliative che-
motherapy was associated with an improved overall median survival  of 7.5 vs. 11 months, in both 
patients with isolated PC and concomitant extra-peritoneal metastases, also after adjustment for 
patient and tumor characteristics (HR 0.7; 95% CI 0.64-0.83). 
Conclusion: 
The results of this nationwide population-based study may support the rationale for bevacizumab 
in addition to palliative chemotherapy in patients with PC of CRC and underline the need for on-
going efforts to precise the position of targeted therapy in the treatment of PC. 
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Introduction 
At initial diagnosis almost one-fourth of all colorectal cancer (CRC) patients present with dis-
seminated disease, with the liver and peritoneum being the most frequently affected sites.1,2 
In the past two decades substantial progress has been made in the systemic treatment of meta-
static CRC. The development of chemotherapeutic regimens combining 5-fluorouracil and oxal-
iplatin or irinotecan and the introduction of targeted agents such as bevacizumab has improved 
the prognosis of patients with stage IV CRC remarkably, defining the backbone of current systemic 
therapy.3-8 
Nevertheless, very little is known about the efficacy of these systemic regimens including targeted 
therapy in the subset of CRC patients with peritoneal carcinomatosis (PC), a frequently encoun-
tered metastatic site with an invariable fatal prognosis.9,10 Despite the development of potentially 
curative loco-regional treatment modalities for a selected group of PC patients, the majority of PC 
patients remains dependent on palliative systemic treatment options. Therefore the aim of this 
nationwide population-based study is to provide data on the usage and effect of targeted ther-
apy in addition to chemotherapy for the palliative treatment of patients with synchronous PC of 
colorectal origin.
Methods
Patients and data
The Netherlands Cancer Registry (NCR) collects data of all patients with newly diagnosed cancer 
in the Netherlands, covering the entire Dutch population of approximately 16 million inhabitants. 
The NCR comprises 9 administrational regions, each covering between 7 and 20 hospitals. These 
regions form a network of health care professionals and institutions for cancer care and pallia-
tive care in the Netherlands. Pathologists enter histopathological and cytopathological reports of 
all diagnosed cancers in the nationwide Dutch Pathology Network (PALGA), which subsequently 
submits data to the NCR. Specially trained registry staff collects data on patient and tumor char-
acteristics from the medical records using the registration and coding manual of the NCR. In this 
registration system, classification of the primary tumor is based on the TNM classification.11 In case 
of missing pathological data, clinical TNM stage is used. Synchronous metastases were defined as 
metastases diagnosed within three months after initial CRC diagnosis and were registered accord-
ing to the International Classification of Disease for Oncology (ICD-O).12 Data on location of distant 
metastases were available and complete in approximately 95% of all patients with metastasized 
disease since 2007 and from 2008 on nearly complete for all patients. 
All patients who were diagnosed between 2007 and 2014 with synchronous PC from colorectal 
cancer were extracted from the nationwide database (n=5117). The current study focused on pa-
tients receiving only systemic therapy with palliative intent. Thus, patients treated with cytore-
ductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) were excluded 
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(CRS-HIPEC, n=526). Moreover, patients primary undergoing surgery (local tumor resection, me-
tastasectomy, debulking n=2074) or palliative treatment without systemic therapy (n=1282) were 
excluded from the current study, resulting in a study population of 1235 patients with PC receiving 
only palliative systemic therapy (Figure1). 
In accordance with the Dutch national treatment guidelines, oxaliplatin-containing chemother-
apy (e.g. CAPOX/FOLFOX) is recommended as the standard combination treatment for patients 
with stage IV CRC since 2001, whereas historically patients received standard first-line monother-
apy with a fluoropyrimidine (5-FU or capecitabine).13 
Both systemic chemotherapy and targeted therapy were registered (yes versus no) up to 6-9 
months after initial diagnosis in the NCR. In the current study period, bevacizumab was the stan-
dard targeted therapy in addition to first-line chemotherapy.14,15 
Figure 1   An overview on the patients diagnosed with synchronous PC from CRC between 2007 and 2014 in  
the Netherlands.
Total synchronous PC
(n=5117)
Synchronous PC
(n=2517)
Chemotherapy (n=799)
Chemotherapy + bevacizumab (n=436)
Systemic therapy
(n=1235)
Excluding: 
CRS-HIPEC (n=526) 
surgery (n=2074)
Excluding:
No systemic therapy (n=1282)
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Statistical analyses
The number of colorectal PC patients treated with palliative chemotherapy and the proportion 
of patients receiving bevacizumab were calculated. Variation in the prescription of bevacizumab 
between the 9 administrational regions of the NCR was assessed and tested by means of a χ2-test. 
Factors associated with the probability of receiving bevacizumab in addition to palliative chemo-
therapy were investigated by multivariable logistic regression analysis adjusted for age, gender, 
year of diagnosis, primary tumor localization, histological subtype, differentiation grade, T and N 
stage and radiotherapy. In addition, survival estimates of PC patients according to treatment (palli-
ative chemotherapy with or without bevacizumab) were calculated using the Kaplan Meier meth-
od and proportions were compared using a log-rank test. Survival was defined as the time from 
diagnosis of CRC until death and patients lost to follow-up or still alive at January 1, 2015 were 
censored. Median survival (MS) was presented with the 95% confidence intervals (CI). Further-
more, multivariable Cox proportional hazards regression analyses were performed to investigate 
the independent prognostic impact of additional bevacizumab in patients with PC. Adjustments 
were made for relevant patient and tumor characteristics. Survival analyses were performed in 
both the total study population of PC patients and after stratification for the presence of concomi-
tant extraperitoneal metastases. SAS/STAT statistical software® (SAS system 9.3, SAS Institute, Cary, 
NC) was used for all analyses. 
Results
In total, 1235 patients with synchronous PC from CRC treated with palliative systemic therapy were 
enrolled in the current study. There were 712 men (58%) and 523 women (42%) with a median 
age of 65 years (min 21 years - max 91 years). Concomitant metastases were present in 69% of the 
patients (n=851). The majority of concomitant  metastases were located in the liver (77%). Pulmo-
nary metastases and lymph node metastases were present in respectively 188 patients (22%) and 
159 patients (19%). Liver metastases were the only site of extra-peritoneal disease in 50% of the 
patients (n=433). 
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Figure 2   Prescription of bevacizumab in addition to palliative chemotherapy in the Netherlands, according to region 
(n=1235).
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All 1235 PC patients received palliative chemotherapy. Bevacizumab was added to palliative che-
motherapy in 35% of the patients, with interregional variation from 24% to 47% (n=436, Figure 
2, p<0.0001). As shown in table 1, patients receiving palliative chemotherapy plus bevacizumab 
were younger than patients receiving chemotherapy without this anti-vascular agent (p<0.0001). 
This was confirmed in multivariable logistic regression analysis, as it was shown that the likeli-
hood of being treated with bevacizumab in addition to palliative chemotherapy was influenced 
by age. Elderly patients (>75 years) were less likely to receive bevacizumab compared to patients 
aged between 60-75 years (OR 0.4, 95%CI 0.29-0.61). Moreover, patients with a primary signet-ring 
cell carcinoma were less likely to receive additional bevacizumab than patients with PC from ad-
enocarcinoma  (OR 0.5, 95%CI 0.32-0.89), as well as patients with colon cancer as compared with 
rectal cancer (OR 0.6, 95%CI 0.46-0.93). Within colonic primary tumor localization, no differences 
were observed between right-sided or left-sided tumors (OR 1.0, 95%CI 0.72-1.52). Finally, it was 
observed that the likelihood of additional bevacizumab prescription was lower in irradiated PC 
patients (OR 0.5, 95%CI 0.26-0.98).
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Table 1   Clinicopathological characteristics of patients diagnosed with colorectal PC between 2007-2014 in  
the Netherlands, according to palliative systemic treatment.  
N=1235 Chemotherapy +  
bevacizumab 
(N=436)
Chemotherapy  
(N=799)
N (%) N (%) P-value
Gender 
   Male 
   Female 
 
255 
181
 
(58) 
(42)
 
457 
342
 
(57) 
(43)
 
0.66
Age (years) 
   <60 
   60-75 
   ≥ 75
 
139 
246 
51
 
(32) 
(56) 
(12)
 
190 
413
196
 
(24) 
(52) 
(24)
<0.0001
Tumor localization
   Rectum 
   Colon
 
86 
350
 
(20) 
(80)
 
115 
684
 
(14) 
(86)
 
<0.01
Histologic subtype 
   Adenocarcinoma
   Mucinous carcinoma
   Signet ring cell carcinoma
   Other  
329 
71 
25 
11
 
(75) 
(16) 
(6) 
(3)
 
564 
144 
67 
24
 
(71) 
(18) 
(8) 
(3)
 
0.23
Tumor grade 
   Well/moderate
   Poor/undifferentiated
   Unknown
 
72 
71 
293
 
(17) 
(15) 
(68)
 
138 
117 
544
 
(15) 
(16) 
(70)
 
0.73
Extent of metastases
   PC only
   PC other
 
121 
315
 
(28) 
(72)
 
263 
536
 
(33) 
(67)
 
0.06
Radiotherapy 15 (3) 39 (5) 0.24
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Table 2   Multivariable logistic regression analysis modelling the odds for bevacizumab in addition to palliative  
chemotherapy. 
(%) OR CI
Gender 
   Male 
   Female 
 
(36) 
(35)
 
Ref 
1.0
 
 
0.80-1.32
Age (years) 
   <60 
   60-75 
   ≥75
 
(42) 
(37) 
(21)
 
1.2  
Ref 
0.4
 
0.94-1.63 
 
0.29-0.61a
Tumor localization
   Rectum 
   Colon
 
(43) 
(34)
 
Ref 
0.6
 
 
0.46-0.93a
Histologic subtype 
   Adenocarcinoma
   Mucinous carcinoma
   Signet cell carcinoma
   Other  
 
(37) 
(33) 
(27) 
(31)
 
Ref 
0.9 
0.5 
0.8
 
 
0.62-1.22 
0.32-0.89a 
0.37-1.68
Tumor grade 
   Well/moderate
   Poor/undifferentiated
   Unknown
 
(34) 
(38) 
(35)
 
Ref 
1.2 
1.0
 
 
0.77-1.85 
0.74-1.45
Extent of metastases
   PC only
   PC other
 
(32) 
(37)
 
Ref 
1.2
 
 
0.94-1.62
Radiotherapy 
   No
   Yes
 
(36) 
(28)
 
Ref 
0.5
 
 
0.26-0.98a
Analysis was also adjusted for year of diagnosis and T and N stage. 
Abbreviations: CI = confidence interval; OR = odds ratio; PC only = isolated peritoneal carcinomatosis; PC other =  
peritoneal carcinomatosis with concomitant extraperitoneal metastases.
a Statistically significant. 
Overall survival 
The addition of bevacizumab to palliative chemotherapy was associated with improved median 
overall survival rates, from 7.4 months (95%CI 6.83-8.24) to 11.0 months (95%CI 9.79-12.09, Figure 
3). Similar results were observed after stratification for the presence of extra-peritoneal metasta-
ses. Median survival rates improved from approximately 7.5 to 11 months with the additional pre-
scription of targeted therapy in both patients with isolated PC (PC-Only, p<0.05) and concomitant 
extra-peritoneal metastases (PC-Other, p<0.0001).  
In multivariable Cox regression analysis with adjustment for relevant prognostic factors, the addi-
tion of bevacizumab to palliative chemotherapy was associated with a decreased risk of death (HR 
0.7; 95% CI 0.64-0.83). 
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Figure 3  Overall survival of patients with synchronous PC from colorectal origin according to treatment (n=1235). 
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Discussion
In this nationwide population-based study we demonstrate the use and potential effect of beva-
cizumab in addition to palliative chemotherapy in a selected group of colorectal PC patients who 
does not meet the criteria for potentially curative treatment procedures. 
In the last decade, remarkable progress has been achieved in the systemic treatment of mCRC.13,14 
In 2001, oxaliplatin was registered in the Netherlands and recommended as a first-line cytostatic 
agent in combination chemotherapy for stage IV CRC. In addition, bevacizumab was registered 
since 2005 for the first-line treatment in mCRC in the Netherlands. Bevacizumab targets the vas-
cular endothelial growth factor (VEGF), which is the most important angiogenic factor. Metastasis 
formation and growth depends on the presence of sufficient oxygen which is supplied by the for-
mation of new bloodvessels (angiogenesis). High levels of VEGF have been associated with metas-
tases in CRC. Moreover, VEGF has been shown to play a role in PM and prognosis.16,17 Blocking VEGF 
could reduce ascites formation and progression. For patients with peritoneal metastases, however, 
the effect of systemic regimens including targeted therapy remains uncertain. Radiographic im-
aging of peritoneal tumor deposits is difficult, limiting the available evidence on this topic. In ad-
dition, the hypothesis that PC should be regarded as loco-regional rather than systemic spread of 
disease caused a shift in clinical attention from systemic towards loco-regional treatment modal-
ities combining CRS and HIPEC. Various large case studies have demonstrated that this treatment 
may now be offered successfully with 5 year survival rates of over 30%.18-20 However, only selected 
PC patients will be likely to benefit from this invasive treatment procedure.20,21 Thus, the majority 
of colorectal PC patients depend on palliative systemic treatment strategies. 
To the best of our knowledge, this is the first nationwide population-based study describing the 
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potential role of bevacizumab in the palliative treatment of colorectal PC. In view of the nation-
wide character, the number of colorectal PC patients receiving this anti-vascular agent was sub-
stantial (n=436). Bevacizumab was prescribed as a part of palliative systemic therapy in 35% of the 
PC patients diagnosed and treated after 2007. Large interregional variation was observed in the 
prescription of this tumor targeting agent, reflecting differences in policy towards the use of this 
novel tumor targeting therapy for the treatment of colorectal PC between the administrational 
regions in the Netherlands. Also, we observed that elderly patients were less likely to receive beva-
cizumab in addition to palliative chemotherapy. Older age has been described as one of the most 
important factors in refraining systemic chemotherapy, especially combination chemotherapy.22-24 
However, it has been shown that it is feasible to treat older patients with chemotherapy, even in 
the presence of widespread peritoneal disease combined with distant metastases.25-27 In addition, 
several recent studies have suggested that age itself is not a contraindication for targeted therapy 
as bevacizumab, the standard recommended target agent in mCRC, is generally well-tolerated.28-30 
Finally, we observed that the prescription of bevacizumab was less likely in patients with colon 
cancer than rectal cancer. We cannot explain this difference, it might be related to tumor or host 
factors for which we could not control for in our analyses, such as metastatic tumor load within 
organs or differences in comorbidity patterns. 
In the current study the addition of bevacizumab to palliative chemotherapy was associated with 
a significant increase in overall median survival of 3.5 months (from 7.5 to 11 months), both in 
patients with isolated PC and concomitant extra-peritoneal metastases (mostly liver metastases). 
In patients with stage IV CRC, the addition of bevacizumab has shown to improve median pro-
gression free survival with approximately 4 months in the first-line treatment.7,31-33 However, most 
of these studies did not show an improvement in overall survival with the additional use of bev-
acizumab.7, 29,34 We hypothesize that in these studies, patients who were assigned not to receive 
bevacizumab in the first-line of treatment, could have received bevacizumab in further lines. How-
ever, patients with PC as described in our study, are unlikely to receive multiple lines of systemic 
treatment due to the notorious prognosis of PC. Therefore, the gain in progression free survival 
with bevacizumab may be translated into an overall survival benefit in these patients.
Evidence on the potential role of targeting agents in the subset of CRC patients presenting with PC 
is scarce and still debatable. Data are derived from few small studies, that did not present stratified 
data according to the presence of concomitant extraperitoneal metastases. In a study by Klaver 
and colleagues on 22 patients with PC, overall median survival improved from 10.1 months to 18.2 
months with the addition of targeted agents.35 In two other small studies, median survival rates 
of respectively 15 and 23 months were observed with addition of targeted therapy, mostly beva-
cizumab.36,37 In comparison to these survival rates, the outcomes as described in our nationwide 
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study are dismal, probably reflecting differences in patient selection. In our study, patients eligible 
for CRS-HIPEC and surgical procedures were excluded which implicates a selection of PC patients 
with unfavorable prognostic characteristics. Moreover, peritoneal tumor burden is expected to 
be extensive in our study population as patients were diagnosed in a non-operative setting ei-
ther clinically and/or by radiographic imaging, which are both inaccurate techniques for the early 
detection of PC. An extensive peritoneal tumor burden often coincides with physical complaints 
such as abdominal discomfort, nausea, loss of appetite, diarrhea, constipation and unexplained 
weight loss or gain, which are invariably associated with a poor outcome. 
 
Due to the nature of this population-based study potential selection bias is inevitable. No data on 
important prognostic factors such as comorbidity, socio-economic status, functional status and 
KRAS or BRAF mutational status were present in our database. Data on differentiation grade were 
missing in 70% of the patients included in the current study, probably due to non- operative set-
ting in which these patients were diagnosed. Detailed information on the prescribed chemother-
apeutic regimen was unavailable in the NCR. 
Conclusion
The results of the current study may support the rationale for the addition of bevacizumab to 
palliative treatment with the best available systemic chemotherapy schedules for patients with PC 
who do not meet the inclusion criteria for CRS and HIPEC or surgery, however, due to the non-ran-
domized nature of this study, results have to interpreted with caution. 
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Abstract
Background: Population-based data on the percentage of colorectal cancer (CRC) patients with 
synchronous peritoneal carcinomatosis (PC) being treated with cytoreductive surgery (CRS) and 
hyperthermic intraperitoneal chemotherapy (HIPEC) are currently lacking. The current popu-
lation-based study describes trends in the use of CRS-HIPEC in the Netherlands, one of the first 
countries where CRS and HIPEC was introduced.
Methods: All patients diagnosed with synchronous PC of CRC between 2005-2012 were extracted 
from the Netherlands Cancer Registry (n=4623). Patients with primary appendiceal cancer were 
excluded resulting in a study population of 4430 patients. Trends in the use of CRS-HIPEC over time 
were analyzed by means of a Cochrane Armitage trend test. Survival proportions were calculated 
as the time between diagnosis and date of death or last follow-up (January 2014). 
Results: Of the total 4430 patients with synchronous PC, 297 (6.4%) underwent treatment with 
CRS-HIPEC. The proportion of colorectal PC patients receiving CRS-HIPEC increased significantly 
over time from 3.6% in 2005-2006 to 9.7% in 2011-2012 (p<0.0001). Overall median survival (MS) 
for patients treated with CRS- HIPEC was 32.3 months, whereas MS rates were respectively 12.6, 
6.1 and 1.5 for months palliative chemotherapy with/without surgery, palliative surgery and best 
supportive care.
Conclusion: The proportion of patients diagnosed with synchronous PC from CRC  treated with 
CRS-HIPEC has increased significantly over time and currently almost 10% of PC patients are treat-
ed with CRS-HIPEC. Median survival in this population based group is 32.3 months.
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Introduction
Peritoneal tumor deposits are relatively common in patients with colorectal cancer and have long 
been considered a terminal condition with an invariable fatal outcome.1 Palliative treatment with 
systemic chemotherapy has been the standard of care for these patients for many years. Recently, 
the understanding that peritoneal carcinomatosis (PC) results from loco-regional rather than sys-
temic spread raised interest in this specific metastatic manifestation resulting in the development 
of loco-regional treatment modalities combining cytoreductive surgery (CRS) and hyperthermic 
intraperitoneal chemotherapy (HIPEC).2 In 2003, this combined technique was shown to be su-
perior to palliative chemotherapy with conventional 5-fluorouracil (5-FU) and leucovorin (LV) or 
irinotecan in a randomized controlled trial.3 Based on this evidence, CRS-HIPEC is adopted by an 
increasing number of centers worldwide. At present, many HIPEC-centers have published their 
experiences and the procedure is now well characterized. However, population-based studies pro-
viding data on the percentage of PC patients being treated with CRS-HIPEC and characterization 
of these patients are currently completely lacking. 
The current population-based study was undertaken in the Netherlands, one of the first countries 
where CRS- HIPEC was introduced about 20 years ago. The trends in the Netherlands since then 
may provide important information on the amount of PC-patients being potentially eligible for 
this treatment in countries where HIPEC was introduced more recently. Therefore the aim of the 
present study was describe the usage and effect of CRS-HIPEC for the treatment of synchronous 
PC from CRC in the Netherlands. 
Methods
Patients’ selection  and data
Data were retrieved from the Netherlands Cancer Registry (NCR). The NCR collects data on all pa-
tients with newly diagnosed cancer in the Netherlands, covering a population of approximately 16 
million inhabitants. Histopathological and cytopathological reports of the diagnosed tumors are 
entered in the nationwide Dutch Pathology Network (PALGA) by pathologists, which subsequent-
ly submits the data to the NCR. Information on patient and tumor characteristics, diagnosis and 
treatment are extracted from the medical records by trained registry staff using the registration 
and coding manual of the NCR. The anatomical site of the tumor and metastases are registered ac-
cording to the International Classification of Diseases for Oncology (ICD-O).4  Synchronous metas-
tases are defined as metastases of colorectal cancer in other organs within 3 months after primary 
tumor diagnosis. Primary tumor staging is based on the TNM Classification of Malignant Tumors.5 
In case of missing pathological data, clinical data is used. 
As since 2005 data on CRS and HIPEC  were available, all consecutive patients diagnosed with 
synchronous PC of colorectal origin between 2005-2012 were extracted from the NCR database 
(n=4623). Patients with primary appendiceal cancer were excluded (n=193) as they reflect a dis-
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tinct entity with different prognosis. Of the remaining 4430 patients, 1109 were untreated, 1044 
patients received only palliative surgery, 1980 patients received palliative chemotherapy (with or 
without surgery) and 297 patients were treated with CRS-HIPEC. Patients undergoing CRS-HIPEC 
or palliative chemotherapy were the main focus in this study.
Statistical analysis
Clinicopathological characteristics of patients with synchronous PC of colorectal cancer treated 
with CRS-HIPEC or palliative chemotherapy were compared using a two-sided χ2 test. Trends in 
the use of CRS-HIPEC for the treatment of colorectal PC across the period 2005-2012 were ana-
lyzed by means of a Cochran-Armitage trend test. Factors influencing the probability of receiving 
CRS-HIPEC were evaluated by multivariable logistic regression analysis, providing odd’s ratio’s (OR) 
with their 95% confidence intervals (CIs). In order to investigate differences in patient selection 
over time, patients were divided into two groups according to period of diagnosis (2005-2008 
& 2009-2012). Survival time was calculated as the time between diagnosis of colorectal cancer 
and date of death. Patients still alive at the end of follow-up (January 1, 2014) and those who 
emigrated were censored. Median survival (MS) was presented in months and corresponding 95% 
confidence intervals (CIs). Crude survival estimates were calculated with the Kaplan-Meier method 
and compared using the log-rank test. Finally, it was investigated in a multivariable Cox regression 
analysis whether period of diagnosis (2009-2012 vs. 2005-2008) was associated with the risk of 
death in patients receiving CRS-HIPEC. The following important prognostic factors were included 
in the model; age, period of diagnosis, differentiation grade, histological subtype, primary tumor 
localization, T- and N-stage and the presence of concomitant liver metastases. All analysis were 
performed with SAS/STAT® statistical software (SAS system 9.3; SAS institute,Cary,NC). 
Results
Patient and tumor characteristics 
In the study period 2005-2012, 4430 patients were diagnosed with synchronous PC from colorec-
tal cancer in the Netherlands. In total, 297 patients were treated with CRS-HIPEC (6.7%) whereas 
palliative chemotherapy was prescribed in 1980 cases (45%). Patient and tumor characteristics are 
presented in Table 1. Except for gender and primary tumor localization, all general and tumor spe-
cific characteristics differed between patients who were treated with CRS-HIPEC and those who 
received palliative chemotherapy (p<0.0001).
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Table 1   General characteristics of patients diagnosed between 2005 and 2012 in the Netherlands with synchronous  
PC of colorectal origin, treated with CRS-HIPEC or palliative chemotherapy. 
CRS-HIPEC 
(N=297)
Palliative  chemotherapy 
(N=1980)
N % N % P value
Gender 
   Male
   Female
 
149 
148
 
50 
50
 
958 
794
 
54 
46
 
 
NS
Age (years) 
   < 60  
   60-70 
   >70
 
143 
106 
48
 
48 
36 
16
 
561 
639 
552
 
31 
36 
33
 
 
 
<0.0001
Period of diagnosis
   2005-2008 
   2009-2012
 
31 
266
 
10 
90
359 
1621
 
18 
82
 
 
<0.0001
Tumor localization 
   Colon
   Rectum 
 
249 
48
 
84 
16
 
1451 
233
 
86 
14
 
 
NS
Tumor morphology         
   Adenocarcinoma
   Mucinous carcinoma
   Signet-ring cell carcinoma 
   Other 
 
156 
106 
32 
3
 
63 
36 
11 
1
 
1162 
373 
114 
35
 
69 
22 
7 
2 <0.0001
Differentiation grade 
   Well/moderately 
   Poorly/undifferentiated
   Unknown
 
134 
74 
89
 
45 
25 
30
 
570 
416 
698
 
34 
25 
41
 
 
 
<0.0001
T stage 
   0-2
   3
   4
   X
 
9 
99 
185 
4
 
3 
33 
63 
1
 
26 
425 
772 
461
 
2 
25 
46 
27 <0.0001
N stage
   0
   1,2
   X
 
57 
230 
10
 
19 
77 
4
 
177 
1058 
449
 
11 
62 
27
Liver metastases 27 9 1077 54 <0.0001
Systemic CTx 213 72 NA NA
NA: not applicable
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The use of CRS-HIPEC over time
Treatment with CRS-HIPEC in the Netherlands increased significantly from 3.6% of colorectal PC 
patients in 2005-2006 to 9.7% in 2011-2012 (Figure 1). Several factors influenced the probability of 
receiving CRS-HIPEC (Table 2). Compared to patients aged between 60-70 years, younger patients 
(<60 years) were more likely to receive this treatment modality (OR 1.9, 95% CI 1.40-2.64) whereas 
elderly patients (>70 years) received CRS-HIPEC less often (OR 0.3, 95% CI 0.18-0.39). In addition, 
patients with poorly or undifferentiated tumors were less likely to undergo CRS-HIPEC, but this 
effect was shown to be dependent on the period of diagnosis. Patients diagnosed with poorly/
undifferentiated tumors between 2005-2008 received CRS-HIPEC less frequently (OR 0.1, CI 0.02-
0.52) whereas no significant OR was observed for patients diagnosed with poorly/undifferentiated 
tumors since 2009 (OR 0.8, CI 0.56-1.16). Most CRS-HIPEC procedures were performed in patients 
with isolated PC. However, a small group of patients with concomitant liver metastases (n=27), 
especially since 2008 (n=26), received treatment with CRS-HIPEC.
Figure 1   Percentage of patients with synchronous PC from colorectal cancer (n=4430) receiving treatment with  
CRS-HIPEC in the period 2005-2012 in the Netherlands. 
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Table 2   Multivariable logistic regression analysis modeling the chance of treatment with CRS-HIPEC among patients 
with synchronous PC from colorectal cancer, diagnosed between 2005 and 2012 in the Netherlands.
N=4430 % OR 95% CI
Gender 
   Male
   Female
 
7 
7
 
Ref 
1.0
 
 
0.77-1.35
Age (years)
   <60 
   60-70 
   >70
 
15 
8 
2
 
1.9 
Ref 
0.3
 
1.40-2.64 
 
0.18-0.39
Period of diagnosis 
   2005-2008 
   2009-2012
4 
7
 
Ref 
3.1
 
 
2.06-4.76
Tumor localization
   Colon
   Rectum
 
6 
8
 
Ref 
1.9
 
 
1.21-2.83
Tumor morphology
   Adenocarcinoma
   Mucinous carcinoma
   Signet-ring cell 
   Other
 
5 
11 
10 
2
 
Ref 
1.6 
1.2 
0.4
 
 
1.20-2.25 
0.74-2.04 
0.10-1.38
Differentiation grade
   Well/moderately
   Poorly/undifferentiated
   Unknown
 
9 
6 
5
 
Ref 
0.7 
1.3
 
 
0.46-0.93 
0.88-1.86
T stage
   0-2
   3
   4
   X
 
9 
9 
9 
0
 
1.4 
Ref 
1.2
0.7
 
0.54-3.57 
 
0.86-1.58 
0.24-2.28
N stage
   0
   1,2
   X
 
10 
9 
1
 
1.4 
Ref 
0.5
 
0.94-2.00 
 
0.21-1.12
Liver metastases  
   No  
   Yes
 
10 
1
 
Ref 
0.1
 
 
0.06-0.15
Systemic chemotherapy
   No
   Yes
 
4 
10
 
Ref 
1.9
 
 
1.41-2.61
 
Data are adjusted for all variables listed. OR, odds ratio; CI, confidence interval. 
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Survival 
Overall median survival (MS) was 32.3 months for patients with colorectal PC treated with CRS-
HIPEC and 12.6 months for patients receiving palliative chemotherapy (Figure 2). In the presence 
of concomitant liver metastases, MS rates were respectively 23.1 months (CI 13.90-36.07) and 12.5 
months (CI 11.3-13.08) for patients treated with CRS-HIPEC or palliative chemotherapy. 
Figure 2   Overall survival of patients with synchronous PC of colorectal origin treated with CRS-HIPEC, systemic  
chemotherapy, palliative surgery or best supportive care (n=4430).
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In a multivariable proportional hazards regression analysis with adjustment for important patient 
and tumor characteristics, period of diagnosis (2005-2008 vs 2009-2012) did not influence the risk 
of dying in patients receiving treatment with CRS-HIPEC (HR 1.0 CI 0.62-1.61). 
Discussion
In the Netherlands, CRS-HIPEC was introduced already 20 years ago. Ever since, the number of 
hospitals offering CRS-HIPEC has increased gradually to the current number of six centers all using 
an uniform technique.3,6 The long tradition of this treatment in the Netherlands provides an op-
portunity to study the trends in treatment over the years. This may provide important information 
to health care providers (e.g. hospital staff and insurance companies) worldwide to anticipate on 
future developments and requirements. Furthermore, the percentage of PC patients being treated 
with CRS and HIPEC may serve as benchmark to compare between countries rather than studies 
reporting absolute numbers only.
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This current study demonstrates that the proportion of colorectal cancer patients with PC treated 
with CRS-HIPEC  increased significantly over time. In 2011-2012, 9.7% of all PC patients under-
went this procedure. This trend confirms the increase in the absolute number of CRS and HIPEC 
procedures as described by several centers worldwide.6,7 The increasing awareness of clinicians in 
referring hospitals probably attributes to this phenomena and will likely result in a further increase 
in the future as it was shown that a plateau was not yet reached in the Netherlands.
Accurate patient selection has shown to be a key predictor of CRS-HIPEC outcome. In specialized 
PC centers, consensus has been established on essential CRS-HIPEC selection criteria.8 CRS and 
HIPEC are usually contraindicated in patients with extensive peritoneal tumor burden, concom-
itant extra-peritoneal metastases, serious comorbidities and a poor performance status.8,9  With 
respect to age, some centers considered elderly patients (>70 years) ineligible 10,11, whereas other 
showed feasibility in these patients. In general, most clinicians agree that age itself should not be 
considered as an absolute contraindication and that elderly patients should be evaluated on an 
individual base.8,9 This study confirmed the presence of stringent patient selection, despite the 
lack of detailed information on CRS-HIPEC selection criteria due to the nature of this population 
based study. Younger patients with moderately or well differentiated tumors are more likely to 
undergo this potentially curative treatment modality compared to patients aged between 60-70 
years whereas elderly patients were less likely to receive CRS-HIPEC. Patients with PC from poorly 
or undifferentiated tumors were less likely to undergo CRS-HIPEC, especially if diagnosed between 
2005-2008. Although differentiation grade is not generally taken into account in patient selection 
for CRS-HIPEC, it is known that a poor differentiation grade generally implies a more aggressive tu-
mor biology 12 which could implicate a more extensive peritoneal tumor burden in these patients. 
In this population-based study, median survival (MS) was found to exceed 32 months for patients 
treated with CRS-HIPEC, which is in line with current literature. In the large multi-institutional 
study by Glehen et al., including 523 colorectal PC patients treated with this therapeutic approach 
an overall MS of 30 months was found.  
Although patients with concomitant extra-peritoneal metastases are generally not considered 
candidates for CRS-HIPEC, the results of our study demonstrated that even a small number of col-
orectal PC patients with limited concomitant liver metastases underwent this procedure, especial-
ly since 2008, with a median survival of 23 months. A non-anatomical wedge resection of the liver 
metastases was performed in the vast majority of these cases.  The fact that a small group of PC 
patients with concomitant liver metastases underwent CRS-HIPEC results from current evidence 
stating that liver involvement should not be considered an absolute contra-indication if metasta-
ses are confined to a maximum of three-well defined lesions.3,13,14 
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Despite the increased proportion of patients treated with CRS-HIPEC over time and perhaps the 
inclusion of patients with more extensive disease (i.e. poorly/ undifferentiated primary tumor and 
concomitant liver metastases) in the recent time period (2009-2012), median survival rates of pa-
tients treated with CRS-HIPEC did not reduce over time. Moreover, major complication rates and 
mortality rates remained comparable to the literature according to a recent study by Kuijpers et 
al.3 In  this  study, a major complication rate of 34% and a mortality rate of 3% was observed after 
CRS and HIPEC.6 These findings may reflect an increase in surgical experience over time and im-
proved insight in relevant predictors of outcome. 
The median survival of patients in our study treated with current palliative systemic treatment 
modalities consisting of 5-FU based chemotherapy often combined with oxaliplatin or irinotecan 
and targeted therapies was approximately 13 months. Historically, with fluoropyrimidine based 
monotherapy (5-FU,capecitabine), MS rates were poor, ranging from approximately 6 months 1,15 
up to a maximum of 12.6 months in a positive selection of patients.16 The effect of modern com-
bined cytostatic regimens is only sparsely studied in the subset of patients with PC, due to the 
difficulty of evaluating treatment response in these patients.17 In the few available studies so far, 
modern systemic regimens were associated with improved survival rates ranging from 10 months 
to 23 months.17-20 Thus, the median survival rate of 13 months as described in our study probably 
reflects the implementation of modern combination systemic therapy in the Netherlands during 
the last decade. 
Due to the inevitable presence of selection bias in our population-based study and the lack of 
data on important prognostic factors such as performance status, extent of peritoneal disease and 
comorbidity were not registered in the NCR, conclusions on the effect of CRS-HIPEC compared to 
chemotherapy cannot be drawn upon these data exclusively. In the only currently available ran-
domized trial, the beneficial effect of CRS-HIPEC compared with conventional chemotherapy (flu-
orouracil-leucovorin) was established.3 Unfortunately, no randomized trials have been published 
ever since. Therefore, evidence on the effectiveness of CRS and HIPEC compared with modern 
combined systemic regimens arises from few studies with methodological limitations. The only 
two currently available controlled studies comparing CRS-HIPEC and modern systemic regimens 
both indicated a trend towards a more beneficial effect in the CRS-HIPEC group.19,20 Despite the ob-
stacles in interpreting these data, an independent effect of the combined treatment modality CRS-
HIPEC is generally accepted. Nevertheless, the independent effect of cytoreduction, hyperthermia 
and intraperitoneal chemotherapy in this combined treatment modality remains unknown. 
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Conclusion
The proportion of patients diagnosed with synchronous PC from colorectal origin treated with 
CRS-HIPEC increased significantly over time and still has not reached a plateau in the Netherlands. 
Currently almost 10% of PC patients appear to be eligible for CRS-HIPEC. This includes primarily 
younger patients with well or moderately differentiated tumors and isolated PC resulting in a me-
dian survival of 32.3 months. 
140  | Chapter 8
References
1 Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal 
carcinomatosis from non-gynecologic malig-
nancies: results of the EVOCAPE 1 multicentric 
prospective study. Cancer. 2000; 88: 358-63.
2 Sugarbaker PH. Peritoneal carcinomatosis: natu-
ral history and rational therapeutic interventions 
using intraperitoneal chemotherapy. Cancer 
treatment and research. 1996; 81: 149-68.
3 Verwaal VJ, Bruin S, Boot H, van Slooten G, van 
Tinteren H. 8-year follow-up of randomized trial: 
cytoreduction and hyperthermic intraperitoneal 
chemotherapy versus systemic chemotherapy 
in patients with peritoneal carcinomatosis of 
colorectal cancer. Ann Surg Oncol. 2008; 15: 
2426-32.
4 Fritz AG, Percy C, Jack A, et al. International Clas-
sification of Diseases for Oncology, 3rd ed. Gene-
va. World Health Organization. 2000.
5 UICC. TNM Classification of Malignant Tumours. 
7th ed. New York: Wiley-Blackwell. 2009.
6 Kuijpers AM, Mirck B, Aalbers AG, et al. Cytore-
duction and HIPEC in the Netherlands: nation-
wide long-term outcome following the Dutch 
protocol. Ann Surg Oncol. 2013; 20: 4224-30.
7 Glehen O, Gilly FN, Boutitie F, et al. Toward cura-
tive treatment of peritoneal carcinomatosis from 
nonovarian origin by cytoreductive surgery 
combined with perioperative intraperitoneal 
chemotherapy: a multi-institutional study of 
1,290 patients. Cancer. 2010; 116: 5608-18.
8 Roviello F, Caruso S, Marrelli D, et al. Treatment 
of peritoneal carcinomatosis with cytoreduc-
tive surgery and hyperthermic intraperitoneal 
chemotherapy: state of the art and future devel-
opments. Surgical oncology. 2011; 20: e38-54.
9 Riss S, Mohamed F, Dayal S, et al. Peritoneal me-
tastases from colorectal cancer: patient selection 
for cytoreductive surgery and hyperthermic in-
traperitoneal chemotherapy. Eur J Surg Oncol. 
2013; 39: 931-7.
10 Rodt AP, Svarrer RO, Iversen LH. Clinical course 
for patients with peritoneal carcinomatosis ex-
cluded from cytoreductive surgery and hyper-
thermic intraperitoneal chemotherapy. World 
journal of surgical oncology. 2013; 11: 232.
11 Glehen O, Mohamed F, Gilly FN. Peritoneal carci-
nomatosis from digestive tract cancer: new man-
agement by cytoreductive surgery and intraperi-
toneal chemohyperthermia. The lancet oncology. 
2004; 5: 219-28.
12 Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, 
Coebergh JW, de Hingh IH. Predictors and sur-
vival of synchronous peritoneal carcinomatosis 
of colorectal origin: a population-based study. 
Int J Cancer. 2011; 128: 2717-25.
13 de Cuba EM, Kwakman R, Knol DL, Bonjer HJ, 
Meijer GA, Te Velde EA. Cytoreductive surgery 
and HIPEC for peritoneal metastases combined 
with curative treatment of colorectal liver me-
tastases: Systematic review of all literature and 
meta-analysis of observational studies. Cancer 
treatment reviews. 2013; 39: 321-7.
14 Cao C, Yan TD, Black D, Morris DL. A systematic re-
view and meta-analysis of cytoreductive surgery 
with perioperative intraperitoneal chemother-
apy for peritoneal carcinomatosis of colorectal 
origin. Ann Surg Oncol. 2009; 16: 2152-65.
15 Jayne DG, Fook S, Loi C, Seow-Choen F. Perito-
neal carcinomatosis from colorectal cancer. Br J 
Surg. 2002; 89: 1545-50.
16 Bloemendaal AL, Verwaal VJ, van Ruth S, Boot 
H, Zoetmulder FA. Conventional surgery and 
systemic chemotherapy for peritoneal carcino-
matosis of colorectal origin: a prospective study. 
European journal of surgical oncology : the journal 
of the European Society of Surgical Oncology and 
the British Association of Surgical Oncology. 2005; 
31: 1145-51.
17 Klaver YL, Leenders BJ, Creemers GJ, et al. Addi-
tion of biological therapies to palliative chemo-
therapy prolongs survival in patients with peri-
toneal carcinomatosis of colorectal origin. Am J 
Clin Oncol. 2013; 36: 157-61.
“Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy” | 141
8
18 Klaver YL, Chua TC, de Hingh IH, Morris DL. Out-
comes of elderly patients undergoing cytoreduc-
tive surgery and perioperative intraperitoneal 
chemotherapy for colorectal cancer peritoneal 
carcinomatosis. J Surg Oncol. 2012; 105: 113-8.
19 Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, 
Bartlett DL, Zeh HJ, 3rd. Cytoreductive surgery 
and hyperthermic intraperitoneal chemoper-
fusion versus systemic chemotherapy alone for 
colorectal peritoneal carcinomatosis. Cancer. 
2010; 116: 3756-62.
20 Elias D, Lefevre JH, Chevalier J, et al. Complete cy-
toreductive surgery plus intraperitoneal chemo-
hyperthermia with oxaliplatin for peritoneal 
carcinomatosis of colorectal origin. J Clin Oncol. 
2009; 27: 681-5.

L.G.E.M. Razenberg | V.E.P.P. Lemmens | V.J. Verwaal
C.J.A. Punt | P.J. Tanis | G.J. Creemers | I.H.J.T. de Hingh
European Journal of Cancer 2016;41:466-71
Chapter 9
“Challenging the dogma of peritoneal metastases as an untreatable  
condition: results of a population based study”
144  | Chapter 9
Abstract
Purpose: To determine the impact of the implementation of novel systemic regimens and loco-re-
gional treatment modalities on survival at population level in colorectal cancer (CRC) patients pre-
senting with peritoneal metastases (PM).
Methods: All consecutive CRC patients with synchronous PM (<3 months) between 1995 and 
2014 were extracted from the Eindhoven area of the Netherlands Cancer Registry. Trends in treat-
ment and overall survival were assessed in four time periods. Multivariable regression analysis was 
used to analyze the impact of systemic and loco-regional treatment modalities on survival. 
Results: A total of 37,036 patients were diagnosed with primary CRC between 1995 and 2014. 
Synchronous PM were diagnosed in 1,661 patients, of whom 55% had also metastases at other 
sites (n=917) and 77% received anticancer therapy (n=1273). Treatment with systemic therapy 
increased from 23% in 1995-1999 to 56% in 2010-2014 (p<0.0001). Cytoreductive surgery with 
hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) was applied since 2005 and increased 
from 10% in 2005-2009 to 23% in 2010-2014. Surgery for lymphatic or hematogenous metastases 
increased from 2% to 10% in these periods. Median overall survival of the complete cohort im-
proved from 6.0 months in 1995-2000 to 12.5 months in 2010-2014 (p<0.0001), with a doubling of 
survival for both PM alone and PM with other involved sites. The influence of year of diagnosis on 
survival (HR 2010-2014 vs 1995-1999; 0.5, 95%CI 0.43-0.62, p<0.0001) disappeared after including 
systemic therapy and loco-regional treatment modalities in subsequent multivariable models.
Conclusion: CRC patients presenting with PM are increasingly offered a multi-disciplinary treat-
ment approach, resulting in an increased overall survival for the entire cohort.  
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Introduction
Peritoneal dissemination is a common manifestation of metastases in patients with colorectal can-
cer (CRC), affecting approximately 10% of CRC patients.1-3 Responses to 5-fluorouracil are poor and 
results after only palliative surgical interventions are disappointing4, resulting in an invariable fatal 
prognosis with conventional treatment.2,3,5 Therefore, patients with peritoneal metastases (PM) are 
considered to be virtually untreatable by many physicians, often resulting in only best supportive 
care in a palliative setting. The introduction of novel systemic regimens combing chemothera-
py and monoclonal antibodies may offer new treatment possibilities for CRC patients with PM. 
However, results from randomized studies on the efficacy of these systemic regimens in patients 
with PM are lacking, as these patients are often excluded from clinical trials given the problems in 
disease measurability by CT imaging.
The hypothesis that PM may be regarded as loco-regional tumor spread rather than systemically 
metastasized CRC resulted in the development of a loco-regional treatment strategy combining 
cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). Although 
promising results have been demonstrated with this treatment, the efficacy of CRS and HIPEC 
in CRC patients with PM remains a matter of debate with only one RCT supporting its beneficial 
value.6
Due to the grim prognosis and the lack of solid evidence on both the systemic and loco-regional 
treatment of PM, peritoneal disease still has a reputation of an untreatable condition. In spite of 
this, patients with PM in The Netherlands are treated with increased frequency and intensity.7 We 
performed a population-based analysis to provide insight on the impact of this practice on surviv-
al in CRC patients presenting with PM.  
Methods
Patients and data
Data from the Eindhoven area of the population-based Netherlands Cancer Registry (NCR) were 
used. This registry collects data of all patients with newly diagnosed cancer in a large part of the 
south-eastern Netherlands and covers an area of approximately 2.4 million inhabitants and is no-
tified by six pathology departments, 10 community hospitals at 17 locations and two large radio-
therapy institutions. Specially trained administrators of the cancer registry extract data on patient 
and tumor characteristics from medical records after notification by pathologists and medical 
registration offices, resulting in high quality of the data. Primary tumors are classified according 
to the TNM classification of Malignant Tumors. In case of missing pathological data, clinical TNM 
is used. Subsites of systemic metastasis at the time of diagnosis are registered according to the 
International Classification of Diseases for Oncology (ICD-O). Synchronous metastases were de-
fined as metastases diagnosed within three months after initial CRC diagnosis. Systemic treatment 
(yes versus no) was defined as prescription of either cytostatic drugs or targeted agents of any 
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kind at initial diagnosis. A distinction in surgical procedures was made between primary tumor 
resection (either open or laparoscopic), surgery for metastases (surgical procedures aiming to 
remove lymphatic or hematogenous metastases) or CRS-HIPEC. Four periods (1995-2000, 2000-
2005, 2005-2010, 2010-2014) were defined based on year of diagnosis to analyze time trends in 
the application of systemic therapy and loco-regional treatment modalities for metastatic CRC as 
well as overall survival. 
All consecutive patients diagnosed with primary CRC (C18.0-C20.9) between 1995 and 2014 were 
extracted (n=37,036). Subsequently, all patients presenting with PM at the time of initial CRC diag-
nosis were included (n=1,661). In all patients, follow-up of vital status was complete until January 
2015. This information was obtained from the municipal administrative databases, in which data 
on all deceased and emigrated persons are collected in The Netherlands. 
Statistical analyses
Descriptive statistics were used to provide an overview of the total study population of patients 
with synchronous PM from CRC. Trends in treatment across the four periods were analyzed by 
means of a Cochran Armitage trend test. Changes in the use of different treatment modalities (sys-
temic therapy, CRS-HIPEC, surgery for lymphatic or hematogenous metastases) were evaluated by 
period and according to a number of relevant patient and tumor characteristics. Overall survival 
time was defined as the time from initial CRC diagnosis to death or lost to follow-up. Patients still 
alive at the end of follow-up (January 1st, 2015) and those who emigrated were censored. Actuarial 
survival estimates according to period of diagnosis were calculated with the Kaplan-Meier method 
and presented up to 48 months in both the total study population of PM patients and according to 
the sites of metastatic disease (PM only, PM + other). A log-rank test was used to compare survival 
between relevant subgroups. Median survival (MS) was expressed in months and corresponding 
95% confidence intervals (CIs) were calculated. Multivariable Cox regression analyses of overall 
survival were performed to estimate hazard ratios (HRs) for the various relevant patient and tu-
mor characteristics, including period of diagnosis. The model was first built without adjustment 
for treatment variables. Subsequently, systemic therapy was included in model 2 and all other 
treatment modalities (primary tumour resection, surgery for lymphatic or hematogenous metas-
tases, CRS-HIPEC) were included in model 3. It was hypothesized that if adjustment for different 
treatment modalities attenuated the association between period of diagnosis and the hazard ratio 
on death, this would suggest that these treatment modalities had contributed to the reduced 
mortality over time. All analyses were performed with SAS/STAT ® statistical software (SAS system 
9.3; SAS institute, Cary, NC).
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Results
Between 1995 and 2014, 1,661 patients were diagnosed with synchronous PM from CRC in the 
Southern part of The Netherlands, representing 4.5% of the total number of CRC diagnoses and 
23% of the stage IV CRC diagnoses during this period. Over time, the absolute number of CRC 
patients diagnosed with PM increased, but the relative proportions remained stable. Patient and 
tumor characteristics are shown in Table 1. 
Table 1   General characteristics of patients with peritoneal metastases (PM) from colorectal origin, diagnosed between 
1995 and 2014 in the south of the Netherlands (n=1661).  
 
N=1661 N (%)
Gender
   Male
   Female
808
853
(49)
(51)
Age (years)
   <70 
   ≥70
917
744
(55)
(45)
Period of diagnosis
   1995-1999
   2000-2004
   2005-2009
   2010-2014
293
333
492
543
(18)
(20)
(29)
(33)
Comorbidity
   Yes 
   No 
   Unknown
897
609
155
(54)
(37)
(9)
Socioeconomic status
   Low 
   Intermediate 
   High
   Institutionalized
   Unknown
 
388 
629 
518 
78 
48
 
(23) 
(38) 
(31) 
(5)
(3)
Localization of primary tumor
   Caecum
   Appendix
   Colon
   Rectosigmoid
   Rectum
376
59
968
84
174
(23)
(4)
(58)
(5)
(10)
T stage of primary tumor
   T1-T2
   T3
   T4
   Tx
42
517
664
438
(3)
(31)
(40)
(26)
N stage of primary tumor
  N0
  N1,2
  Nx
N=1661
128
689
844
N
(8)
(41)
(51)
(%)
Differentiation grade primary tumor
   Well/moderate
   Poor/undifferentiated
   Unknown
625
480
556
(38)
(29)
(33)
Sites of metastatic disease
   PM only
   PM and other sites
744
917
(45)
(55)
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The treatment of PM over time
Over time, the proportion of PM patients receiving any registered treatment modality increased 
slightly from 73% in the time periods 1995-1999 and 2000-2004 to 78% in 2005-2010 and 79% in 
the most recent time period 2010-2014 (p<0.05). In total, 1,273 PM patients received any antican-
cer treatment (77%). However, type of treatment changed over time, as shown in Figure 1. Treat-
ment with systemic therapy increased from 23% in 1995-1999 to 56% in 2010-2014 (p<0.0001). 
CRS-HIPEC was applied since 2005 with increasing percentages thereafter (10% 2005-2009; 23% in 
2010-2014). The increase in the use of these treatment modalities was observed regardless of age, 
comorbidity and the involved sites of metastatic disease. Details are shown in Table 2. Surgery for 
lymphatic or hematogenous metastases significantly increased as well (p<0.0001), especially in 
the most recent time period 2010-2014 (10%). In contrast, there was a decrease in primary tumor 
resections from 62% in 1995-1999 to 52% in 2010-2014 (p<0.01). 
Figure 1  Treatment of colorectal PM, by period of diagnosis.
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Table 2   Percentage of patients who received systemic therapy, cytoreductive surgery with hyperthermic intraperitoneal 
chemotherapy (CRS-HIPEC) and/or surgery for lymphatic or hematogenous metastases, by period and accord-
ing to a number of relevant patient and tumor characteristics
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Trends in survival
Median overall survival (OS) improved over time in the total population of PM patients, from 6.0 
months in 1995-1999 to 12.5 months in 2010-2014 (p<0.0001, Table 3). This increase was observed 
in both patients with isolated PM (PM Only) and PM plus other sites of metastases (PM + Other), 
as shown in Figure 2.
 
Figure 2   Overall survival of patients with A. PM-Only B. PM-Other, by period of diagnosis (n=1661).
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Table 3   Median overall survival (in months) of patients with peritoneal metastases (PM) from colorectal origin 
(n=1,661), separated for whether or not other metastatic sites were involved and period of diagnosis.  
 
1995-1999 2000-2004 2005-2009 2010-2014
MS CI MS CI MS CI MS CI
PM total 
     PM Only 
     PM + Other
6.0  
7.6 
5.0
4.96-7.42 
5.46-9.33 
3.88-6.54
6.5 
7.8 
5.5
4.96-7.22 
4.89-9.95 
4.27-6.73
8.0 
9.8 
6.1
6.76-9.75 
7.75-12.25 
4.99-8.94
12.5 
14.0 
9.9
9.56-13.53
10.41-16.16
7.85-12.48
CI, confidence interval; MS, median survival; PM, peritoneal metastasis. 
p- values: overall / PC-Only/PC-Other p<0.0001 
Multivariable proportional hazards regression analysis modelling the risk for death for patients 
with synchronous PM from CRC is shown in Table 4. Patients diagnosed between 2005-2009 and 
2010-2014 had a decreased risk of death as compared to patients diagnosed in the two earlier 
periods of time (model 1). The difference was not observed any more for patients diagnosed in 
the period 2005-2009 after adjusting for systemic therapy (model 2), but remained for patients 
diagnosed in the most recent time period (2010-2014) compared to earlier periods of diagnosis. 
If adjustments were made for all treatment modalities that were applied in the most recent time 
period (model 3), the lower risk of death disappeared for the period 2010-2014. Other beneficial 
prognostic factors identified by multivariable analysis were the absence of lymph node metas-
tases and a well or moderate differentiation grade of the primary tumor. Poor prognostic factors 
were higher age (≥70 years). 
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Table 4   Multivariable proportional Cox regression analysis modelling the risk for death for patients with synchronous 
PM from CRC, diagnosed between 1995-2014 (n=1661).  
Model 1 Model 2 Model 3
HR 95% CI     P-value HR 95 % CI    P-value HR 95% CI 
P-value
Gender
   Male
   Female
Ref
1.0
0.93-1.17   0.40
Age (years)
   <70 
   ≥70
Ref
1.7
1.52-1.90   <0.0001
Period of diagnosis
   1995-1999
   2000-2004
   2005-2009
   2010-2014
Ref
0.9
0.7
0.5
0.76-1.06   0.23
0.60-0.83   <0.0001
0.44-0.62   <0.0001
Ref
1.0
0.9
0.7
0.88-1.23   0.64
0.78-1.09   0.35
0.62-0.88  <0.001
Ref
1.0
1.0
0.9
0.88-1.24
0.87-1.21
0.74-1.06
0.59
0.78
0.19
Comorbidity
   No
   Yes
Ref
1.0
0.95-1.19   0.28
Socioeconomic status
  Low 
  Mid
  High
  Institutionalized 
 
1.2 
1.1 
Ref 
1.8
 
1.01-1.36   <0.05 
0.97-1.26   0.13 
 
1.40-2.31    <0.0001
 
 
Localization primary tumor
   Colon 
   Rectum 
Ref
0.9
0.77-1.04    0.16
T stage primary tumor
   T1-T2
   T3
   T4
   Tx
0.7
Ref
1.0
1.3
0.47-1.10    0.13
0.88-1.15    0.88
1.11-1.57    <0.01
N stage primary tumor
  N0
  N1,2
  Nx
0.5
Ref
1.5
0.39-0.65   <0.0001
1.33-1.78    <0.0001
Differentiation grade primary tumor
   Well/moderate
   Poor/undifferentiated
   Unknown
Ref
1.5
1.2
1.31-1.72    <0.0001
1.07-1.41    <0.01
Sites of metastatic disease
   PM only
   PM + other
Ref
1.4
1.27-1.60     <0.0001
*Ref=reference category.  Model1; without adjustment for treatment. Model2; with adjustment for systemic chemotherapy. Model 3;with adjustment for all treat-
ment modalities (systemic chemotherapy; primary tumor resection, surgery for lymphatic or hematogenous metastases, cytoreductive surgery and hyperthermic 
intraperitoneal chemotherapy (CRS-HIPEC)
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Discussion
The present population-based study including 1,661 consecutive CRC patients with PM shows that 
treatment has changed remarkably over the last two decades. Both systemic therapy and loco-re-
gional treatment modalities are increasingly offered to these patients. To the best of our knowl-
edge, this is the first study demonstrating an increased overall survival for the entire cohort of PM 
patients, compellingly challenging the dogma of PM as an untreatable condition.
In patients with metastatic CRC, the introduction of systemic schedules combining various cyto-
toxic agents and targeted agents resulted in a substantial improvement in overall survival, with 
increased median survival rates from approximately 6 months to more than 20 months. 8-12 Prom-
ising data from small pooled analyses13-15 led to the suggestion that, also in the presence of PM, 
novel systemic regimens could be of use. In France, this resulted in a substantial increase in the 
proportion of patients receiving chemotherapy over time, from 11% before 1997 to 48% in 2011 
for synchronous PM and from 3% to 38% for metachronous PM.16 Treatment with palliative system-
ic therapy in the Netherlands increased from 16% in 1995 to 46% in 2008 according to data from 
a previous-population based study by Klaver and colleagues.17 As demonstrated in the current 
study, the application of systemic therapy for PM increased even further over time up to 56% in 
the most recent time period. During the study period, there was a slight but significant decrease 
in the proportion of PM patients undergoing primary tumor resection. This might be related to 
the increasing availability of more effective systemic therapy providing an alternative to palliative 
surgery in most recent years. This phenomenon was previously described in other gastrointestinal 
cancers.18 Although detailed data on the prescribed systemic regimen were not available in the 
NCR, the increasing use of systemic therapy in daily practice probably implicates treatment inten-
sification not only by an increased proportion of patients being treated, but also by the implemen-
tation of more potential systemic regimens. 
The two most recent time periods evaluated in this study (2005-2009, 2010-2014) reflect a period 
in which not only novel systemic regimens but also loco-regional treatment strategies (includ-
ing surgery for lymphatic or hematogenous metastases and CRS-HIPEC) were implemented in the 
Netherlands. In 2003, the RCT by Verwaal and colleagues demonstrated an improved overall sur-
vival with CRS-HIPEC compared to conventional fluorouracil based-chemotherapy.6,19 Since then, 
no new randomized data have become available. Various large case studies have demonstrated 
that this treatment may now be offered successfully with 5-year survival rates of over 30%,19-21 also 
in the current era with modern combination chemotherapy.22 These results are currently compa-
rable to those obtained with resection of liver metastases only.23 Opponents of CRS and HIPEC 
claim that these results may be primarily obtained by selection bias, with treatment being offered 
to relatively young patients in a good general condition with limited PM. Nevertheless, the intro-
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duction of CRS-HIPEC has resulted in the increasing usage of CRS-HIPEC nationwide 15,21 as was also 
confirmed in the current study. In the most recent time period 2010-2014, 23% of the patients un-
derwent CRS-HIPEC: 28% in PM only and 18% in PM with other metastatic sites involved. Although 
regarded as peritoneal metastases by some, metastases to the ovary are defined as “systemic me-
tastasis” in the NCR. This explains the relatively high percentage of 18% of PM patients with “other 
metastases” that received CRS-HPEC in the most recent time period. Besides ovarian metastases, 
this group also included patients with metastases in the liver or distant lymph nodes. Resection 
of ovarian metastases also attributes to the high number of patients undergoing surgery for lym-
phatic or hematogenous metastases (10% in 2010-2014). 
In the current study, median overall survival rates of PM patients were 6.0 months in 1995-2000 
and 12.5 months in 2010-2014. These survival rates seem in line with current literature. With pallia-
tive treatment only, overall survival rates in patients with peritoneal tumor spread typically ranged 
around 6 months3,5,24,25, whereas with novel combined systemic regimens and loco-regional pro-
cedures (CRS-HIPEC) higher survival rates even exceeding 30 months have been reported.15,22,26 
 
The improved survival rates over time remained present after stratifying for other involved met-
astatic sites. Multivariable analyses were applied to investigate the independent effect of recent 
diagnosis (and the concomitant availability of more potential systemic/loco-regional  treatment 
modalities) on the risk of death. The observation that the lower risk of death for diagnosis between 
2010-2014 disappeared after including all treatment modalities into the multivariable model 
strongly supports our hypothesis that improved survival rates can be contributed to a multi-disci-
plinary approach, consisting of both systemic and loco-regional (CRS-HIPEC, surgery for lymphatic 
or hematogenous metastases) treatment options. Although these non-randomized data need to 
be interpreted with caution, it might be stated that PM should no longer be regarded as an un-
treatable condition. 
This large population-based study has the advantage of omitting any selection bias by including 
a long-term series of consecutive patients. The results from this study accurately reflect daily prac-
tice. Of course, the population-based nature of this study also presents a potential risk of bias. Data 
on the extent of peritoneal burden, functional status of patients, BRAF and KRAS mutational status 
and other prognostic factors were not available in the NCR. Moreover, lead time bias might be 
expected as one could hypothesize that patients with PM in recent time periods were diagnosed 
at an earlier stage. However, this seems unlikely as accurate diagnostic tools for PM are still lacking 
and peritoneal tumor deposits are still difficult to detect with currently available imaging tech-
niques.27,28. This is also illustrated by the fact that the relative proportion of patients presenting 
with PM remained stable in the last two decades.
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Conclusion
In this population based study, survival of patients with PM increased significantly over time and 
this seems to be related to a multi-disciplinary approach in treating these patients incorporating 
both modern systemic regimens and loco-regional surgical procedures. Therefore, in spite of the 
lack of data from randomized trials, patients with PM should be considered for multidisciplinary 
treatment whenever possible.  
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Chapter 10
Summary and general discussion
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In this chapter, the main findings of the studies performed in this thesis are summarized and sub-
sequently discussed in a broader context. Next, several methodological issues are discussed that 
should be considered when interpreting findings of the studies presented in this thesis. Future 
direction and implications for clinical practice and future research are discussed as well.  
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Summary of results 
The research underlying this thesis aimed to bridge the gap between clinical studies and daily 
practice, by providing insight into the real-world use, tolerability and effectiveness of the various 
systemic treatment options among unselected colorectal cancer patients. 
The main objectives of the studies described in this thesis were: 
•  To provide insight in the everyday use and tolerability of adjuvant chemotherapy regimens 
and its impact on the palliative systemic treatment of metastases in patients with colon cancer 
(part I).
•  To assess the daily-based use and impact of age on the palliative systemic treatment of 
patients with metachronous metastases from primary resected colorectal cancer (part II).
•  To evaluate the role of currently available treatment options in colorectal cancer patients with 
peritoneal metastases (part III). 
Part I of this thesis started by evaluating the intensity and tolerability of the most commonly used 
adjuvant chemotherapy regimens in unselected elderly stage III colon cancer patients (chapter 2). 
For this study, additional data was collected within the Netherlands Cancer Registry for all stage 
III colon cancer patients aged ≥70 years diagnosed in the ten hospitals in the southeast part of 
the Netherlands between 2005 and 2012. Of the patients who were treated with adjuvant chemo-
therapy, a large majority received capecitabine-oxaliplatin (CAPOX) or capecitabine monotherapy 
(CapMono). In the most recent study period (2011-2012), the proportion of CAPOX and CapMono 
versus other regimens was as high as 98%. Patients receiving CAPOX less frequently completed 
all planned cycles (33% vs. 55%) and received a lower median cumulative dosage of capecitabine 
(163,744mg/m2 vs. 189,195mg/m2) compared to patients receiving CapMono. Besides, CAPOX was 
associated with significantly more grade III-V toxicity than CapMono (54% vs. 38%). With CAPOX, 
the most common toxicities were gastrointestinal (mainly nausea/vomiting and diarrhoea, 29%), 
haematological (14%), neurological (i.e. neuropathy, 11%) and other toxicity (mainly fatigue, 13%). 
With CapMono, dermatological (i.e. hand-foot syndrome, 17%), gastrointestinal (mainly diarrhoea, 
13%) and other toxicity (mostly fatigue, 11%) were the most common. In general, toxicity that 
occurred rapidly (such as gastrointestinal toxicity) was associated with a lower median number 
of cycles and cumulative dosage received. Other toxicity that appeared in a later stage during 
the treatment course (such as hand-foot syndrome and neuropathy) was cumulative and did not 
result in lower median number of cycles and cumulative dosages received. 
In chapter 3, insight was provided into the impact of prior adjuvant chemotherapy on the subse-
quent use of different types of palliative chemotherapy for the treatment of metachronous me-
tastases from colon cancer. In the current era of modern adjuvant chemotherapy, treatment of 
recurrent metastatic colon cancer presents clinicians with significant challenges. In this study with 
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a consecutive series of 224 colon cancer patients with metachronous metastases, we found that 
oncologists’ choice of first-line palliative chemotherapy was significantly influenced by prior ad-
juvant therapy. Overall, 111 patients (50%) were previously exposed to adjuvant chemotherapy. 
Prior adjuvant therapy was associated with a lower odds for treatment with first-line combination 
chemotherapy (mostly oxaliplatin-based) if metastases occurred <1 year compared to no prior 
adjuvant therapy (OR 0.3, 95% CI 0.13-0.89), but no such differences were observed if metastases 
developed > 1 year after primary tumour diagnosis (OR 0.6, 95% CI 0.30-1.14).
In Part II of this thesis we studied the everyday use, tolerability and efficacy of palliative systemic 
therapy in unselected patients with metachronous metastases from colorectal cancer, an underre-
ported topic in population based studies as data collection on recurrences is very time consuming 
and costly. Additional data on the development and treatment of recurrences was collected within 
the Netherlands Cancer Registry for all stage I-III colorectal cancer patients diagnosed between 
2003-2008 in the ten hospitals in the southeast part of the Netherlands (n=5,671). 
In chapter 4, we provided a reflection on the everyday use of bevacizumab over the period in 
which this targeted agent was adopted as standard first-line therapy in the Netherlands. The study 
demonstrated significant inter-hospital differences in the prescription of bevacizumab, with pro-
portions varying from 36% to 80%. Overall, approximately half of the patients (51%) received ad-
ditional bevacizumab. In a multivariable regression analysis, several factors were shown to influ-
ence the probability to receive additional first-line bevacizumab. Patients who received first-line 
combination chemotherapy (CAPOX/FOLFOX in 97%) were more likely to receive bevacizumab 
than patients who received single-agent chemotherapy (OR 9.9, 95 % CI 5.51-18.00). Besides, the 
odds for treatment with bevacizumab was higher for patients diagnosed with metastases in a 
recent time period than patients diagnosed with metastases shortly after the introduction of bev-
acizumab in Dutch guidelines (2005-2006). The probability to receive bevacizumab was lower for 
patients with ≥2 comorbidities than patients without comorbidity (OR 0.4, 95 % CI 0.21–0.81), but 
no association was observed between age and the use of bevacizumab. However, elderly patients 
(≥75 years) were less likely to receive combination chemotherapy (OR 0.2, 95 % CI 0.11–0.30) and 
therefore indirectly less susceptible for treatment with bevacizumab. Besides reflecting on usage 
patterns, the study investigated survival outcomes with the use of bevacizumab in everyday clin-
ical practice and demonstrated that the addition of bevacizumab to palliative chemotherapy was 
associated with an improved median overall survival, from 14 months to 22 months. This effect 
remained present after adjustment for patients- and tumour characteristics and the prescribed 
chemotherapeutic regimen (HR 0.6, 95 % CI 0.45-0.73), also when additional efforts were made 
to limit potential endogeneity bias (propensity score matched analysis, HR 0.3; 95% CI 0.14-0.79).
Decisions on the optimal management for the growing number of elderly metastatic colorectal 
patients poses significant challenges to cancer specialists. In chapter 5, we provided insight into 
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the impact of age on palliative systemic therapy in patients with metachronous metastases from 
colorectal cancer, in order to optimize the decision-making process. The study showed a clear de-
cline in the use of palliative systemic therapy with increasing age, in particular after the age of 
75 years. Especially in these patients (≥75 years), there was a remarkable variation in the use of 
palliative systemic therapy between hospitals (17%-63%, p<.05). Overall, patients aged ≥75 years 
were less likely to receive combination-chemotherapy than single-agent chemotherapy. Even in 
selected elderly patients, first-line treatment with CAPOX was associated with less cycles (51% ≤3 
oxaliplatin cycles, 43% ≤3 capecitabine cycles) and lower cumulative dosages of both cytostatic 
agents compared to younger patients, although initial dosages were similar. With single-agent flu-
oropyrimidine therapy (CapMono), however, no differences were observed in either the number of 
received cycles or the cumulative dosage, despite even lower starting dosages in elderly patients 
(2,414 mg/m2/d <75 years, 1,992 mg/m2/d ≥75 years). 
With an ongoing view of metastatic colorectal cancer as a continuum of care, we were interested 
to evaluate the impact of age on further lines of treatment as well. In chapter 6, the age-related 
systemic treatment and survival of patients with metachronous metastases from colorectal cancer 
was evaluated. Elderly patients mostly received first-line single-agent chemotherapy (often with-
out additional targeted therapy) and only 26% of the patients aged ≥75 years received second-line 
treatment. In a multivariable logistic regression analysis, advanced age (≥75 years) was associated 
with a lower probability of receiving all active cytotoxic agents compared to patients aged <60 
years at time of diagnosis of metastases (OR 0.2, 95% CI 0.10-0.77), which was the only predictor 
of death in a multivariable Cox regression analysis with adjustment for age and other relevant 
prognostic factors (HR 0.7, 95% CI 0.61-0.81). 
In part III of this thesis, special focus was directed to the subset of colorectal cancer patients with 
peritoneal metastases (PM). Even though a relevant proportion of colorectal cancer patients de-
velops PM, patients with PM are not frequently studied. In clinical trials, they are underrepresented 
or not included at all due to the difficulty of evaluating response to treatment. Compared to other 
metastatic sites, such as the liver, patients with PM are believed to benefit less from convention-
al chemotherapy. The role of novel systemic regimens including targeted therapy, is largely un-
known. 
In chapter 7 of this thesis, the potential role of bevacizumab- the standard choice of targeted ther-
apy in addition to first-line chemotherapy in metastatic patients- was evaluated in this particular 
subset of patients. All colorectal cancer patients with synchronous PM (stage IV) diagnosed be-
tween 2007 -2014 in the Netherlands were extracted from the Netherlands Cancer Registry. Only 
patients treated with palliative systemic therapy were included in the study (n=1,235). In total, 436 
of the patients received additional bevacizumab (35%). Elderly patients and patients with PM from 
colonic tumours were less likely to receive additional bevacizumab. The addition of bevacizumab 
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to palliative chemotherapy was associated with an improved overall median survival of 11 versus 
7.5 months (p<.0001), in both patients with isolated PM and those with concomitant extra-peri-
toneal metastases The improvement remained present after adjustment for patient and tumour 
characteristics (HR 0.7, 95% CI 0.64-0.83).
In chapter 8, we evaluated the use of another, potentially even curative, treatment modality for 
PM being cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). 
Population-based studies providing data on the percentage of PM patients being treated with 
CRS-HIPEC and characterization of these patients have been lacking. Therefore, the aim of this 
study was to evaluate trends in the use of CRS-HIPEC in the Netherlands where CRS-HIPEC was 
introduced about 20 years ago. The trends in the Netherlands since then may provide important 
information on the amount of PM patients being potentially eligibly for this treatment modality 
in countries where HIPEC was introduced more recently. Between 2005 and 2012, all patients di-
agnosed with synchronous PM of colorectal cancer were extracted from the Netherlands Cancer 
Registry. Of the total number of 4,430 patients, 6.4% underwent treatment with CRS-HIPEC. There 
was a significant increase over time, from 3.6% in 2005-2006 to 9.7% in 2011-2012. The study con-
firmed the presence of stringent patient selection, despite the lack of detailed information on 
CRS-HIPEC criteria due to the nature of the population-based study. Several factors, including age, 
period of diagnosis, differentiation grade and the presence of liver metastases were shown to in-
fluence the probability of treatment with CRS-HIPEC. Overall, CRS-HIPEC was associated with an 
overall median survival exceeding 32 months. 
Despite the ongoing improvements in treatment modalities for PM, the dogma of PM as an un-
treatable disease remains. In chapter 9, we intended to challenge this dogma of PM as an un-
treatable disease, by evaluating trends in treatment and survival of PM patients diagnosed in the 
southeast part of the Netherlands over the past 2 decades. In this study, we included 1,661 pa-
tients and demonstrated that the overall median survival of PM patients more than doubled over 
time, from 6.0 months in 1995-2000 to 12.5 months in 2010-2014. We revealed a strong correlation 
between this improved survival over time and the increasing use of a multidisciplinary treatment, 
including both loco-regional surgery (CRS-HIPEC) and systemic therapy (chemotherapy +/- target-
ed therapy). 
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General discussion
As a result of the introduction of the national screening program on colorectal cancer and demo-
graphic developments, the absolute number of colorectal cancer patients is increasing rapidly.1 
With the evolution of systemic therapy and results of large randomized phase III trials, treatment 
guidelines on colorectal cancer changed, even though patients as seen in everyday clinical prac-
tice are often underrepresented or even excluded from these trials. In the current era of personal-
ized cancer medicine, it is of utmost importance to bridge the gap between knowledge that is cur-
rently present between clinical studies and daily practice. Therefore, this thesis aimed to provide 
insight into the real-world use, tolerability and effectiveness of the various systemic treatment 
options among unselected colorectal cancer patients in whom there is a current lack of evidence.
Adjuvant chemotherapy for advanced (stage III) colon cancer
Even though adjuvant chemotherapy has been the standard of care for stage III colon cancer pa-
tients since 19902,3, there are still many uncertainties regarding its use in elderly patients due to 
the insufficient number of patients over 75 years participating in clinical trials.11,12
The probability to receive adjuvant chemotherapy following complete surgical resection has 
shown to decline with increasing age.4-10 Reasons for non-treatment vary between hospitals, but 
mostly include the presence of comorbidities, frailty/poor performance score, patient refusal 
or surgical complications.11,12 In case an elderly patient is treated with adjuvant chemotherapy, 
they are less often treated with oxaliplatin-containing regimens than their younger counterparts 
as the optimal regimen for elderly patients is still uncertain.13-15 In the elderly, questions remain 
with respect to toxicity and the survival benefit of adding oxaliplatin to a 5-FU based adjuvant 
chemotherapy regimen. The available data are conflicting. Some studies have shown a potential 
benefit of oxaliplatin across all age groups16,17, although results from the MOSAIC trial (biweekly 
infusional 5-FU/LV with and without oxaliplatin)18 and the NSABP C-07 trial (bolus weekly FU and 
LV with and without oxaliplatin)19 doubt the benefit of oxaliplatin in the elderly. In subgroup anal-
ysis of both trials, the significant disease-free survival benefit of adding oxaliplatin was present 
only in patients under the age of 70. This thesis with unselected elderly patients (aged ≥70 years) 
as seen in everyday clinical practice, demonstrates that if elderly stage III colon cancer patients 
receive an oxaliplatin-based regimen (CAPOX), they less frequently completed all planned cycles 
compared to patients receiving single-agent chemotherapy (CapMono) with respectively 33% vs. 
55% (p<.0001). Although the median number of capecitabine cycles did not differ between these 
regimens, the median cumulative dosages of capecitabine was lower for patients who received 
CAPOX (163,744 mg/m2) compared to patients who received CapMono (189,195mg/m2, p<.001). 
This might be counterproductive, since the main benefit of adjuvant treatment is derived from the 
fluoropyrimidine. Besides, our research shows that the incidence of severe toxicity (grade III-V) was 
significantly higher with CAPOX (54%) than with CapMono (38%, p<.01). Toxicity that occurred 
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rapidly – nausea, vomiting and diarrhoea – was associated with a lower median number of cycles 
and cumulative dosage derived. Other toxicity that occurred in a later stage during the treatment 
course (polyneuropathy, hand-foot syndrome) did not result in lower median number of cycles 
and cumulative dosages received, but may have influenced quality of life later on.20,21 Chemother-
apy-induced peripheral neuropathy (CIPN) is frequently encountered if oxaliplatin is used and 
previous studies demonstrated that it may persist even until 11 years after cessation of therapy.22 
According to our results, it may even influence the subsequent use of palliative chemotherapy if 
patients develop metachronous metastases. Prior adjuvant therapy was associated with a lower 
probability of subsequent combination-chemotherapy (mostly oxaliplatin-based) if metastases 
developed within 1 year after primary tumour diagnosis, which probably indicates the presence 
of troublesome neuropathy and the consideration of refractory disease in these patients.23,24 All 
together, these results question the standard of oxaliplatin-containing adjuvant therapy in stage 
III elderly patients and indicate the need for the refinement of patient selection in elderly patients. 
Nowadays, evaluation of mismatch repair enzymes (MMR) should be considered, as tumours with 
microsatellite instability (MSI, the biologic footprint of MMR enzyme deficiency) have a favourable 
prognosis and appear to be resistant to fluoropyrimidines25-27, but not to oxaliplatin-containing 
regimens28. In case of stage III MSI tumours, only oxaliplatin-containing chemotherapy should be 
offered.29 In elderly patients, the MSI or MMR detection could be used as a tool in the decision 
of adjuvant therapy. In addition, a comprehensive geriatric assessment (CGA) may be useful to 
determine whether or not an individual elderly patient is a candidate for adjuvant therapy and 
to derive all patients with the appropriate adjuvant regimen, by balancing potential benefits and 
side effects of therapy.30 
 
Palliative systemic therapy for metachronous metastatic colorectal cancer 
Despite technologic advances in the surgical treatment of colorectal cancer and the implemen-
tation of (neo)adjuvant therapy, recurrence rates for initially non-metastasized colorectal cancer 
patients are still relatively high (20-75%)31, depending on numerous factors such as tumour grade 
and the number of lymph nodes involved.24 In the present thesis, the proportion of patients de-
veloping metachronous metastases after primary tumour resection for stage I-III colorectal cancer 
was as high as 18%. Even though curation may be achieved in some patients with localized meta-
static disease35,36, the majority of these patients (74%) had metastatic disease that was not consid-
ered suitable for potentially curative therapy. In these patients, palliative systemic therapy may be 
considered in an attempt to improve the quality and quantity of life. Nowadays, oncologists have 
a wide range of cytotoxic agents and regimens to chose for the treatment of advanced colorectal 
cancer. However, their optimal use and sequence in real-life practice remains unclear. Trials estab-
lishing the evidence for the various available systemic regimens generally do not include patients 
as seen in everyday clinical practice. 
Since 2004, several targeted agents (bevacizumab, cetuximab and panitumumab) have been ap-
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proved for the treatment of metastatic colorectal cancer following randomized clinical trials that 
established improvements in patient outcome.32-34 Bevacizumab was FDA-approved and adopted 
as the standard of care in addition to first-line chemotherapy following the landmark publication 
by Hurwitz et al in which a survival benefit was demonstrated with irinotecan, bolus fluorouracil 
and leucovorin (IFL).33 As a result, a rapid increase has been observed in the use of first-line bev-
acizumab.35,36 This thesis with data from everyday clinical practice demonstrates bevacizumab as 
the most commonly used targeted agent in first-line treatment, representing approximately half 
of all first-line treatment initiations. However, the presence of a large variation between hospitals 
in the southern part of the Netherlands with regard to the use of bevacizumab indicates important 
differences in attitude and policy towards the use of this anti-vascular agent in clinical practice. 
By the time of regulatory approval of bevacizumab, IFL was no longer considered the preferred 
first-line backbone regimen. Other regimens, including FOLFIRI and the European prevailing ox-
aliplatin-based regimen (FOLFOX), gradually replaced the IFL regimen. Even though several clini-
cal trials37-43 and large non-randomized prospective cohort studies44-47 evaluated bevacizumab in 
combination with other chemotherapy regimens, they provided less convincing results compared 
with the AVF trial.33 In the NO16966 trial, there was only a modestly longer progression free surviv-
al with the addition of bevacizumab to an oxaliplatin-based regimen (CAPOX or FOLFOX4, 9.4 vs. 
8.0 months, p=.002) and no statistically significant improvement in overall survival (21.3 vs. 19.9 
months, p=.077).37 As a result, a gap between “believers” and “non believers” was created, resulting 
in differences in the use of bevacizumab. According to our thesis, the likelihood of bevacizumab 
was shown to depend strongly on the prescribed chemotherapeutic regimen. If a patient was 
considered a candidate for combination-chemotherapy (according to Dutch guidelines mostly 
oxaliplatin-based), bevacizumab was prescribed in approximately 70% of the cases. On the op-
posite, if single-agent chemotherapy was prescribed (mostly capecitabine), only 23% of the pa-
tients received bevacizumab, which is in line with results from observational cohort studies. 44,45,47 
Consequently, advanced age was indirectly associated with a lower probability of treatment with 
bevacizumab. This observation reflects the lack of conclusive data on the risk/benefit ratio of bev-
acizumab in older patients. Even though two randomized trials demonstrated improved progres-
sion-free survival rates with the addition of bevacizumab to first-line single-agent chemotherapy 
(5-FU/LV or capecitabine), they failed to demonstrate a statistically significant survival benefit.42,43 
However, results of recent non-randomized studies suggest a significant benefit from the addition 
of bevacizumab to standard chemotherapy for elderly patients, comparable with that observed 
in younger patients.48,49 Therefore, it is now believed that age alone should not be considered an 
absolute contraindication for the use of bevacizumab.
Patients aged ≥75 years represented more than 40% of the cases with non-resectable metachro-
nous metastases. In line with prior population-based studies13,48-52, we demonstrated a decrease in 
the likelihood of palliative systemic therapy with increasing age. The main decline was observed in 
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patients aged 75 years or more. In these patients, there was a significant inter-hospital variation in 
the prescription of palliative systemic therapy, which indicates the complexity of systemic therapy 
in the elderly. Clinical trials conducted in adult populations typically included younger patients, 
limiting the available evidence for elderly patients in treatment guidelines.53 Therefore, most of 
the currently available evidence for elderly patients is derived from subgroup or pooled analyses 
of prospective clinical trials. However, these analyses are potentially biased by the relatively small 
sample size and the variable age criteria used to defined the elderly population. In particular in 
the heterogeneous subset of elderly patients, efforts should be made to help clinicians balancing 
potential side effects, tolerability and toxicity against the primary aim of treatment and its ben-
efits. Even though first-line combination chemotherapy (±targeted therapy) has been associat-
ed with prolonged progression-free survival and overall survival in the general population37,54-56, 
it should be questioned whether this derives the preferred option in elderly patients. In elderly 
patients, there is an increased incidence of physiological changes and comorbidities, which are 
risk factors for altered pharmacokinetics and pharmacodynamics, potentially leading to increased 
treatment-related toxicity.13 Up to date, the results of clinical trials have been controversial. In the 
FOCUS2 trial, the addition of oxaliplatin to capecitabine/5-FU improved the overall response rate 
but failed to significantly improve progression-free survival in frail or not fit patients.57 Besides, 
a more recent meta-analysis showed that combination-chemotherapy was associated only with 
a modest benefit in terms of progression-free survival, but no benefit in overall survival58, even 
though the addition of intravenous chemotherapy has been associated with increasing adverse 
events.59,60 As a result, this thesis showed that only a minority of the elderly patients as seen in 
everyday clinical practice received first-line combination chemotherapy (37%). More important-
ly, our thesis demonstrates that even if selected elderly patients were considered candidates for 
combination-chemotherapy (CAPOX), first-line treatment was discontinued earlier compared 
to younger patients, resulting in lower cumulative dosages of both cytostatic agents. With sin-
gle-agent chemotherapy (CapMono), however, no such differences were observed in either the 
received number of cycles or the received cumulative dosage, despite lower starting dosages in 
elderly patients. Altogether, these results question the definition as first-line combination chemo-
therapy as the standard of care in elderly patients. 
With an ongoing view as metastatic colorectal cancer treatment as a continuum of care, it has 
been hypothesized that, at least in a subset of metastatic colorectal cancer patients, the sequential 
use of active single agents might be preferable to initial combination chemotherapy. This could 
conceivably reduce overall toxicity, while providing a similar benefit to initial combination treat-
ment.61,62 In the present thesis, we indicate the complexity of such an approach in everyday clinical 
practice, with a large proportion of elderly patients, who often do not receive second-line treat-
ment. Dropout rates as presented in this thesis were even higher than dropout rates reported in 
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prior research63, reflecting the relatively large number of elderly patients as seen in everyday clini-
cal care.64 Besides, we demonstrated the total number of received cytotoxic agents to be the only 
factor associated with survival outcome. In the light of these results, attempts should be made 
to individually tailor treatment. In elderly patients (≥75 years), initial treatment with the highest 
potential of improving both survival and maintaining quality of life may be indicated, as most 
of these patients are not candidates for second-line treatment. Targeted therapy should be con-
sidered and not be out-ruled based on advanced age itself51,65-67, especially since many elderly 
patients may not be candidates for intensive (combination)chemotherapy. In order to derive all 
elderly patients with an optimal treatment strategy, an individual evaluation of the benefit/risk ra-
tio should be performed. Factors such as life expectancy, presence of comorbidities, performance 
status/frailty and patient’s choice should be taken into account. Instruments such as geriatric as-
sessments may be helpful to measure independent clinical predictors of morbidity and mortali-
ty.30 Besides, when deciding on the dosage of fluoropyrimidine, an important consideration is the 
presence of dihydropyrimidine dehydrogenase (DPD) deficiency, encoded by the gene DPYD. DPD 
deficiency, expressed by the variants DPYD*2A, c.1679T>G, c.2846A>T and c.1236G>A/HapB3, has 
been associated with increased risk for severe and life-threatening fluoropyrimidine-associated 
(haematological and gastrointestinal) toxicity68,69. Therefore, dose reductions of 50% for the first 
two variants and 25% for the latter variant are now recommended69,70.
Treating peritoneal metastases from colorectal cancer 
Peritoneal dissemination is a common and debilitating manifestation in patients with CRC.71-73 
The disease is characterized by the spread of tumour deposits throughout the peritoneal surface, 
which can ultimately invade any abdominal organ and lead to blockage of the lymphatic drainage 
system. Due to the fact that peritoneal metastases (PM) were thought to be relatively resistant to 
systemic chemotherapy74 and results with palliative interventions were disappointing75, patients 
with PM were considered to be virtually untreatable by many physicians. The present thesis, how-
ever, challenges the dogma of PM as an untreatable condition. Over the past 20 years, median 
overall survival rates for patients with PM doubled (from 6.0 to 12.5 months). This increase in over-
all survival was shown to be related to the increasing use of a multidisciplinary treatment, incorpo-
rating both modern systemic regimens and loco-regional surgical procedures (CRS-HIPEC). 
Although the notion of PM as loco-regional tumour spread was raised already in the early nine-
ties76, aggressive loco-regional treatment modalities were not available until the beginning of the 
twentieth century. In 2003, a phase III randomized trial comparing cytoreductive surgery (CRS) and 
hyperthermic intraperitoneal chemotherapy (HIPEC) with standard palliative care provided bene-
ficial survival rates with CRS-HIPEC (22.4 months vs. 12.6 months). 77,78 Since then, no new random-
ized data have become available. Nevertheless, the introduction of CRS-HIPEC has resulted in the 
increasing usage of CRS-HIPEC nationwide.15,79 In the Netherlands – one of the first countries where 
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CRS-HIPEC was introduced about 20 years ago – we demonstrated an increase in the use of CRS-
HIPEC from 3.6% in 2005-2006 to 9.7% in 2011-2012. Even higher rates may be expected nowa-
days, as proportions were even higher in 2010-2014 in the southeastern of the Netherlands (23%). 
In line with previous large case-studies demonstrating 5-year survival rates of over 30%77,79,80, our 
thesis demonstrated median overall survival rates exceeding 32 months. Opponents, however, 
claim that these results may be primarily obtained by selection bias, with treatment being offered 
to relatively young patients in a good general condition with limited PM. Our thesis confirms the 
presence of stringent patient selection for CRS-HIPEC, which is of utmost importance to select 
patients who will benefit the most from this extensive treatment along with acceptable morbidity 
and mortality. However, we also showed that the survival in the entire population - regardless of 
treatment – doubled over the last two decades, a result being highly dependent on the intensified 
treatment with CRS and HIPEC together with systemic therapy. Over time, several attempts have 
been made to develop tools to assist clinicians in the decision about performing CRS and HIPEC, 
such as the Peritoneal Cancer Index (PCI), Peritoneal Surface Disease Severity Score (PSDSS)81 and 
Colorectal Peritoneal Metastases Prognostic Surgical Score (COMPASS).82 These tools, including 
previously identified prognostic factors such as the extent of PM, the presence of clinical symp-
toms and histopathological features of the primary tumour, may aid in predicting postoperative 
survival outcomes.82-84 
Even though a substantial proportion of PM patients is receiving potentially curative treatment, 
the majority of PM patients will still not be considered candidates for extensive treatment and re-
main dependent on palliative systemic therapy. Prior research has shown that even with effective 
chemotherapy the prognosis of patients with PM remains worse compared to patients with metas-
tases elsewhere.85,86 Nevertheless, this thesis demonstrated an increasing use of palliative systemic 
therapy over time, also in patients with PM. The role of targeted therapy, however, still seems a 
topic of much debate as there were large inter-regional variations in the prescription of bevaci-
zumab, the standard choice of targeted therapy in addition to first-line chemotherapy. This seems 
counterproductive, since in particular these patients may benefit from additional targeted therapy 
as there is an susceptibility of increased chemotherapy resistance in patients with PM. Besides, the 
present thesis demonstrated a potential survival benefit with the addition of bevacizumab, which 
is in line with previous literature.87-89 
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Methodological considerations
The studies in this thesis have several strengths and weaknesses related to the data sources and 
study designs that were used. 
Strengths and limitations of the data sources
Netherlands Cancer Registry
The studies that are described in this thesis are based on data from the Netherlands Cancer Regis-
try (NCR), or the southeast part of the NCR (formerly known as the Eindhoven Cancer Registry). The 
NCR routinely collects data on all newly diagnosed cancer patients in the Netherlands. Detailed 
information regarding patient and tumour characteristics, cancer diagnosis, stage and primary 
treatment are routinely available. Since 1995, the southeast of the Netherlands registers comor-
bidity at cancer diagnosis, which is unique as compared to other cancer registries worldwide. 
Although data on systemic primary cancer therapy were obtained, no details were available on the 
type of agent, dosage and treatment regimen used. Besides, data on the development and treat-
ment of recurrences was also not yet collected. These data were additionally collected for several 
studies included in this thesis (chapter 1-6). A limitation is that information on the performance 
status of the patients was frequently missing from the medical files and could not be included. 
Besides, data regarding mutational status (KRAS/BRAF), MSI, the extensiveness of disease (tumour 
load) and reasons (not) too prescribe systemic therapy were also lacking. 
Study design 
All studies in this thesis had an observational design. The interval validity of population-based 
studies compared to randomized clinical trials (RCTs) is inferior, but the generalizability is better 
as it provides the opportunity of evaluating a large consecutive series of non-selected patients, as 
seen in everyday clinical practice. Therefore, the observational nature of population-based studies 
has the ability to provide an unique insight into the use, safety and effects of treatments in every-
day clinical practice. Especially for subsets of patients who do not meet the eligibility criteria from 
RCTs, as addressed in this thesis, observational studies are of utmost importance. Nevertheless, 
several biases are inherent to population-based observational studies and should be considered 
when interpreting the results of the studies included in this thesis. 
Bias and confounding
Here, the most important biases and how these biases were dealt with are discussed.
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Selection bias 
Selection bias may refer to either the selective recruitment of patients into the study who are not 
a representative of the population intended to be analysed, or to systematic differences between 
baseline characteristics of the groups that are compared in the study.
Attempts were made to limit the first type of selection bias by including a long-term series of 
consecutive patients in all studies. Data were extracted from the NCR, which collects data on all 
newly diagnosed cancer patients. Therefore, the NCR data will be a representative of the popula-
tion as seen in everyday clinical practice. In several studies (chapters 2-6,9), data were derived from 
the southeast area of the Netherlands (Eindhoven area), which comprises an area of 2.4 million 
inhabitants served by 10 community hospitals. Although no academic hospitals are included in 
this region, the data from the Eindhoven are believed to be representative for the total population 
of colorectal cancer patients. For part I and part II of this thesis (chapters 2-6), additional data were 
collected for two subsets of patients in the Eindhoven area; all stage III colon cancer patients aged 
≥70 years who underwent resection and were diagnosed between 2005 and 2012, and all primary 
resected stage I-III colorectal cancer patients who were diagnosed between 2003 and 2008. For 
the latter, data on the development and treatment of metachronous metastases were collected 
between 2010-2011, resulting a median time from primary diagnosis to data collection of 5.3 years 
(range 1.5-8.8 years). Prior research has shown that almost 90% of the metastases arises within 3 
years after primary tumour diagnosis.90-93 In both additional data collections, data were collected 
for all consecutive series of patients.
The second type of selection bias is present in all studies included in this thesis as patients were 
grouped according to (systemic) therapy receipt. There were significant differences on several pa-
tients and tumour characteristics such as age and comorbidity between treatment groups. In or-
der to limit this potential form of selection bias, we used statistical techniques to adjust for these 
imbalances between treatment groups. Statistical regression models were used to produce esti-
mates of treatment effects adjusted for relevant patient and tumour characteristics (covariates). Of 
course, we could only adjust for the patient and tumour characteristics that were available in the 
NCR. Due to the lack of information on other prognostic factors, this analysis alone cannot fully 
out rule selection bias. Therefore, we also used propensity score matching if possible (chapter 4). 
In this study, the propensity score was estimated using logistic regression model in which beva-
cizumab was the variable of interest and the independent variables were factors potentially asso-
ciated with the use of bevacizumab (similar to variables taken into account in the multivariable 
logistic regression analysis). Patients were matched within tight bounds of the propensity scores 
(probability could vary by no more than 1%), to create two groups comparable on baseline charac-
teristics. Crude survival estimates were calculated and multivariable Cox regression analysis were 
performed in both the total study population and propensity score matched sample to evaluate 
the independent effect of additional bevacizumab on the risk of death. 
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Immortal time bias
Some studies presented in the present thesis may have been exposed to immortal time bias, since 
time between cancer diagnosis (primary cancer diagnosis, metachronous metastases diagnosis) 
and treatment initiation was taken into account in survival analyses (chapters 4&6). In this period, 
death could not occur, since patients must have been alive to receive treatment. Therefore, a peri-
od of ‘immortal time’ was present. This bias may result in an overestimation of the effect of a treat-
ment. To minimize this immortal time bias, the starting points for survival analyses were chosen 
as adequately as possible. For studies on metachronous metastases (chapter 4-6), the date of first 
metachronous metastases diagnosis was used to evaluate overall survival according to treatment 
modality. Unfortunately, no data were available on the date of the receipt of specific therapy, and 
therefore a more appropriate time-dependent Cox regression analysis was not possible. 
Stage migration 
When interpreting trends in treatment and survival (chapter 9), one should take potential stage mi-
gration and related forms of bias (lead time bias) into account. Hypothetically, improved diagnos-
tic techniques in a later period may lead to detection of disease that would have been missed in 
an earlier period. The result is that a person with extensive disease is counted in a “more extensive 
stage” in the later period, whereas in the earlier period such a person would have been counted in 
a “less extensive” stage. The effect is an apparent improved survival within each stage over time, 
even though no actual improvement has taken place. In chapter 9, however, this seems unlikely as 
accurate diagnostic tools for PM are still lacking and peritoneal tumour deposits are still difficult 
to detect with currently available imaging techniques. This was also illustrated by the fact that the 
relative proportion of patients presenting with PM remained stable in the last two decades. 
Implications of the main findings and directions for the future
Implications for clinical practice
In the current era of evolving systemic therapy and the shift towards personalized cancer therapy, 
medical specialists will be increasingly challenged with the gap of knowledge between clinical 
studies and daily practice. Based on the findings of this thesis, a number of recommendations on 
the use of the various available systemic regimens among unselected colorectal cancer patients 
are formulated.
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Part I: Adjuvant treatment and the treatment of metastases
When deciding on adjuvant treatment in elderly stage III colon cancer patients (aged ≥ 75 years), 
an oxaliplatin-based regimen should not be considered the standard regimen. The choice to pre-
scribe an oxaliplatin-based regimen should be made on an individual level, including patient and 
tumour related prognostic factors. Tumour related prognostic factors include the number of in-
volved lymph nodes and the mismatch repair status (MMR). Patient related factors – including 
performance score, comorbidities, polypharmacy, activity of daily living, nutritional status and pa-
tients preference (i.e. with regard to preservation of independence or functional status) – should 
be taken into account to balance potential benefits and side effects of therapy. 
Part II: The palliative systemic treatment of metachronous metastases  
In patients with unresectable metachronous metastases, palliative systemic therapy including 
both chemotherapy and targeted therapy should be considered. Advanced age itself should not 
be regarded an absolute contra-indication for palliative systemic therapy. First-line combina-
tion-chemotherapy, however, does not derive the preferred first-line treatment for elderly patients 
(≥75 years). In particular in elderly patients, decisions regarding the prescribed (first-line) regimen 
should be individually tailored and discussed as most of the elderly patients are not candidates for 
second line treatment. In the case of extensive disease and the risk of rapid deterioration, attempts 
should be made to derive individual patients with initial treatment with the highest potential of 
improving both survival and maintaining quality of life. In particular in elderly patients, a combi-
nation of single agent chemotherapy with the addition of targeted therapy should be considered, 
since most patients will not be candidates for intensive combination-chemotherapy (with or with-
out targeted therapy).
Part III: The treatment of peritoneal metastases
Colorectal cancer patients with peritoneal metastases should no longer be regarded as untreat-
able. In selected patients with isolated peritoneal metastases (or with limited liver metastases), 
CRS-HIPEC should be considered. Attempts should be made to predict which patients will benefit 
the most from this extensive treatment, along with acceptable morbidity and mortality. Additional 
tools may be helpful. In the remaining subset of patients with peritoneal metastases who are not 
deemed candidates for CRS-HIPEC, one should consider palliative systemic treatment whenever 
possible, including both chemotherapy and targeted therapy. 
Implications for further research
Unselected colorectal cancer patients need to become the focus of future colorectal cancer 
research as the gap of knowledge between clinical studies and everyday practice needs to be 
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bridged in order to realize personalized cancer therapy for all advanced colorectal cancer patients. 
Efforts should be made to design clinical trials and prospective observational studies for the frail 
and elderly patients. In these studies, patient characteristics should be described extensively (i.e. 
performance score, comorbidity) and appropriate outcomes should be evaluated, including qual-
ity of life. Future efforts are needed to discover predictors of individual response, prognosis and 
tolerability. A focus should be derived on the potential role of targeted therapy in elderly patients, 
who are often not candidates for intensive combination-chemotherapy or multiple lines of che-
motherapy. For patients with peritoneal metastases, future efforts are needed to establish the role 
of the various available systemic regimens in addition to loco-regional treatment modalities (CRS-
HIPEC) and to derive insight into the potential role of palliative systemic therapy in these patients. 
Concluding remarks 
There is a current gap between clinical studies and everyday clinical practice, which will expand 
even further in the near future due to demographic developments and the ongoing evolution of 
systemic therapy. This thesis provides accurate insight into the actual state of care of advanced 
colorectal cancer patients in real-life practice and provides evidence on the use, tolerability and 
effectiveness of the various systemic treatment options. It was shown that oxaliplatin-based regi-
mens should not be considered the standard (adjuvant and first-line) regimen for elderly patients. 
An individual evaluation of the benefit/risk ratio should be performed, both in the adjuvant and 
metastatic setting. In particular in elderly patients, who often are not candidates for intensive che-
motherapy, consideration of additional targeted therapy is warranted. If metastases are defined 
to the peritoneum, patients should  no longer be regarded as untreatable. Treatment modalities 
including CRS-HIPEC and systemic therapy (chemotherapy + targeted therapy) should be consid-
ered if possible.
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Inleiding
Door de vergrijzing van de bevolking, de verhoogde levensverwachting en de invoer van het 
landelijke bevolkingsonderzoek neemt het aantal mensen dat dikkedarmkanker heeft sterk toe, 
van maar liefst 7,100 in 1990 naar 15,549 in 2015. Oudere patiënten vormen een groot deel van de 
dikkedarmkanker patiënten; een derde van de patiënten is 75 jaar of ouder. 
Ondanks dat een groot deel van de patiënten ten tijde van de diagnose dikkedarmkanker nog 
geen uitzaaiingen heeft (80%), zal een aanzienlijk deel van de patiënten deze alsnog later ontwik-
kelen (“metachrone uitzaaiingen”). Voorheen impliceerde de aanwezigheid van uitzaaiingen dat 
genezing niet meer mogelijk was. Omdat palliatieve behandelopties gering waren, was de alge-
hele prognose beperkt. 
Gelukkig zijn er de afgelopen decennia aanzienlijke vorderingen gemaakt in de behandeling van 
uitgezaaide dikkedarmkanker. Waar we voorheen maar één soort chemotherapie voor handen 
hadden, hebben we nu meerdere chemotherapie middelen welke we kunnen combineren of ach-
tereenvolgens kunnen geven. Tevens heeft de opkomst van “doelgerichte middelen” (ook wel “tar-
geted agents” genoemd) voor een nog breder scala aan “systemische” behandelopties gezorgd. 
Van deze middelen is de werkzaamheid onderzocht in verschillende klinische studies, op grond 
waarvan ze inmiddels worden ingezet bij de alledaagse behandeling van uitgezaaide en gevor-
derde dikkedarmkanker.
Echter, klinische studies omvatten veelal niet de patiënten zoals deze in de alledaagse praktijk 
worden gezien. Oudere patiënten, patiënten die in een beperkte conditie verkeren en patiënten 
met uitzaaiingen die moeilijk te vervolgen zijn (bv. buikvliesuitzaaiingen), zijn ondervertegen-
woordigd of zelfs geheel ontbrekend in klinische studies. Derhalve beschikken we over weinig 
informatie omtrent het gebruik, de verdraagzaamheid en effectiviteit van de verschillende syste-
mische behandelopties bij juist deze groep patiënten.
Doel van dit proefschrift 
Het doel van dit proefschrift is om de vertaalslag te leggen tussen klinische studies en de dageli-
jkse praktijk. Het verschaft inzicht in het alledaagse gebruik, de verdraagbaarheid en effectiviteit 
van de diverse systemische behandelopties bij ongeselecteerde patiënten met uitgezaaide dikke-
darmkanker, zoals deze in de dagelijkse praktijk worden gezien.
De belangrijkste doelstellingen van dit proefschrift zijn als volgt:
•  Inzicht verschaffen in het alledaagse gebruik en de verdraagbaarheid van adjuvante 
chemotherapie en de invloed daarvan op de behandeling van metachrone uitzaaiingen van 
dikkedarmkanker (deel I)
Dutch summary | 185
•  Het alledaagse gebruik en de invloed van leeftijd op het gebruik van palliatieve systemische 
therapie onderzoeken bij patiënten met metachrone uitzaaiingen van dikkedarmkanker  
(deel II).
•  De rol evalueren van huidige behandelingsmethoden voor dikkedarmkanker patiënten met 
buikvlies uitzaaiingen (deel III).
Belangrijkste bevindingen
In deel I van dit proefschrift is bekeken hoe de meest gebruikte adjuvante chemotherapie sche-
ma’s worden verdragen door oudere dikkedarmkanker patiënten met lymfeklieruitzaaiingen 
(stadium III, hoofdstuk 2). Voor deze studie werden alle 70+ patiënten meegenomen die tussen 
2005 en 2012 de diagnose stadium III dikkedarmkanker kregen in zuidoost Nederland. Het over-
grote deel van de patiënten dat werd na behandeld met chemotherapie bleek een behandeling 
te hebben gehad met capecitabine alleen (CapMono), of met capecitabine in combinatie met ox-
aliplatin (CAPOX). Het gebruik van CAPOX bleek geassocieerd te zijn met meer bijwerkingen dan 
CapMono. Daarnaast bleken patiënten die CAPOX kregen minder vaak de gehele behandeling te 
voltooien dan patiënten die CapMono kregen. Bijwerkingen die vroeg optraden (zoals diarree, 
misselijkheid/braken) bleek geassocieerd te zijn met een kortere duur en lagere dosering, terwijl 
andere bijwerkingen die later optraden (hand-voet syndroom, neuropathie) niet leken te zorgen 
voor een lagere dosering of kortere duur.  
 In hoofdstuk 3, werd vervolgens bekeken wat de invloed was van een eerdere behan-
deling met adjuvante chemotherapie op de keuze van palliatieve chemotherapie wanneer er 
later uitzaaiingen optraden (metachrone uitzaaiingen). In deze studie met 224 dikkedarmkanker 
patiënten bleek dat maar liefst de helft eerder adjuvante chemotherapie had gehad. De keuze 
van palliatieve systemische therapie bleek te worden beïnvloed door eerdere nabehandeling met 
chemotherapie (adjuvante chemotherapie). Deze patiënten bleken een kleinere kans te hebben 
om te worden behandeld met combinatie-chemotherapie (meestal oxaliplatin-bevattend), maar 
alleen wanneer uitzaaiingen optraden binnen 1 jaar na de oorspronkelijke diagnose. Wanneer 
uitzaaiingen later (na 1 jaar) waren ontstaan, werd dit effect niet gezien. 
In deel II van dit proefschrift onderzochten we het alledaagse gebruik, de verdraagzaamheid en 
de effectiviteit van de verschillende palliatieve systemische behandelopties bij dikkedarmkank-
er patiënten met metachrone uitzaaiingen. Tot op heden is dit een veelal onderbelicht onder-
werp, aangezien het vastleggen van gegevens over metachrone uitzaaiingen erg tijdrovend is. 
Voor deze studie werden additionele gegevens verzameld over de ontwikkeling en behandeling 
van metachrone uitzaaiingen, voor patiënten die tussen 2003-2008 werden gediagnosticeerd met 
dikkedarmkanker in zuidoost Nederland (n=5,671). 
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In hoofdstuk 4, verschaften we een reflectie van het alledaagse gebruik van bevacizumab (een 
doelgericht middel dat vaatgroei tegen gaat) in de periode waarin dit middel werd aangenomen 
als de standaard behandeling voor uitgezaaide dikkedarmkanker in Nederland. Deze studie 
toonde aanzienlijke verschillen in het gebruik van bevacizumab tussen ziekenhuizen in de regio 
zuidoost Nederland, met percentages variërend tussen de 36% en 80%. Over het geheel kreeg 
ongeveer de helft (51%) van de patiënten bevacizumab. Met name patiënten die geschikt werden 
geacht voor combinatie-chemotherapie (meerdere middelen chemotherapie) bleken bevacizum-
ab te krijgen. Alhoewel oudere patiënten niet direct minder vaak bevacizumab kregen, bleken 
zij wel indirect minder waarschijnlijk om bevacizumab te krijgen aangezien zij minder vaak een 
kandidaat waren voor combinatie-chemotherapie. De studie toonde ook dat, zelfs na correctie 
voor vertekenende factoren, patiënten die zowel chemotherapie als bevacizumab kregen langer 
leefden dan patiënten die geen bevacizumab kregen. 
 Juist de behandeling van oudere patiënten met uitgezaaide dikke darmkanker is in de 
praktijk lastig en stelt de medisch specialist voor een dilemma. In hoofdstuk 5, onderzochten 
we daarom de invloed van leeftijd op de keuze van palliatieve chemotherapie voor de behandel-
ing van metachrone uitzaaiingen van dikkedarmkanker. We vonden een evidente afname in het 
gebruik van palliatieve systemische therapie met het stijgen van de leeftijd, waarbij de grootste 
afname leek plaats te vinden vanaf een leeftijd van 75 jaar. Vooral bij deze patiënten groep (75+) 
zagen we een aanzienlijke variatie in het gebruik van palliatieve systemische therapie tussen de 
ziekenhuizen, variërend van 17% tot 63%. Oudere patiënten bleken niet alleen minder vaak palli-
atieve systemische therapie te krijgen, maar kregen ook minder vaak combinatie-chemotherapie 
(meerdere middelen) dan monotherapie (1 middel). Zelfs bij de zorgvuldig geselecteerde groep 
oudere patiënten die wel combinatie-chemotherapie kregen, zagen we dat er minder kuren en la-
gere doseringen werden gegeven van beide middelen. Wanneer één middel werd gegeven (Cap-
Mono), zagen we geen verschil in het aantal kuren of de dosering, terwijl startdoseringen wel lager 
waren bij oudere patiënten dan bij jongere patiënten.
 In hoofdstuk 6, werd de impact van leeftijd op de totale behandeling en overleving 
onderzocht. Oudere patiënten bleken niet alleen vaker te starten met monotherapie - vaak zonder 
doelgerichte middelen - maar bleken ook vaak niet toe te komen aan een vervolg behandeling 
(tweede lijn). Een gevorderde leeftijd bleek geassocieerd met een kleinere kans op het ontvangen 
van alle middelen tijdens het beloop van de ziekte, terwijl dit de enige voorspeller bleek te zijn van 
overleving. 
In deel III werd een speciale focus gelegd op de groep dikkedarmkanker patiënten met uitzaaiin-
gen naar het buikvlies (peritoneale metastasen; PM). Ondanks dat een groot deel van de patiënt-
en met dikkedarmkanker buikvlies uitzaaiingen ontwikkelt, zijn er maar weinig studies naar deze 
groep patiënten omdat het moeilijk is om te evalueren wat het effect van een behandeling is. 
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Met beeldvorming zijn buikvliesuitzaaiingen namelijk moeilijk te zien. Vergeleken met andere 
uitzaaiingen, zoals lever uitzaaiingen, lijken buikvliesuitzaaiingen minder baat te hebben bij een 
behandeling met conventionele chemotherapie. De rol van nieuwe behandelschema’s, waarin 
doelgerichte middelen zijn opgenomen, is veelal onbekend.
 In hoofdstuk 7 van dit proefschrift onderzochten wij de rol van bevacizumab (de standaard 
1e keus) in toevoeging aan chemotherapie bij deze specifieke patiënten groep. Voor deze studie 
namen wij alle dikkedarmkanker patiënten mee die tussen 2007 en 2014 in Nederland werden gedi-
agnosticeerd met naar het buikvlies uitgezaaide dikkedarmkanker (1,235). In totaal kreeg ongeveer 
een derde van de patiënten bevacizumab. Oudere patiënte bleken minder vaak bevacizumab te 
krijgen. De toevoeging van bevacizumab aan chemotherapie bleek te zorgen voor een verbeterde 
overleving, van 7.5 maand naar 11.0 maanden, bij zowel patiënten met alleen buikvliesuitzaaiingen 
als bij patiënten met zowel buikvliesuitzaaiingen als andere uitzaaiingen.
 In hoofdstuk 8, werd een andere – potentieel curatieve - behandelingsoptie voor bui-
kvliesuitzaaiingen geëvalueerd. Dit betreft een behandeling waarbij een operatie wordt verricht 
om alle zichtbare tumor te verwijderen (“cytoreductive surgery”; CRS) en waarna de buik wordt 
gespoeld met een verwarmde chemotherapie-vloeistof (HIPEC). Deze behandeling (CRS-HIPEC) 
bleek in toenemende mate te zijn gebruikt in Nederland over de afgelopen 20 jaar. Tussen 2005-
2006 kreeg 3.6% van de patiënten met buikvliesuitzaaiingen deze behandeling, terwijl het per-
centage in 2011-2012 al 9.7% was. Alleen strikt geselecteerde patiënten ondergingen de behan-
deling. Verschillende factoren zoals leeftijd, periode van diagnose, de aanwezigheid van lever 
uitzaaiingen beïnvloedde de kans op het ondergaan van CRS-HIPEC. Bij deze groep patiënten 
resulteerde een behandeling met CRS-HIPEC in een overlevingsduur van meer dan 32 maanden. 
 Ondanks dat er de afgelopen decennia allerlei behandelingen voor buikvliesuitzaaiingen 
zijn verschenen, blijft veelal het dogma bestaan dat buikvliesuitzaaiingen onbehandelbaar zijn. In 
hoofdstuk 9, trachtten wij dit dogma te doorbreken. In deze studie evalueerden wij de behan-
deling en overleving van patiënten met buikvliesuitzaaiingen van dikkedarmkanker over de afge-
lopen 2 decennia. We namen de gegevens van 1,661 patiënten mee en zagen dat de overleving 
meer dan verdubbelde (van 6.0 maanden in 1995-2000 naar 12.5 maand in 2010-2014). Daarnaast 
bleek deze verbeterde overleving sterk samen te hangen met de invoer van een multidisciplinaire 
aanpak, waarbij zowel CRS-HIPEC als systemische therapie (chemotherapie en doelgerichte mid-
delen) een rol lijken te spelen. 
 
Concluderende opmerkingen 
In de huidige tijd met continue ontwikkelingen in behandelmogelijkheden en de behoefte 
aan geïndividualiseerde zorg, worden medisch specialisten steeds meer geconfronteerd met 
het gebrek aan kennis tussen klinische studies en de dagelijkse praktijk. Dit proefschrift ver-
schaft inzicht in het alledaagse gebruik, de verdraagzaamheid en effectiviteit van diverse sys-
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temische behandelmethoden bij uitgezaaide dikkedarmkanker patiënten, zoals deze in de 
dagelijkse praktijk worden gezien. Het toont dat oxaliplatin-bevattende schema’s niet de stan-
daard zouden moeten zijn bij oudere stadium III dikkedarmkanker patiënten. Daarnaast toont 
het dat men bij oudere patiënten met metachrone uitzaaiingen van dikkedarmkanker, die 
vaak geen kandidaat zijn voor intensieve combinatie-chemotherapie of tweedelijns behan-
deling, ook de potentiele rol van doelgerichte middelen in acht zou moeten nemen. Tenslotte 
laat het onderzoek uit dit proefschrift zien dat patiënten met uitzaaiingen naar het buikvlies 
niet als onbehandelbaar beschouwd moeten worden.  Behandelopties zoals CRS-HIPEC, syste-
mische therapie (chemotherapie, doelgerichte middelen) zouden overwogen moeten worden. 
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